Clinical trial NCT02499497
Conditions: Prostate Cancer
Keywords: Prostate Cancer
Sponsor: Dana-Farber Cancer Institute
Start date: 2016-02-29; Completion date: 2020-10-31
Enrollment: 114 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as a possible improvement in quality of life for participants who have undergone radical prostatectomy. Androgens are a group of hormones that play a role in male traits and reproductive activity.

The names of the study interventions involved in this study are:

\- LY2452473

Detailed description:
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved LY SARM/LY2452473 as a treatment for any disease.

In this research study, the investigators are studying a new investigational drug called LY SARM (LY2452473). Concerns about the potential adverse effects of testosterone on the prostate have led to the development of molecules called SARMs (Selective Androgen Receptor Modulators). This investigational drug may improve sexual function, quality of life, muscle and bone mass in men with prostate cancer. This molecule was chosen because there is some evidence that shows it may help to improve sexual function and aid in the improvement of muscle mass while not having any influence on the prostate.

Arms: arm 1: Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle. arm 2: Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle. arm 3: Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1 or LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle. arm 4: Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
Interventions: intervention 1: LY2452473 intervention 2: Placebo
Intervention descriptions: intervention 1: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate. intervention 2: The participants will receive pills containing no active drug.

Protocol documents:
Prot_SAP_000.pdf: 
DF/HCC BIOMEDICAL PROTOCOL 
Version:  February 5, 2019 
 
NCI Protocol #: 
Not Applicable 
 
DF/HCC Protocol #:  15-120 
DF/HCC Biomedical Protocol:  02/05/2019 
 
TITLE: A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer 
Protocol Version Date: 02/05/2019 Version  20.0 
 
 
Coordinating Center: 
 
 
Brigham and Women’s Hospital 
 
*Principal Investigator (PI): 
Shalender Bhasin, MD 
 
Brigham and Women’s Hospital 
 
 
Other Investigators: 
Shehzad Basaria, MD 
Brigham and Women’s Hospital 
 
 
Adam Kibel, MD 
Dana Farber Cancer Institute 
 
 
Donna Berry, PhD 
Dana Farber Cancer Institute 
 
 
Grace Huang, MD 
Brigham and Women’s Hospital 
 
 
Arthur Burnett, MD 
Johns Hopkins Medical Institute 
 
 
Thomas Storer, PhD 
Brigham and Women’s Hospital 
 
 
Peter Chang, MD, MPH 
Beth Israel Deaconess Medical Center 
 
Statistician: 
Study Coordinators: 
Maricelle Ramirez 
Brigham and Women’s Hospital 
617-525-9027 
FAX: 617-525-9148 
mramirez5@partners.org 
 
Responsible Research Nurse: 
Haley J. Schram, N.P. 
Brigham and Women’s Hospital 
617-525-9027 
FAX: 617-525-9196 
hschram@partners.org 
Karol Pencina, PhD 
Brigham and Women’s Hospital 
617-525-9049 
kpencina@partners.org 
 
Emily Heckel 
Brigham and Women’s Hospital 
617-525-8407  
FAX: 617-525-9148 
eheckel@partners.org 
Responsible Data Manager: N/A  
 
 
 
 
 
 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
2 
 
 
 
NCI-Supplied Agent(s):  N/A 
Other Agent(s):  N/A  
 
 
Below, please describe the IND Status of this study by choosing IND #/Sponsor OR Exemption from IND 
requirements, making sure to delete the inapplicable field(s). 
 
IND#: 126806.  We have now received final approval from the FDA on our IND. 
IND Sponsor: Shalender Bhasin, the PI of the study is the IND holder. 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
3 
 
TABLE OF CONTENTS 
1. 
OBJECTIVES ......................................................................................................................5 
1.1 
Study Design ....................................................................................................................... 5 
1.2 
Primary Objectives.............................................................................................................. 5 
1.3 
Secondary Objectives.......................................................................................................... 5 
2. 
BACKGROUND .................................................................................................................6 
2.1 
Study Disease(s) ................................................................................................................. 6 
2.2 
IND Agent ........................................................................................................................... 6 
2.3 
Rationale ............................................................................................................................. 7 
2.4 
Correlative Studies Background ......................................................................................... 8 
3. 
PARTICIPANT SELECTION .............................................................................................8 
3.1 
Eligibility Criteria ............................................................................................................... 9 
3.2 
Exclusion Criteria ............................................................................................................... 9 
3.3 
Screening, Recruitment, and Enrollment .......................................................................... 10 
4. 
REGISTRATION PROCEDURES ...................................................................................11 
4.1 
General Guidelines for DF/HCC and DF/PCC Institutions .............................................. 11 
4.2 
Registration Process for DF/HCC and DF/PCC Institutions ............................................ 11 
4.3 
General Guidelines for Other Investigative Sites ............................................................. 12 
4.4 
Registration Process for Other Investigative Sites ............................................................ 12 
5. 
TREATMENT AND/OR IMAGING PLAN .....................................................................12 
5.1 
Criteria and Process for Unblinding ................................................................................. 12 
5.2 
Treatment Regimen ........................................................................................................... 12 
5.3 
Pre-Treatment Criteria ...................................................................................................... 14 
5.4 
Agent Administration........................................................................................................ 14 
5.5 
General Concomitant Medication and Supportive Care Guidelines ................................. 15 
5.6 
Criteria for Taking a Participant Off Protocol Therapy .................................................... 16 
5.7 
Duration of Follow Up ...................................................................................................... 17 
5.8 
Criteria for Taking a Participant Off Study ...................................................................... 17 
5.9 
Study Stopping Rules ........................................................................................................ 18 
6. 
DOSING DELAYS/DOSE MODIFICATIONS ...............................................................18 
7. 
ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS ............................18 
7.1 
Adverse Event List(s) for LY SARM ............................................................................... 19 
7.2 
Adverse Event Characteristics .......................................................................................... 19 
7.3 
Expedited Adverse Event Reporting ................................................................................. 19 
7.4 
Expedited Reporting to the Food and Drug Administration (FDA) ................................. 20 
7.5 
Expedited Reporting to Hospital Risk Management ......................................................... 20 
7.6 
Routine Adverse Event Reporting .................................................................................... 20 
8. 
PHARMACEUTICAL INFORMATION ..........................................................................21 
8.1 
LY SARM ......................................................................................................................... 21 
8.2 
Placebo .............................................................................................................................. 23 
9. 
STUDY CALENDAR .......................................................................................................24 
10. 
MEASUREMENT OF EFFECT........................................................................................26 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
4 
 
10.1 
Primary Outcome .............................................................................................................. 26 
10.2 
Secondary outcomes ......................................................................................................... 26 
11. 
DATA REPORTING / REGULATORY REQUIREMENTS ...........................................27  
11.1 
Data Reporting .................................................................................................................. 27 
11.2 
Data Safety Monitoring..................................................................................................... 28 
11.3 
Transmission of DSMB Recommendations and Summary Reports of Adverse Events to IRBs ... 28 
11.4 
Transmission of Summary of Closed Deliberations to the NINR Staff ............................ 28 
11.5 
Protecting the Confidentiality of Participant Data ............................................................ 28 
11.6 
Multicenter Guidelines...................................................................................................... 28 
11.7 
Collaborative Agreements Language ................................................................................ 28 
12. 
STATISTICAL CONSIDERATIONS...............................................................................28 
12.1 
Descriptive Analyses ........................................................................................................ 29 
12.2 
Compliance Analysis ........................................................................................................ 29 
12.3 
Analytic plan ..................................................................................................................... 29 
12.4 
Missing data ...................................................................................................................... 30 
12.5 
Sample Size Estimates and Power Considerations ........................................................... 30 
12.6 
DATA MANAGEMENT.................................................................................................. 31 
12.7 
Sample Size, Accrual Rate and Study Duration ............................................................... 32 
12.8 
Stratification Factors ......................................................................................................... 33 
12.9 
Interim Monitoring Plan ................................................................................................... 33 
12.10 Analysis of Primary Endpoints ......................................................................................... 33 
12.11 Analysis of Secondary Endpoints ..................................................................................... 33 
12.12 Reporting and Exclusions ................................................................................................. 33 
12.13 Evaluation of Toxicity ...................................................................................................... 33 
12.14 Evaluation of the Primary Efficacy Endpoint ................................................................... 33 
13. 
PUBLICATION PLAN .....................................................................................................33 
REFERENCES ..............................................................................................................................34 
APPENDIX A ................................................................................................................................53 
APPENDIX B ................................................................................................................................66 
APPENDIX C ................................................................................................................................71 
 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
5 
 
1. OBJECTIVES 
 
Androgen deficiency is common and associated with bothersome symptoms of sexual dysfunction, physical 
dysfunction, and fatigue in men with organ-localized prostate cancer who have undergone radical 
prostatectomy and have undetectable PSA levels for 2 or more years after their surgery. LY2452473 (LY 
SARM), a highly selective SARM, is particularly attractive for the treatment of symptoms of androgen 
deficiency in these patients because it displays agonist activities on sexual function and muscle but 
antagonist activity in the prostate in preclinical models and in human trials of up to 6 months duration. Our 
overall objective is to conduct a double-blind, placebo-controlled, parallel group, randomized dose ranging 
trial to determine the efficacy and safety of a SARM in improving the symptoms of androgen deficiency 
(sexual symptoms, fatigue/low vitality, and physical dysfunction) in men with prostate cancer who have 
undergone radical prostatectomy for organ-localized prostate cancer (pT2,N0,M0), Gleason score < 7 (3+4) 
, who have undetectable PSA (<0.1 ng/mL using a sensitive PSA assay) for > 2 years after radical 
prostatectomy, and who have androgen deficiency. In addition to demonstrating its safety, our first aim is to 
compare  0, 1,5 or 15 mg of LY SARM in men, who have undergone radical prostatectomy for organ-
localized prostate cancer, have symptomatic androgen deficiency and very low risk of disease recurrence, 
with regard to sexual function (sexual activity score, sexual desire, erectile function, distress and sexual life 
quality). The second aim is to compare the effects of 0, 1, 5 or 15 mg of SARM on fatigue, well-being and 
affectivity balance, and disease-specific quality of life. Our third aim is to determine whether SARM 
administration improves muscle mass and strength, and self-reported and performance-based measures of 
physical function, and aerobic capacity (VO2max , VO2 peak, and lactate threshold)more than placebo.   
 
1.1 
Study Design 
 
This will be a staged phase IIA randomized, placebo-controlled, parallel group, double blind trial in men, 19 
years of age or older, who have undergone radical prostatectomy for organ-localized prostate cancer, have 
low testosterone levels and associated symptoms, and are deemed to be at low risk of recurrence. At the end,  
114 subjects will have been randomized to placebo (n=36), 1 mg (n=28), 5 mg (n=36), and 15 mg (n=14) 
doses.  A target sample size of 114participants from three trial sites will have 90% power to test the primary 
hypothesis. 
 
1.2 
Primary Objectives 
 
Our overall objective is to conduct a double-blind, placebo-controlled, parallel group, randomized dose 
ranging trial to determine the efficacy and safety of a SARM in improving the symptoms of androgen 
deficiency (sexual symptoms, fatigue/low vitality, and physical dysfunction) in men with prostate cancer 
who have undergone radical prostatectomy for organ-localized prostate cancer (pT2,N0,M0), Gleason score 
<7 (3+4) who have undetectable PSA (<0.1 ng/mL using a sensitive PSA assay) for > 2 years after radical 
prostatectomy, and who have androgen deficiency. In addition to demonstrating its safety, our first aim is to 
compare  0, 1, 5 or 15 mg of LY SARM in men, who have undergone radical prostatectomy for organ-
localized prostate cancer, have symptomatic androgen deficiency and very low risk of disease recurrence, 
with regard to sexual function (sexual activity score, sexual desire, erectile function, distress and sexual life 
quality).  
 
1.3 
Secondary Objectives 
 
• To compare the effects of 0, 1, 5 or 15 mg of SARM on fatigue, well-being and affectivity balance, and 
disease-specific quality of life.  


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
6 
 
• To determine whether SARM administration improves muscle mass and strength, and self-reported and 
performance-based measures of physical function, and aerobic capacity (VO2max , VO2 peak, and lactate 
threshold)more than placebo.   
 
2. BACKGROUND 
 
2.1 
Study Disease(s) 
 
Prostate cancer is the most common malignancy in American men, accounting for 29% of all diagnosed 
cancers and approximately 13% of all cancer deaths; its incidence is on the rise, partly due to increased 
screening with PSA52. In 2010, approximately 217,730 new cases of prostate cancer were diagnosed in the 
United States, and there were 32,050 deaths related to prostate cancer53. The majority of these men have 
low-grade, organ-confined prostate cancer and excellent prospects of long term survival54-57. Substantial 
improvement in survival in men with prostate cancer has focused attention on the high prevalence of sexual 
dysfunction, physical dysfunction, and low vitality in these men11-25, 58-61, which are important contributors 
to poor quality of life among these patients11-18, 23. The pathophysiology of these symptoms - sexual 
dysfunction, fatigue/low vitality, and depressed mood - after radical prostatectomy is multifactorial, but 
androgen deficiency is an important remediable contributor to these symptoms.  
 
2.2 
IND Agent 
 
Preclinical and Phase I and II Experience with LY SARM 
LY SARM, an oral, tissue-specific SARM, displays agonist effects on sexual function, anabolic effects on the 
muscle and bone, with antagonist effect on the prostate. Because of its AR antagonist properties on the prostate, 
its application is also being explored for the treatment of benign prostatic hypertrophy and prostate cancer.  
There were no potentially serious or life threatening toxicities for LY SARM in preclinical toxicology 
studies. LY SARM-induced pharmacological effects consistent with androgen receptor agonism in repeat dose 
toxicological studies. The primary adverse effects in rats and dogs involved changes in reproductive organs 
consistent with the expected effects of an androgen receptor agonist. Safety pharmacology studies of up to 6-
month duration indicate a high safety margin for the drug.  In toxicological studies, LY SARM demonstrated no 
drug-related effects at doses up to 1000 mg/kg in gastrointestinal (GI), renal, pulmonary, and cardiovascular 
function studies.  
In gonadectomized rodent model, LY SARM demonstrated anabolic effects on muscle and 
osteoanabolic properties on bone mass and biomechanical strength at doses that had no significant effect on 
prostate and seminal vesicles. Its nearly complete selectivity for AR has been demonstrated in preclinical 
models, and in phase I and II human trials. LY SARM has demonstrated agonistic activity on sexual function 
(stimulated mating behavior, sexual arousal, NOS, and PDE5 expression).  
LY SARM has shown high degree of tissue selectivity. In a canine model, the administration of LY 
SARM was associated with a 40% reduction of prostate volume, consistent with its AR antagonist properties in 
the prostate. In mice bearing explants of AR+ prostate cancer, LY SARM suppressed the growth of explants.   


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
7 
 
LY SARM has undergone testing in multiple phase I and II trials, which have established its safety in 
doses of up to 75 mg daily in humans. Clinical trials of up to 6-month duration have been conducted. In phase I 
dose ranging studies of 21 day duration (figure 1), LY SARM increased muscle volume by pQCT (figure 1, left 
panel) and suppressed PSA levels (figure 1, right panel), and exhibited no grade 2 or 3 toxicity.  LY SARM 
shares with other oral androgens the property of lowering HDL cholesterol as well as total cholesterol modestly. 
These data demonstrate LY SARM’s safety and tissue selectivity; it is an agonist on the skeletal muscle and an 
antagonist on the prostate. Consequently, unlike testosterone or other androgens, LY SARM would not be 
expected to promote the growth of prostate cancer. This is analogous to the use of tamoxifen, a selective 
estrogen receptor modulator (SERM), which acts as an agonist on the uterus and bone but as an antagonist in 
the breast tissue.  
 
 
 
 
 
 
In phase II efficacy trials of 12 week duration, 5 mg LY SARM daily was demonstrated to be safe 
and increased lean body mass by ~1.5 kg and muscle volume (by CT) by 4-6%, and significantly 
reduced fat mass in line with other SARMs and replacement doses of testosterone.  There was an 
expected decrease in total cholesterol and HDL cholesterol. No grade 2 or 3 toxicity was recorded.     
 
 
 
Several other SARM molecules have undergone phase I and II trials and one has undergone a 
phase III trial in patients with cancer cachexia. These trials have shown these SARM molecules to be 
generally safe. The class effects include a modest reversible decrease in total and HDL cholesterol, 
and mild transaminase elevations in a small fraction of subjects. 
 
2.3 
Rationale 
 
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0 mg
1 mg
5 mg
15 mg
25 mg
Change from Baseline (ug/L
ay
8
S
a es o
y
4000
-3000
-2000
-1000
0
1000
2000
3000
4000
0 mg
1 mg
5 mg
Lean Body Mass Change (g)
Females
Males
Lean muscle 
with DEXA
Figure 1. Dose ranging study of LY2452473 in healthy volunteers demonstrates dose-dependent 
gains in muscle cross-sectional area measured by quantitative CT scan of thigh muscles (left panel) 
and a dose-related lowering of PSA levels (right panel). These data demonstrate LY SARM’s tissue 
selectivity; it is an agonist on the skeletal muscle and an antagonist on the prostate.  
Figure 2. In a phase II trial, healthy men and 
women were treated with 0, 1 or 5 mg SARM 
daily for 6 months.  Dose-dependent gains in 
LBM, measured by DXA are shown.  
-8
-6
-4
-2
0
2
4
6
8
10
12
0 mg
5 mg
25 mg
Muscle Area Change (cm2)
Left Side
Right Side
pQCT calf muscle area change


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
8 
 
Androgen deficiency in men who have undergone prostatectomy for organ-localized prostate cancer is 
common1-12 and often associated with bothersome symptoms13-17 and other adverse health effects that 
contribute to poor health-related quality of life (HRQOL)18-23. Improved survival of men with prostate 
cancer has focused attention on strategies to treat symptoms and improve the overall HRQOL18-23.  
Androgen signaling plays an important role in prostate cancer growth24-31. Testosterone therapy promotes 
the growth of metastatic prostate cancer and androgen deprivation causes regression of metastatic prostate 
cancer32-34. Not surprisingly, the expert guidelines of many professional societies list prostate cancer as a 
contraindication for androgen supplementation24-25. This proscriptive guidance does not fully reflect our 
new understanding of the complex relationship between testosterone and prostate cancer1-5, 34-42. 
Epidemiologic studies have revealed no consistent relationship between testosterone levels and prostate 
cancer risk34-40.  
Several elegant studies have found little or no effect of testosterone administration on intraprostatic 
androgen concentrations or on androgen-dependent gene expression in the prostate41-42. Several open-label 
trials of testosterone have reported very low rates of disease recurrence in men with prostate cancer who 
have undergone radical prostatectomy1-11,43-44. Consequently, testosterone use among men who have 
undergone radical prostatectomy has been increasing, even though neither the safety nor the efficacy of 
testosterone therapy in improving outcomes has been established in these patients. A confluence of 
historical factors – improved survival of men with prostate cancer, a growing recognition of the importance 
of symptom control in the lives of cancer survivors, increasing off-label use of testosterone in patients who 
have undergone radical prostatectomy, and accumulation of clinical experience from nonrandomized trials - 
has highlighted the need for randomized trials of androgen therapy in men with a history of prostate cancer, 
particularly for those, who experience symptoms of androgen deficiency – sexual dysfunction, fatigue, and 
physical dysfunction.  
Selective androgen receptor modulators (SARMs) are a new class of ligands that displays tissue-selective 
anabolic activity in the muscle, anti-resorptive and anabolic activity in bone, androgenic activity in 
maintaining sexual behavior, and robust selectivity for muscle versus prostate45-51. LY2452473 (LY 
SARM), a highly selective SARM, is particularly attractive in men with prostate cancer because it displays 
agonist activity on sexual function and muscle but antagonist activity in the prostate in preclinical models 
and in human trials of up to 6-month duration. Unlike testosterone, LY SARM induces prostate atrophy in 
dogs and lowers PSA in men. Consequently, the administration of Lilly SARM would not be expected to 
increase the risk of disease recurrence; it is, in fact, possible that it may reduce prostate cancer recurrence 
risk. This is analogous to the use of tamoxifen in women with breast cancer; tamoxifen, a selective estrogen 
receptor modulator (SERM), is an estrogen antagonist in the breast but an agonist on the endometrium and 
bone.  Thus, we believe that the clinical application of such a selective, prostate sparing SARM would be a 
very major scientific breakthrough. 
 
2.4 
Correlative Studies Background 
 
Not applicable 
 
3. PARTICIPANT SELECTION 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
9 
 
This will be a phase IIA randomized, placebo-controlled, parallel group, double blind trial in men, 19 years 
of age or older, who have undergone radical prostatectomy for organ-localized prostate cancer, have low 
testosterone levels and associated symptoms, and are deemed to be at low risk of recurrence. At the end, a 
total of 135 subjects will have been randomized; 36, 28, 26 and 14 men to placebo, 1 mg, 5 mg and 15 mg 
doses, respectively.   
 
3.1 
Eligibility Criteria 
 
3.1.1 Age 19 years or older.   
3.1.2 Prostate cancer, with organ-localized disease with very low risk of disease recurrence, as indicated by 
Stage pT2, N0, M0 lesions(if AJCC staging is not available in medical records, the investigators will 
infer the staging based on extensive review of the pathology report),combined Gleason score of 7 (3+4) 
or less, and preoperative PSA<10 ng/ml.The rationale for selecting men with these criteria is that this 
group of men has <0.5% disease recurrence rate over ten years [if pre-operative PSA is not available in 
medical records, low-risk subjects with a Gleason score of 6(3+3) and who are at least 5 years out of 
surgery will be considered for enrollment]. 
3.1.3 Stable and undetectable PSA level (PSA<0.1 ng/mL using an assay that has a functional sensitivity of 
0.1 ng/mL) for at least two years after radical prostatectomy  
3.1.4 Serum testosterone, measured by LC-MS/MS, <300 ng/dL and/or calculated free testosterone ≤70 
pg/mL.  
3.1.5 Self-reported sexual dysfunction (DISF-M-II score ≤20 in the sexual desire domain), and/or fatigue 
(FACIT-F score<30), or physical dysfunction (self-reported difficulty in walking a 1/4 mile or climbing 
two flights of stairs, and short physical performance battery score (SPPB) between 4 to 9).  
3.1.6 Ability to understand and willingness to sign a written informed consent document. 
3.1.7 Agreeing to use adequate contraception prior to receiving the study drug, for the duration of study 
participation, and 4 months after completion of LY SARM administration. The effects of LY2452473 
(LY SARM) on the developing human fetus are unknown.  For this reason and because SARM agents are 
known to be teratogenic, women of child-bearing potential and men must agree to use adequate 
contraception (hormonal or barrier method of birth control, or abstinence) prior to study entry and for 
the duration of study participation.  Should a woman become pregnant or suspect she is pregnant while 
her partner is participating in this study, she should inform her treating physician immediately.   
 
3.2 
Exclusion Criteria 
3.2.1 Men who have undergone radiation therapy alone will be excluded because defining biochemical 
recurrence can be difficult in these men due to fluctuating PSA levels.  
3.2.2 Prior or current androgen deprivation therapy 
3.2.3 Hematocrit > 50% 
3.2.4 Severe untreated sleep apnea (treatment is defined as therapy with CPAP, BiPAP, ASV, or other 
positive air pressure device) 
3.2.5 Uncontrolled heart failure as defined by New York Heart Association(NYHA)class 3 or 4 
3.2.6 History of HIV (protease inhibitors can have interaction with the SARM)  
3.2.7 Myocardial infarction, acute coronary syndrome, revascularization surgery, or stroke within 3 months 
3.2.8 Serum creatinine >2.5 mg/dL; ALT or AST outside normal limits for the lab being used 
3.2.9 Hemoglobin A1c >7.5% or diabetes requiring insulin therapy 
3.2.10 Body mass index (BMI) >40 kg/m2 
3.2.11 Major psychiatric disorder, such as schizophrenia, bipolar disorder, or untreated depression (treatment 
for depression is defined as current therapy with antidepressant medication or cognitive behavioral 
therapy (CBT)). 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
10 
 
3.2.12 Use of any of the following medications within the past 6 months: testosterone, DHEA, estrogens, 
GnRH analogs, antiandrogens, spironolactone, ketoconazole, rhGH, megesterol acetate, prednisone 20 
mg daily or equivalent doses of other glucocorticoids for more than two weeks 
3.2.13 Use of any of the following medications within the past 6 months: Clarithromycin, telithromycin, 
chloramphenicol, itraconazole, nefazodone, cobicistat. 
 
3.2.14 Use of the following treatments for erectile dysfunction (ED): penile implants, vacuum pump devices,  
intracavernosal injections 
 
3.3 
Screening, Recruitment, and Enrollment 
 
Participant Screening 
 
Participants identified through institutional urology groups will be prescreened using medical records to 
determine if they are potentially eligible.  The potentially eligible subjects will be contacted for further 
screening.  If participants are interested, verbal consent will be obtained via an IRB approved script prior to 
administering a telephone screening with a standardized script and questionnaire.  
 
At the Brigham and Women’s Hospital site (BWH), use of EPIC and at the Beth Israel Deaconess Medical 
Center (BIDMC) subject referring site, use of the PIMS will be utilized to identify potential study subjects. 
 
After obtaining consent, to determine eligibility, a directed medical history will be obtained and blood 
count, chemistries, total and free testosterone, and PSA will be measured. The pathological stage and 
pretreatment PSA level will be obtained from medical records. Subjects meeting eligibility criteria will be 
scheduled for baseline studies. 
 
Participant Recruitment and Enrollment 
Participants will be enrolled from the urology clinics at BWH and BIDMC (subject referring site only), 
from the oncology clinics at Dana Farber Cancer Center at the Boston site, from the Brady Urological 
Research Institute at the Johns Hopkins Medical Institute at the Baltimore site, and from the urology clinics 
and from the general community at the UFL site. At BWH we also will employ direct mailings to patients 
with prostate cancer identified through the institutional urology groups and medical records, institutional 
portals such as the Research Patient Data Registry (RPDR) and Research Study Volunteer Program (RSVP), 
whose use for subject recruitment has been IRB-approved.  
 
RPDR is a centralized clinical data registry, or data warehouse. The RPDR gathers data from various 
hospital legacy systems and stores it in one place. The RPDR has two related but separate functions. First, 
an online Query Tool provides users with aggregate numbers of patients with user-defined characteristics 
such as diagnoses, procedures and/or laboratory results. Patient identifiers are not available at this function 
level. Secondly, the RPDR Data Acquisition Engine (DAE) allows the user to receive more detailed medical 
record information about the queried patients. 
 
Research Study Volunteer Program (RSVP for Health) is a database that allows researchers to search by 
disease area, age, race, gender, and ethnicity. Once the researcher identifies the population they'd like to 
contact, RSVP for Health sends potential volunteers an email containing the IRB-approved study 
announcement and prepares letters for those who wish to be contacted through US mail. The identity of 
potential volunteers is maintained until they choose to contact the research team.  
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
11 
 
4. REGISTRATION PROCEDURES 
 
4.1 
General Guidelines for DF/HCC and DF/PCC Institutions 
 
Institutions will register eligible participants with the DF/HCC Office of Data Quality (ODQ) central 
registration system. Registrations must occur prior to the initiation of protocol therapy. Any participant not 
registered to the protocol before protocol therapy begins will be considered ineligible and registration will 
be denied. 
 
An investigator will confirm eligibility criteria and a member of the study team will complete the (ODQ) 
protocol-specific eligibility checklist. 
 
Patients are randomized at the time of registration, and treatment assignment will be communicated to each 
respective site investigational pharmacy so that the proper treatment assignment can be allocated to each 
patient. The biostatistician will provide the (ODQ) Registrars with the treatment assignment list prior to 
study activation. At the time of registration, the confirmation of registration would be sent to the study team, 
while the treatment assignment would be sent directly to pharmacy. 
 
Following registration, participants may begin protocol therapy. Issues that would cause treatment delays 
should be discussed with the Overall Principal Investigator (PI). Notify the (ODQ) Registrar of registration 
cancellations as soon as possible. 
 
4.2 
Registration Process for DF/HCC and DF/PCC Institutions 
 
The (ODQ) registration staff is accessible on Monday through Friday, from 8:00 AM to 5:00 PM Eastern 
Standard Time. In emergency situations when a participant must begin protocol therapy during off-hours or 
holidays, call the (ODQ) registration line at 617-632-3761 and follow the instructions for registering 
participants after hours. 
 
The registration procedures are as follows: 
 
• Obtain written informed consent from the participant prior to the performance of any protocol 
specific procedures or assessments.  
 
• Complete the (ODQ) protocol-specific eligibility checklist using the eligibility assessment 
documented in the participant’s medical record and/or research chart. To be eligible for registration 
to the protocol, the participant must meet all inclusion and exclusion criterion as described in 
the protocol and reflected on the eligibility checklist. 
 
• Reminder: Confirm eligibility for ancillary studies at the same time as eligibility for a treatment 
protocol. Registration to both treatment and ancillary protocols will not be completed if eligibility 
requirements are not met for all studies.  
 
• Fax the eligibility checklist(s) and all pages of the consent form(s) to the (ODQ) at 617-632-2295. 
For Phase I protocols, attach participant dose level assignment confirmation from the sponsor. 
 
• The (ODQ) Registrar will (a) review the eligibility checklist, (b) register the participant on the 
protocol, and (c) randomize the participant when applicable. 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
12 
 
 
• An email confirmation of the registration will be sent to the Overall PI, study coordinator(s) from the 
Lead Site, treating investigator and registering person immediately following the registration. 
Treatment assignment will be sent directly to pharmacy via fax. 
 
4.3 
General Guidelines for Other Investigative Sites 
 
Eligible participants will be entered in to the study centrally at the Brigham and Women’s Hospital by the 
Study Coordinator.   
 
Following registration, participants should begin protocol therapy within 5 days. Issues that would cause 
treatment delays should be discussed with the Overall PI.  The Study Coordinator should be notified of 
cancellations as soon as possible. 
 
Research activities for participants originating from Beth Israel Deaconess Medical Center will occur at 
Brigham and Women’s Hospital and will be registered by the Brigham and Women’s Hospital study 
coordinator.  Participants referred from BIDMC will continue their routine clinical care outside of the 
research protocol. 
 
4.4 
Registration Process for Other Investigative Sites 
 
The registration process for other investigative sites is located in the DSMP in section 15.7.1. 
 
 
5. TREATMENT AND/OR IMAGING PLAN 
 
5.1 
Criteria and Process for Unblinding 
In both urgent and non-urgent situations: Only the trial’s Data and Safety Monitoring Board is authorized to 
request unblinding of participant-level intervention assignment in one or more subjects in non-urgent 
situations should a safety concern so warrants. In urgent situations, the Principal Investigator may direct the 
study physician to unblind the intervention assignment should this information be deemed necessary by the 
patient’s primary care provider or emergency department clinician to manage an urgent medical condition.  
 
5.2 
Treatment Regimen 
 
LY SARM or Placebo will be administered daily for a period of 12 weeks.  LY SARM or Placebo will be 
dispensed to the subject in pill form in four week supplies.  The drug or placebo will be dispensed at 
baseline (Visit 2b), week 4, and week8.   Reported adverse events and potential risks are described in 
Section 7.  No investigational or prohibited therapies other than those described below may be administered 
during the course of this study. 
 
The study medication should be taken daily in the morning on an empty stomach at about the same time 
each day.  The medication should be swallowed whole with water.  The bottle containing the medication 
should be stored at room temperature.  The medication does not need refrigeration.  If the subject vomits 
after taking the dose and sees the study drug capsule in the emesis, he should wait for an hour and then 
retake a new capsule of the medication.  If the subject does not see the study drug capsule in the emesis, he 
should not take another dose.  If the subject forgets to take the drug in the morning and remembers it later 
during the day including bedtime, he should go ahead and take the drug for that day as soon as it is 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
13 
 
remembered.  The medication is best taken in the morning on a fasting stomach at least 30 minutes before 
any meal, although if the participant forgets to take a dose but remembers later in the day, he should take the 
medication at that time. It may not be practical for many individuals, who are employed, to fast during the 
day.   Breakfast can be eaten 30 minutes or later after taking the study medication.  There are no prohibited 
foods.  The drug is supplied in capsules. At one time, subjects will be provided sufficient medicine for a 
period of 4 weeks. At the end of the 4 week period, they should return any unused medication to the study 
staff along with the filled–in drug diary.  
 
We will measure compliance using medication logs and pill counts, which provide the best trade-off 
between accuracy and cost283-284. The participant will be requested to maintain a medication diary of each 
dose of medication that will be provided to them by the study staff.  The medication diary will be returned 
to clinic staff at the end of each cycle.  Furthermore, pill counts will be done to measure compliance.  
Medication logs will be collected and unused pills will be counted. Adherence will be assessed as number of 
pills used divided by number of days.  
 
1. LY2452473 is supplied as an oral capsule drug product in size 2 opaque white gelatin capsules. Each 
capsule contains 1 mg, 5 mg or 15 mg of LY2452473 and the inactive ingredients pregelatinized starch 
and dimethicone. LY2452473 is intended to be supplied for the proposed clinical trial as capsules 
packaged in 30 count white, induction sealed high density polyethylene (HDPE) bottles with child-
resistant closures.  
2. The drug product will be packaged and supplied to the IDS by Catalent Pharma Solutions, Kansas 
City, Missouri, USA. 
3. The drug product will be stored at room temperature (25°C) with allowable excursions between 15 - 
30°C. 
4. The drug will be dispensed by the IDS in an amount sufficient for 30 days.  
5. The IDS will release the study medication to an authorized study staff upon receipt of a prescription 
written and signed by a study clinician. The study staff will dispense the study medication to the 
participant in accordance with the study protocol along with a set of written instructions on how to 
take the medication. 
6. The study staff will retrieve the unused medication from the participant for the purpose of assessing 
adherence.    
 
Subject Intervention  
The study intervention includes placebo and three doses of LY SARM (1, 5 and 15 mg daily). Subjects who 
meet the eligibility criteria, will be randomized, to either placebo, 1 mg SARM, 5 mg SARM or 15 mg 
SARM daily.  The subject assignment will be based on the randomization tables, using permuted blocks 
with varying blocks sizes. Subjects will be stratified by age (19-50 and >50) and use of phosphodiesterase 5 
inhibitors (PDEIs); PDEIs may influence sexual function (and mood and HRQOL) independently228-231. 
Stratification variables will be included as covariates in analyses. 
 
SARM Doses and Regimen 
The participants will be randomly assigned to receive either placebo, 1 mg LY SARM, 5 mg LY SARM, or 
15 mg LY SARM daily for 12 weeks. In phase II trials of up to 6-month duration, these doses were safe and 
effective in increasing lean body mass. 5 mg dose increased fat-free mass by an average 1.5 kg in men.  
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
14 
 
Intervention Duration 
The effects of SARM as well as testosterone on sexual function, muscle mass, strength, well being and 
mood become apparent within 3 months48, 171-177; PSA levels rise within 3-4 weeks and reach a plateau by 
12-weeks109-110. Thus, 3-month duration will be sufficient to detect meaningful changes in outcomes and 
PSA. 
 
Phosphodiesterase Inhibitors Use 
PDEIs may independently affect sexual function (and HRQOL)226-231. To minimize confounding due to 
PDEI use, we will stratify randomization based on PDEI use. PDEI use will be used as a covariate in 
analyses. 
 
5.3 
Pre-Treatment Criteria 
 
Prior to subject’s enrollment, the study coordinators will explain the purpose of the study, the study 
procedures, and potential risks and benefits of participation in this trial, and answer any questions. The 
subjects will be asked to sign the IRB-approved consent form. To determine eligibility, a directed medical 
history will be obtained, and blood count, chemistries, total and free testosterone, and PSA will be 
measured. The pathological stage and pretreatment PSA level will be obtained from medical records. 
Subjects meeting eligibility criteria will be scheduled for baseline studies. Subjects, who meet the eligibility 
criteria will undergo baseline studies, which include baseline complete blood count, blood chemistries, and 
baseline assessment of physical function, sexual function, fatigue, as described in the protocol. The subjects 
who are eligible and have completed the baseline assessments will be randomized.  
 
5.4 
Agent Administration 
 
Administration –The dose will be 0 mg (placebo), 1 mg, 5 mg, or 15 mg of LY SARM depending upon 
which study group that the subject is randomly assigned to.  LY SARM or Placebo will be taken orally, 
once per day.  The intervention period is twelve weeks.  Subjects will be given the drug in four week 
supplies at baseline (Visit 2b), week 4 and week 8.  Their compliance will be measured by pill counts at 
week 4, week 8 and week 12.  In addition, medication logs will be given to subjects. 
 
Protocol specific procedures –A study physician will obtain consent. The safety laboratory results will be 
reviewed by one of the study physicians. During each visit, a research coordinator will ask the participants 
about any adverse events. A study clinician will perform a physical examination at screening and during 
weeks 6 and 12.A study physician will be available if an issue arises at the study visits with the research 
coordinator. 
 
The research staff will take interim status during baseline, weeks 2, 4, 6, 8, and 12.  During interim status, 
the subject will be asked questions about any changes in health or medication.  Blood tests will be done at 
screening, baseline, as well as during weeks 2, 4, 6, and 12.  DXA and strength assessments will be 
performed at baseline and during week 12.   
 
Infusion Reactions – Subjects will be monitored for PSA level, hematocrit, hemoglobin, HDL level, and 
liver enzymes. 
 
Sometimes due to scheduling issues, staff availability, inclement weather or subject availability, we may ask 
the subject to return to our research clinic in order to complete a visit or a specific procedure at a different 
time or day. This may affect some of the procedures at any visit. In case of such an event, if the subject 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
15 
 
parks in our valet parking area, their parking will be validated.  
 
The investigators may omit any strength assessments (muscle performance or physical function procedures) 
for safety purposes. In such instances, the investigators will determine which procedures will be omitted and 
this will be documented in the subject’s study file.   
 
Caregiver Precautions -  
Nurse’s/ Study Staff’s Instructions to Patients  
1. The medication should not be dispensed by a woman who is pregnant or may become pregnant. 
Women who are pregnant or may become pregnant must use caution when cleaning up vomited 
matter. 
2. Please, take your study medication daily in the morning on an empty stomach at about the same time 
each day. 
3. The medication should be swallowed whole with water. 
4. The bottle containing the medication should be stored at room temperature.  The medication does not 
need refrigeration. 
5. If you vomit after taking the dose, please wait for an hour and then retake the medication. 
6. If you forget to take your medication in the morning and remember it later during the day including 
bedtime, please go ahead and take your medication for that day as soon as you remember it. If you 
forget to take your dose in the morning after an overnight fast, please do not eat or drink anything 
(other than water) for two hours prior to taking the drug.  Once you have taken the drug, please do 
not eat or drink anything other than water for 30 minutes. After that, you may resume your regular 
diet. 
7. The medication is best taken in the morning on a fasting stomach and continue fasting for at least 30 
minutes before any meal. 
8. You can eat your breakfast 30 minutes or later after taking the study medication.  
9. There are no prohibited foods.  
10. Please record the medication in the drug diary as soon as you take the medication. The drug diary 
will be provided to you by the study staff. 
11. The drug is supplied in capsules. At one time, you will be provided sufficient medicine for a period 
of 4 weeks. At the end of the 4 week period, please return any unused medication to the study staff 
along with the filled–in drug diary.  
 
5.4.1 IND agent 
The IND agent is discussed in detail in Section 8. 
 
5.4.2 Other Agent(s) 
N/A 
 
5.4.3 Other Modality(ies) or Procedures 
N/A 
 
5.4.4 Investigational Imaging Agent Administration 
N/A 
 
5.5 
General Concomitant Medication and Supportive Care Guidelines 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
16 
 
The case report form will be developed to capture the concurrent use of all other drugs, over-the-counter 
medications, or alternative therapies.   
 
• The use of the following medications if not allowed during the course of the study: testosterone, 
DHEA, estrogens, GnRH analogs, antiandrogens, spironolactone, ketoconazole, rhGH, megesterol 
acetate, prednisone 20 mg daily or equivalent doses of other glucocorticoids 
 
5.6 
Criteria for Taking a Participant Off Protocol Therapy 
 
Treatment will continue for 12 weeks or until one of the following criteria applies: 
 
• An increase in PSA to 0.2 ng/mL or higher, if confirmed by a repeated test, will result in treatment 
discontinuation and referral to a urologist. An increase in PSA will be confirmed by a repeat test which 
may result in removal from the study. The study team will contact the participant within a week after 
test result becomes available for scheduling the repeat test if the first test revealed an increase in PSA. 
If the repeat test confirms the elevation, the intervention will be stopped and the participant will 
continue to be followed in the study per intent-treat analytical design. The study medication will 
continue until the results of the repeated test become available. The participant will also be referred to 
a urologist, medical oncologist, or a primary care provider depending on the nature of the problem. If 
the repeat test does not confirm the elevation, the participant will continue in the study and have the 
next set of lab tests per study protocol. 
• Any other sign of disease recurrence (e.g., evidence of bone metastasis detected by the subject’s 
oncologist) 
• Myocardial infarction or stroke   
• Unacceptable adverse event(s) 
• Participant demonstrates an inability or unwillingness to comply with the oral medication regimen 
and/or documentation requirements 
• Participant decides to withdraw from the protocol therapy 
• General or specific changes in the participant's condition render the participant unacceptable for 
further treatment in the judgment of the treating investigator 
• Other DLTs include hematocrit increase above 54% and transaminase elevation above 1.25 times the 
upper limit of normal, confirmed by repeating these tests. An increase in hematocrit and transaminase 
will be confirmed by a repeat test which may result in removal from the study. The study team will 
contact the participant within a week after test result becomes available for scheduling the repeat test 
if the first test revealed an increase in hematocrit or transaminases. If the repeat test confirms the 
elevation, the intervention will be stopped and the participant will continue to be followed in the study 
per intent-treat analytical design. The study medication will continue until the results of the repeated 
test become available. The participant will also be referred to a urologist, medical oncologist, or a 
primary care provider depending on the nature of the problem. If the repeat test does not confirm the 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
17 
 
elevation, the participant will continue in the study and have the next set of lab tests per study protocol. 
Any abnormal liver function test, defined by a value that is greater than 1.25 times the upper limit of 
normal, will also require a repeat blood test within 3-7 days, to confirm the result and observe the 
trend. If the participant’s levels do not exceed 1.25 times the upper limit of normal, they will continue 
on the study medication and transaminases will be monitored.  
 
 
Note that for an abnormal lab value to meet the DLT definition, the lab test must be repeated and the repeat 
test must confirm the elevation.  
 
If the participants experience a grade 4 non-hematological toxicity, the study medication will be stopped and 
the participant will be referred to his medical oncologist, urologist, or the primary care provider depending 
on the nature of the toxicity. However, study assessments will continue per study’s intent-to-treat design. 
 
Participants will be removed from the protocol therapy when any of these criteria apply.  The reason for 
removal from protocol therapy, and the date the participant was removed, will be documented in the case 
report form (CRF). Alternative care options will be discussed with the participant. 
 
A ODQ Treatment Ended/Off Study Form will be filled out when a participant is removed from protocol 
therapy. This form can be found on the ODQ website or obtained from the ODQ registration staff. The 
QACT Treatment Ended/Off Study Form will be completed by each site and then sent the Coordinating 
Center for all study participants. 
 
In the event of unusual or life-threatening complications, treating investigators must immediately notify the 
Overall PI, Shalender Bhasin, MD at 617-525-9040.  
 
5.7 
Duration of Follow Up 
 
The subjects who come off the study medication for disease recurrence or adverse events will be referred to 
their urologist or medical oncologist or primary care provider for further evaluation and treatment, 
depending on the nature of the problem. Because of the intent-to-treat analytical design, they will continue 
to be followed in the study for further study assessments per protocol. 
 
5.8 
Criteria for Taking a Participant Off Study 
 
Participants will be removed from study when any of the following criteria apply: 
• Lost to follow-up 
• Withdrawal of consent 
• Death 
Consistent with the intent-to-treat primary analytical strategy, we will encourage all participants, including 
those in whom the study medication is discontinued because of the reasons listed above, to continue with 
their follow-up study assessments.  
 
The reason for taking a participant off study, and the date the participant was removed, will be documented 
in the case report form (CRF). 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
18 
 
A ODQ Treatment Ended/Off Study Form will be filled out when a participant comes off study. This form 
can be found on the ODQ website or obtained from the ODQ registration staff.  
 
The ODQ Treatment Ended/Off Study Form will be completed by each site and then sent to the 
Coordinating Center for all study participants. 
 
5.9 
Study Stopping Rules 
 
In light of the phase I and II trials data, we anticipate very low rates of grade II or III toxicity. The main 
reason for trial’s early termination would be unexpectedly high rates of PSA recurrence. By virtue of the 
eligibility criteria, this population should have very low recurrence rates (<0.5% over 5 years).  
 
Among the first 50 enrolled subjects, we assume that we should have about 16 in placebo and about 34 or so 
in the two SARM arms.   
 
In the control group, we expect a recurrence rate of <0.5% over 5 years (for the purpose of this calculation, we 
assumed a recurrence rate of 0.5% over 5 years). We will accept a difference of no more than 3 between the 
placebo and the   SARM arms in aggregate after 50 subjects have been randomized. If the PSA recurrence 
occurs in 3 or more cases in the two SARM arms in aggregate or 3 or more cases in any one SARM arm, the 
DSMB may stop the trial. The probability of a single recurrence is 0.005 (probability of 'not recurrent' is 
0.995 at 5 years). Thus, if the bar is set at 3 recurrences, the probability of making an error and stopping early 
when in fact there is no extra risk conferred by SARM is only 1 in 1250.   
 
At 4 or more recurrences, the chance of erroneous early stoppage is 1 in 25000, which seems large. Therefore, 
we submit that a difference of 3 recurrences between the placebo arm and the 2 SARM arms in aggregate is 
reasonable as a stopping rule that DSMB will consider in its decision. The DSMB has the discretion of 
stopping the trial for other reasons.  
 
6. DOSING DELAYS/DOSE MODIFICATIONS 
 
No dose modifications are allowed. Dose modification is not planned in the context of this double blind 
phase II randomized trial for several reasons. One aim of the trial is to assess the dose response relationship 
of dose with the study’s outcomes, which could be compromised if the dose adjustment were to occur. The 
study is blinded; dose adjustment may unblind the study. Also, the drug will be manufactured in either 1 
mg, 5 mg or 15 mg capsules. Therefore, we do not have any mechanism for administering intermediate 
doses.  Furthermore, based on the preclinical animal data, and phase I and II previous human studies, we 
anticipate very low frequency of DLT. Also, we do not have any previous data to guide rational dose 
adjustment. 
 
If the subject forgets to take one or more doses, he will be asked to record the missed doses in the 
medication log and re-initiate the usual daily dosing. Study staff will encourage all participants to take all 
the pills as specified in the protocol. We will also perform pill counts and use drug logs to monitor 
compliance. However, because of the intent-to-treat analytical plan, the participants will continue in the 
study for their assessments per protocol. 
 
7. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS 
 
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The following list of 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
19 
 
reported and/or potential AEs (Section 7.1) and the characteristics of an observed AE (Section 7.2) will 
determine whether the event requires expedited reporting in addition to routine reporting. 
 
7.1 
Adverse Event List(s) for LY SARM 
In previous phase I and II studies of LY SARM, the drug was well tolerated and no drug-related grade II or III 
toxicities were recorded. A modest decrease in total cholesterol and HDL cholesterol was noted, which is a 
class effect of oral androgens. There were no clinically significant changes in liver function. No significant 
changes in hemoglobin and hematocrit were noted. In phase I studies, a decrease in PSA was noted. The class 
effects of oral androgens and SARMs include a decrease in total and HDL cholesterol, increase in hematocrit 
(not observed with this SARM), and mild increases in AST and ALT. There may also be a risk of disease 
recurrence although that risk would be very small because of LY SARM’s selectivity. 
 
7.2 
Adverse Event Characteristics 
 
• CTCAE term (AE description) and grade:  The descriptions and grading scales found in the revised 
NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE 
reporting.  All appropriate treatment areas should have access to a copy of the CTCAE version 4.0.  A 
copy of the CTCAE version 4.0 can be downloaded from the CTEP web site 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
 
• For expedited reporting purposes only:   
- 
AEs for the agent(s) that are listed above should be reported only if the adverse event varies in 
nature, intensity or frequency from the expected toxicity information which is provided. 
- 
Other AEs for the protocol that do not require expedited reporting are outlined in the next 
section(Expedited Adverse Event Reporting) under the sub-heading of Protocol-Specific Expedited 
Adverse Event Reporting Exclusions. 
 
• Attribution of the AE: 
- 
Definite – The AE is clearly related to the study treatment. 
- 
Probable – The AE is likely related to the study treatment. 
- 
Possible – The AE may be related to the study treatment. 
- 
Unlikely – The AE is doubtfully related to the study treatment. 
- 
Unrelated – The AE is clearly NOT related to the study treatment. 
 
7.3 
Expedited Adverse Event Reporting 
 
7.3.1 Investigators must report to the Overall PI any serious adverse event (SAE) that occurs after the initial 
dose of study treatment, during treatment, or within 30 days of the last dose of treatment on the local 
institutional SAE form.  
 
7.3.2 For multi-institution studies where a DF/HCC investigator is serving as the Overall Principal 
Investigator, each participating institution must abide by the reporting requirements set by the DF/HCC. 
This applies to any medical event equivalent to an unexpected grade 2 or 3 with a possible, probable or 
definite attribution, unexpected grade 4 toxicities, and grade 5 (death) regardless of study phase or 
attribution. 
 
7.3.3 
DF/HCC Expedited Reporting Guidelines 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
20 
 
Investigative sites within DF/HCC and DF/PCC will report SAEs directly to the DFCI Office for Human 
Research Studies (OHRS) per the DFCI IRB reporting policy. 
 
Other investigative sites will report SAEs to their respective IRB according to the local IRB’s policies 
and procedures in reporting adverse events. A copy of the submitted institutional SAE form will be 
forwarded to the Overall PI within the timeframes detailed in the table below.  
 
 
 
 
Attribution 
DF/HCC Reportable AEs 
Gr. 2 & 3 AE 
Expected 
Gr. 2 & 3 AE 
Unexpected 
Gr. 4 AE Expected 
Gr. 4 AE 
Unexpected 
Gr. 5 AE 
Expected or 
Unexpected 
Unrelated 
Unlikely 
Not required 
Not required 
5 calendar days# 
5 calendar days 
24 hours* 
Possible 
Probable 
Definite 
 
Not required 
 
5 calendar days 
 
5 calendar days# 
 
5 calendar days 
 
24 hours* 
# If listed in protocol as expected and not requiring expedited reporting, event does not need to be reported. 
 
* For participants enrolled and actively participating in the study or for AEs occurring within 30 days of the last 
intervention, the AE should be reported within 24 business hours of learning of the event. 
 
 
The Overall PI will submit SAE reports from outside institutions to the DFCI OHRS according to DFCI 
IRB policies and procedures in reporting adverse events.  
 
7.3.4 
Protocol-Specific Expedited Adverse Event Reporting Exclusions 
N/A 
 
7.4 
Expedited Reporting to the Food and Drug Administration (FDA) 
 
The Overall PI, as study sponsor, will be responsible for all communications with the FDA. The Overall PI 
will report to the FDA, regardless of the site of occurrence, any serious adverse event that meets the FDA’s 
criteria for expedited reporting following the reporting requirements and timelines set by the FDA. 
 
7.5 
Expedited Reporting to Hospital Risk Management 
 
Participating investigators will report to their local Risk Management office any participant safety reports or 
sentinel events that require reporting according to institutional policy.  
 
7.6 
Routine Adverse Event Reporting 
 
All Adverse Events must be reported in routine study data submissions to the Overall PI on the toxicity case 
report forms.  AEs reported through expedited processes (e.g., reported to the IRB, FDA, etc.) must 
also be reported in routine study data submissions. 
 
7.7Adverse Event Reporting to Sponsor 
 
A summary report of adverse events that the DCC will prepare for the DSMB report will be sent to 
Transition Therapeutics. 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
21 
 
8. PHARMACEUTICALINFORMATION 
 
A list of the adverse events and potential risks associated with the investigational agent administered in this 
study can be found in Section 7.1. 
 
8.1 
LY SARM 
 
8.1.1 
Description 
 
LY2452473 is a white to practically white solid. The chemical name is: carbamic acid, N-[(2S)-7-cyano-
1,2,3,4-tetrahydro-4-(2-pyridinylmethyl)cyclopent[b]indol-2-yl]-,1-methylester. The alternate chemical 
name is: (S)-(7-cyano-4-pyridin-2-ylmethyl-1,2,3,4-tetrahydro-cyclopenta[b]-carbamic acid isopropyl 
ester. The molecular formula is C22H22N4O2 and the molecular weight is 374.45 gmol-1. LY2452473 is 
practically insoluble in water, has a pKa of 3.17, pH of 9.2 and is stable when stored at room temperature. 
The chemical structure of LY2452473 is presented below: 
 
 
The plasma concentration-time profiles for LY2452473 after single dose up to 1000 mg showed 
measurable concentrations from 1 hour postdose, with maximum observed drug concentrations Cmax 4 to 
5 hours following dosing. The LY2452473 concentrations appeared to decline in a biexponential fashion 
characterized by a short distribution phase and a long terminal phase, with median terminal half-lives (t1/2) 
ranging between 26.6 and 55.1 hours across doses. Mean apparent oral clearance was low to moderate, 
ranging from 10.9 to 41.5 L/h across dose levels. The mean apparent volume of distribution at steady state 
(Vss/F) ranged from 388 to 2290 L across doses. Multiple dosing at 1 mg and 5 mg of LY2452473, also 
showed decline in a biexponential fashion characterized by a short distribution phase and a long terminal 
phase, with median terminal t½ ranging between 23.3 and 44.4 hours across doses The variability of Cmax 
at steady state (Cmax,ss) ranged from 14% to 84% across dose levels. The variability of AUC over the 
dosing interval at steady state (AUC[τ,ss]) ranged from 9% to 70% across dose levels. The pharmacokinetic 
characteristics observed supported once daily (QD) dosing. 
8.1.2 
Form 
LY2452473 is supplied for clinical use as an oral capsule drug product in size 2 opaque white gelatin 
capsules. Each capsule contains 1 mg, 5 mg or 15 mg of LY2452473 and the inactive ingredients 
pregelatinized starch and dimethicone. LY2452473 is intended to be supplied for the proposed clinical 
trial as capsules packaged in 30 count white, induction sealed high density polyethylene (HDPE) bottles 
with child-resistant closures. 
Our contractual agreement is with Transition Therapeutics.  The drug product will be packaged and 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
22 
 
distributed by Catalent Pharma Solutions, Kansas City, Missouri, USA. 
8.1.3 
Storage and Stability 
 
The drug product will be stored at room temperature (25°C) with allowable excursions between 15 - 
30°C. The drug product, previously packaged in blister packages (2 mil Aclar, 10 count), was shown to 
be stable for 2 years under long-term storage conditions and for 6 months under accelerated storage 
conditions. Stability of the drug product in the current packaging configuration (HDPE bottle with child 
resistant closure) will be monitored under both long-term and accelerated conditions to ensure that the 
product meets stability specifications over the duration of the proposed clinical trial.     
8.1.4 
Compatibility 
 
Not applicable, as no adjunctive therapies will be used. 
 
8.1.5 
Handling 
 
Qualified personnel, familiar with procedures that minimize undue exposure to themselves and the 
environment, should undertake the preparation, handling, and safe disposal of the chemotherapeutic 
agent in a self-contained and protective environment.  
 
Since the drug product is supplied as an oral capsule, no special precautions or safety equipment are 
required for dispensing of the drug. The drug product must be stored at room temperature (25°C). 
 
8.1.6 
Availability 
 
Collaborative Agreement – Not available 
 
The drug product will be packaged and distributed by Catalent Pharma Solutions, Kansas City, 
Missouri, USA. 
 
8.1.7 
Preparation 
 
Not Applicable. The drug will be supplied as an oral capsule (size 2 opaque white gelatin) packaged in 
30 count white, induction sealed high density polyethylene (HDPE) bottles with child-resistant closures.  
 
8.1.8 
Administration 
 
The study medication will be taken orally, daily for 12-weeks. 
 
8.1.9 
Ordering 
 
The investigational drug will be ordered through Transition Therapeutics via the Data Coordinating 
Center.  The drug product will then be shipped directly to each site’s pharmacy.   
 
8.1.10 Accountability 
 
The investigator, or a responsible party designated by the investigator, should maintain a careful record 
of the inventory and disposition of the agent using the NCI Drug Accountability Record Form (DARF) 
or another comparable drug accountability form.  (See the NCI Investigator’s Handbook for Procedures 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 02/05/2019 
23 
 
for Drug Accountability and Storage.) 
 
The site study staff, designated by the investigator, will maintain a record of the inventory and 
disposition of the drug using the drug accountability form. The BWH Investigational Drug Services will 
also maintain a record of the study medication received from the manufacturer, the amount of study drug 
dispensed, and the amount returned or destroyed. 
 
8.1.11 Destruction and Return 
 
The unused supplies of the study drug will be returned by the study staff to BWH Investigational Drug 
Services, recorded, and destroyed by the BWH IDS. 
 
8.2 
Placebo 
 
The capsules containing the placebo and the LY SARM will be identical and they will be packaged in 
identical bottles and the label will not indicate whether the bottle contains active medication or placebo. 
Each capsule contains inactive ingredients pregelatinized starch and dimethicone similar in amount to that in 
active drug-containing capsules.  
 
The manufacturer will provide bulk supplies of placebo and active LY SARM 1 mg, 5 mg and 15 mg 
capsules. Although the placebo and LY SARM capsules will be identical in appearance and will have 
identical packaging, the pharmacy will have information on which bottles contain placebo and which 
contain active drug.  The BWH Investigational Drug Service utilizes the Investigational Drug Service 
Informatics System (IDSIS) to dispense placebo and investigational products in numerous clinical trials. 
The Investigational Drug Service Informatics System (IDSIS) employs bar scanning technology to verify 
the investigational medications dispensed against the subject’s treatment assignment in the clinical trials. 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
24 
9. STUDY CALENDAR 
Table 3. Schedule of Events 
 
Pre-screening 
Screening 
Baseline 
Intervention Period 
Off Treatment 
Day or Week 
 
Day -42 to 
Randomization 
Week 
2 
Week 
4 
Week 
6 
Week 
8 
Week 
12 
30 Days Post 
Last Dose 
Visit Number 
 
1 
2A 
2B 
 3 
 4 
 5 
 6 
7A 
7B 
 
Study Procedure 
 
 
 
 
 
 
 
 
 
Phone Prescreening 
X 
 
 
 
 
 
 
 
 
Informed Consent 
 
X 
 
 
 
 
 
 
 
Demographics 
 
X 
 
 
 
 
 
 
 
Review of Eligibility Criteria 
 
X 
 
 
 
 
 
 
 
Medical History 
 
X 
 
 
 
 
 
 
 
Concomitant Medications 
 
X 
 
 
 
 
 
 
 
Short Physical Performance Battery (SPPB) 
 
X 
 
 
 
 
 
 
 
Average Weekly Alcohol Consumption 
X 
X 
X 
X 
X 
X 
X 
X 
 
Questionnaires 
 
X 
X 
 
 
X 
 
X 
 
- 
FACIT-F, DISF 
 
X 
 
 
 
X 
 
X 
 
- 
Harbor-UCLA 7-Day Diary, EPIC, MSHQ, PANAS, SF-36, IPSS, IIEF, 
HED, SAID 
 
 
X 
 
 
X 
 
X 
 
Vital Signs 
 
X 
X 
 
 
X 
 
X 
 
Blood Draw* 
 
X 
X 
X 
X 
X 
 
X 
 
- 
HbA1c 
 
X 
 
 
 
 
 
 
 
- 
CBC, CMP with eGFR§, lipid panel 
 
X 
X 
 
 
X 
 
X 
 
- 
PSA 
 
X 
 
X 
X 
X 
 
X 
 
- 
Total testosterone, calculated free testosterone, SHBG 
 
X 
X 
 
 
X 
 
X 
 
- 
DHT, LH, estradiol 
 
 
X 
 
 
X 
 
X 
 
Physical Exam 
 
X 
 
 
 
X 
 
X 
 
EKG 
 
X 
 
 
 
 
 
 
 
Whole Body DXA 
 
 
X 
 
 
 
 
X 
 
Muscle Performance, Physical Function, and Aerobic Capacity Tests** 
 
 
X 
 
 
 
 
X 
 
Randomization 
 
 
X 
 
 
 
 
 
 
Drug Dispensing
 
 
X 
 
X 
 
X 
 
 
Adverse Events Monitoring 
 
 
X 
X 
X 
X 
X 
X 
X 
Interim Status 
 
 
X 
X 
X 
X 
X 
X 
X 
Medication Compliance Check 
 
 
 
 
X 
 
X 
X 
 
Planned Follow-Up Phone Call 
 
 
 
 
 
 
 
 
X 
Additional Blood Draw for Substudy*** 
- 
Bone markers (osteocalcin, C-telopeptide, P1NP, bone specific 
alkaline phosphatase), Apolipoproteins (A1 and B, lipoprotein 
particles),  Inflammatory markers (CRP, IL-6, C1 esterase inhibitor), 
HDL efflux, (TC) Insulin, (TC) HbA1c
 
 
X 
 
 
X 
 
X 
 
Note: Intervention visits window is +/- 3 days. Screening procedures may take place over the course of two visits if necessary.  
Baseline and Week 12 procedures will take place over the course of two visits. 
*All blood draws are fasting and will be completed at or before 11:00. 
**Aerobic capacity testing and muscle strength and physical function testing will take place on separate days. 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
25 
***Optional substudy participants only 
§ eGFR will be calculated retrospectively. 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
26 
 
10. MEASUREMENT OF EFFECT 
10.1 
Primary Outcome 
Our primary outcome is change in sexual activity score, assessed by the Harbor-UCLA 7-day Sexual Function 
Questionnaire, because sexual dysfunction is one of the most prevalent symptoms in men, who have undergone 
radical prostatectomy, and it affects HRQOL. This scale has been used widely in testosterone trials, and sexual 
activity scores, assessed by this instrument, are responsive to therapy. The scale covers 3domains: 1) sexual desire 
and enjoyment;2) sexual activity; and 3) mood.  
 
10.2 
Secondary outcomes 
Other measures of sexual function. Erectile function will be assessed by IIEF, SAID, and DISF-M-II.  
The IIEF which has been validated in many trials of ED therapies, and shown to be responsive to androgen therapy 
in men with ED and low testosterone. The IIEF is a 15-item questionnaire that evaluates 5 response domains, 
including erectile function, intercourse satisfaction, and overall satisfaction. It has been shown to have high degree 
of specificity and sensitivity, reliability, internal consistency, and construct validity.  
The DISF-M-IIis a 25-item questionnaire that provides an estimate of perceived quality of sexual activities in 5 
response domains: sexual desire/drive, sexual arousal, sexual activity, orgasm, and sexual satisfaction/partner 
relationship. It comprehensively evaluates sexual desire and has been shown to have androgen-treatment sensitivity. 
The DISF-M was the main sexual function questionnaire in the NIA-funded The Testosterone Trial which is a trial of 
800 men evaluating the role of androgens on sexual function.  
The SAID is an 8-item questionnaire that evaluates 3 response domains, including sexual thinking, sexual arousal, 
and sexual activity. This questionnaire was validated using separate qualitative studies and provides an assessment 
of items associated with hypogonadism291, 292. 
Sexual desire will be assessed by Men’s Sexual Health Questionnaire (MSHQ) and by libido-related questions in 
IIEF, SAID, and DISF-M-II. MSHQ, a25-item questionnaire, provides a more robust assessment of libido than IIEF, 
especially in men with urogenital symptoms240, has high degree of internal consistency, reliability, and ability to 
discriminate between men with and without lower urinary tract symptoms (LUTS) and sexual dysfunction.  
We will measure the impact of androgen deficiency and sexual dysfunction on HRQOL using the hormonal and 
sexual domains of the Expanded Prostate Cancer Index Composite (EPIC). The EPIC is a 50-item, disease-
specific HRQOL questionnaire designed to evaluate the impact of treatments on HRQOL in men with prostate 
cancer. Of its four domains, we will utilize the sexual and hormonal domains, which are affected by androgen 
deficiency and expected to improve with SARM therapy, and which are important to men with prostate cancer but 
are not weighed appropriately in generic HRQOL instruments. This instrument has been used in numerous prostate 
cancer trials, and shown to have high Cronbach alpha coefficient, construct validity, and excellent sensitivity to 
change in response to hormonal treatment.  
Fatigue will be assessed by the 13-item Functional Assessment of Chronic Illness Therapy fatigue scale(FACIT-F) 
and by the 4-item Hypogonadism Energy Diary (HED).  
The FACIT-F has been well-validated and responsive to treatment. SF-36 Vitality scale has also been used to assess 
vitality, but the FACIT-F is more sensitive to change in those with low vitality/high fatigue than SF36. Another 
reason for selecting FACIT-F is its inclusion as “legacy instrument” for the NIH Roadmap PROMIS Fatigue item 
bank. This will ensure comparability to PROMIS.  
The HED has been validated using separate qualitative studies and provides an assessment of low energy related to 
hypogonadism291, 292. 
Mood and well-being will be assessed by PANAS affectivity balance scale, which includes 10 questions each for 
Positive Affect and Negative Affect. Many behavioral scientists consider affectivity balance as the cleanest window 
on an individual’s wellbeing. The affectivity balance incorporates negative affects (e.g., anxiety, depression) as well 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
27 
as positive affects (e.g., joy).Testosterone has been reported to improve mood and affect in hypogonadal men. 
Alphas for negative and positive affect scales are 0.85 and 0.88, respectively; one-week test-retest reliabilities are 
0.81 and 0.79. The instrument can detect changes in well being related to chronic illnesses and cancer. 
Muscle Performance and Physical Function. We will assess physical function by measuring walking speed in the 
6-min walk, stair climbing power, and load carrying time, self-reported physical function by the PF10 (physical 
function domain of MOS SF-36), maximal voluntary strength in the leg press exercise by the 1-RM method, and 
skeletal muscle mass by dual energy X-ray absorptiometry (DXA). We have used these measures in many previous 
trials and they have been shown to be androgen-responsive.  
Hormone Levels. Total testosterone, DHT and estradiol will be measured by LC-MS/MS, free testosterone by 
equilibrium dialysis, and LH by an IFMA. These methods have been used in PI’s lab for >25 yrs.  
Safety measures: We will measure PSA, complete blood counts, plasma lipids, AST, ALT, bilirubin and alkaline 
phosphatase levels for safety monitoring.  A structured evaluation of cardiovascular adverse events will be 
performed using a form, developed for NIA-funded T trials. 
Physiologic measures. We will measure lean body mass using dual energy X-ray absorptiometry (DXA), and 
maximal voluntary strength as mediators of improvements in physical function. VO2max and to a lesser extent VO2 
peak are markers of a person’s aerobic capacity. The lactate threshold is a marker of one’s capacity for prolonged, 
submaximal work without lactate accumulation and fatigue. We recognize that relationships of these physiologic 
mechanisms for aerobic energy production to fatigue are complex because in addition to these physiologic 
mechanisms, psychological factors, such as depressive symptoms, mood and wellbeing affect an individual’s 
perception of fatigue; accordingly, we will also assess mood and depressive symptoms. We propose to split the 
assessments for muscle performance and physical function into two non-consecutive days of testing in order to 
reduce subject burden and ensure more accurate data. 
At baseline, we propose to perform the cardiopulmonary exercise test (CPXT) alone on the first day of baseline 
testing. It is a longer test requiring progressively increasing subject effort to volitional fatigue and requires about 60 
minutes to administer. It also provides valuable safety data that may be used prior to other physical function 
assessments. The remainder of the tests (the 6-minute walk test, the stair climb power tests, the 50-m walk tests, and 
the leg press strength test)will be administered on the second day of baseline testing with appropriate and 
standardized rest periods between tests.  
At baseline, we propose to perform the cardiopulmonary exercise test (CPXT) alone on the first day of testing. It is a 
longer test requiring progressively increasing subject effort to volitional fatigue and requires about 60 minutes to 
administer. It also provides valuable safety data that may be used prior to other physical function assessments. The 
remainder of the tests (the 6-minute walk test, the stair climb power tests, the 50-m walk tests, and the leg press 
strength test)will be administered on the second day of baseline testing with appropriate and standardized rest 
periods between tests.  
For the Week-12 (end of study) assessments, efforts will be made to repeat the test procedures in the same sequence 
and time of day; however, they could be altered to accommodate subject convenience and scheduling.  
 
11. DATA REPORTING / REGULATORY REQUIREMENTS 
 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0 (Adverse Events: List 
and Reporting Requirements). 
 
11.1 
Data Reporting 
 
11.1.1 Method 
 
The ODQ will manage and coordinate quality checks on the data for this study. 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
28 
 
11.1.2 Responsibility for Data Submission 
 
All investigative sites are responsible for submitting data and/or data forms to the ODQ according to the 
schedule set by the ODQ. 
 
11.2 
Data Safety Monitoring 
 
In accordance with the National Institute of Nursing Research (NINR) requirements, an independent Data and 
Safety Monitoring Board will review and monitor study progress, toxicity, safety and other data from this study. The 
components of this committee and their safety review procedures are described in the NINR Data and Safety 
Monitoring Plan, located in Appendix B.” 
 
11.3 
Transmission of DSMB Recommendations and Summary Reports of Adverse Events to IRBs 
 
The transmission of DSMB Recommendations and Summary Reports of Adverse Events to IRBs for this trial is 
described in Appendix B.   
 
11.4 
Transmission of Summary of Closed Deliberations to the NINR Staff 
 
This is described in Appendix B.   
 
11.5 
Protecting the Confidentiality of Participant Data 
 
This is described in Appendix B.   
 
11.6 
Multicenter Guidelines 
 
This protocol will adhere to the policies and requirements of the DF/HCC Multi-Center Data and Safety Monitoring 
Plan.  The specific responsibilities of the Overall PI, Coordinating Center, and Participating Institutions and the 
procedures for auditing are presented in Appendix A. 
 
• The Overall PI/Coordinating Center is responsible for distributing all IND Action Letters or Safety Reports 
to all participating institutions for submission to their individual IRBs for action as required. 
 
• Mechanisms will be in place to ensure quality assurance, protocol compliance, and adverse event reporting at 
each site. 
 
• Except in very unusual circumstances, each participating institution will order the study agent(s) directly 
from supplier.  A participating site may order the agent(s) only after the initial IRB approval for the site has 
been forwarded to the Coordinating Center. 
 
11.7 
Collaborative Agreements Language 
N/A 
 
12. STATISTICAL CONSIDERATIONS 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
29 
STATISTICAL ANALYSIS 
 
12.1 
Descriptive Analyses 
 
Descriptive measures for each outcome and potential covariate will be computed. Graphical and tabular displays 
will be used to establish the distributional properties of outcomes and assess need for transformation. Preliminary 
assessments of association between covariates and outcomes will be obtained using semiparametric penalized 
likelihood approach implemented in generalized additive models256. We will use summary statistics and graphical 
techniques to compare baseline characteristics of groups.  
 
12.2 
Compliance Analysis 
 
Subject’s compliance will be assessed in terms of the number of doses used, based on pill counts, expressed as a 
percent of the total number of doses that should have been used.  
 
12.3 
Analytic plan 
 
Following appropriate variable transformations, the primary analysis will utilize mixed effects regression controlling 
for baseline values, randomization, and stratification. Primary inferential targets of interest will be difference in 
outcomes measures between the 4 arms, estimated using treatment contrasts. Secondary analyses will incorporate 
control for additional factors based on the results of exploratory analyses mentioned above. We will consider the 
possibility of potential bias due to three stages of enrollment by performing sensitivity analyses with stage effect 
adjustment293,294.Missing data will be accommodated using multiple imputation, with imputed values generated in 
accordance with the mixed effects model as implemented in the mice library in R257-259. Point estimates will be 
accompanied by 95% confidence intervals, and type-I error probability for hypothesis testing set at 0.05. Statistical 
analyses will be conducted using SAS version 9.3 or higher and R version 2.15.0.  
Specific Aim 1 is concerned with change in sexual function as measured by the Harbor-UCLA 7-day Sexual 
Function Questionnaire (SFQ) and other outcomes measured at baseline and during weeks 6 and 12. Six and 12 
week data will be analyzed simultaneously using mixed effects linear regression controlling for baseline measures as 
well as stratification factors (age and PDEI use), with site and subject treated as random effects. The primary 
analysis will be supplemented by comparisons of 12 week change in function, estimated via treatment contrast with 
statistical significance evaluated via likelihood ratio test. We will also compare the proportion of men achieving 
increase of >1 point on sexual function score (thought to approximate the minimal clinically important difference on 
the SFQ) using generalized estimating equations256 and modified Poisson regression approach257-259, which can 
accommodate repeated measurements and is preferable to odds ratio in prospective designs. If the rate of 
improvement is very low, a zero-inflated alternative will be considered210.  
 
Secondary Hypotheses. Specific Aim 2 is concerned with estimation of the effects of SARM administration on 
well-being, affectivity balance, fatigue and HRQOL. These will be obtained at randomization and at 6 and 12 
weeks. We will follow an analytic plan parallel to that described for Aim 1. Aim 3 is concerned with the effects of 
SARM on strength and physical function. As in Aims 1 and 2 we will utilize mixed effects regression. 
We will also consider further exploratory analyses of the primary endpoint. For example, we will use linear 
regression to determine whether changes in muscle strength and measures of physical function correlate with 
changes in muscle mass and whether improvements in aerobic capacity are associated with improved fatigue scores. 
Appropriate techniques will assess assumptions of linearity and homoscedasticity. 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
30 
12.4 
Missing data 
 
All subjects who are randomized will be included in the analyses. We will use multiple imputation using chained 
equations (MICE) to accommodate missing data. Further, our analyses will use simple linear mixed models that use 
additional intermediate time points when available. These methods use available information more efficiently, thus 
reducing type II error. We recognize that missingness may be associated with outcome, in which case there exists 
the potential for biased estimates of treatment effect. Sensitivity analyses will be employed to assess this possibility.  
 
12.5 
Sample Size Estimates and Power Considerations 
 
Initially, we had estimated that 126 men will be needed to test the primary hypothesis based on assumptions of two 
sided type I error rate of 0.05, attrition rate of 20% and 90% power. Our primary outcome is change in sexual 
activity score derived from Harbor-UCLA Seven Day Sexual Function Questionnaire221. The primary targets of 
estimation was overall dose effect as well as the direct comparison of highest dose group (15 mg) to placebo, 
however due to stoppage of 15-mg dose group, the primary aim of this study will be comparison of 5-mg group to 
placebo. There are no randomized trial data on the effects of SARM on sexual function in men with prostate cancer. 
In several trials in hypogonadal men178, 183-184, testosterone therapy increased sexual activity score by an average of 
1.5 points. Here we assume that the difference of interest in the change in sexual activity score between the 15 mg 
dose and placebo over 3 months is 1.5 points with a standard deviation of 1.8 (1.27 within each group). We estimate 
that the difference between 1 mg and placebo is 0.3 points with SD 1.2 and, as previously assumed, between 5 mg 
and placebo is 1.2 with SD 1.8. Under these assumptions, group allocation of 36:28:36:14 (for placebo, 1mg, 5 mg 
and 15 mg groups, respectively) subjects per arm will achieve more than 95% power to reject the null hypothesis of 
no overall dose effect, and to detect the difference between the 15 mg group and placebo. As enrollment to 15-mg 
group has been stopped and insufficient number of participants were randomized to this group (N=14), there will not 
be any formal analysis testing difference between 15-mg arm to placebo. 
 
We will similarly obtain good power to detect clinically meaningful effects on other measures of sexual function. 
We hypothesize that the mean difference in change in sexual desire scores between the 15 mg and placebo groups is 
1.8 (SD 2.1). The proposed sample size has >95% power to detect this difference. Similarly, we will obtain >95% 
power to detect between group differences of 4 points in change in erectile function domain (EFD) of International 
Index of Erectile Dysfunction (IIEF) (assumed SD 6 points), a threshold deemed clinically significant222-225. The 
average increase in EFD score in trials of PDE5 inhibitors is 7153, 226-228. 
 
Assuming mean (SD) LBM changes of 0 (1) kg in placebo, 0.8 (1.2) at 1 mg, 1.5 (2.1) kg at 5 mg and 1.8 (2.1) kg at 
15 mg dose, simulation results indicate that this design achieves more than 90% power to demonstrate an overall 
dose-response relationship and to detect the advantage of 15 mg dose over placebo, where both tests are performed 
at the 0.05 level. Using the Holm-Bonferroni correction for these two non-independent hypotheses (both hypotheses 
must be rejected at the 0.05 level, and at least one at the 0.025 level, preserving the overall type-I error rate of 0.05), 
results indicate that the design achieves more than 80% power to reject both nulls simultaneously. Recent SARM 
trials have reported average gains of ~1.5 kg in lean body mass45, 48,116. In a testosterone trial in HIV-infected men, a 
difference of 2.9 kg in fat-free mass was observed between testosterone and placebo groups173. Testosterone trials in 
older men that used smaller doses of testosterone observed an increase of ~1.5 kg186.  
 
We anticipate that the change in leg press strength at 15 mg dose will be 15 kg (SD 18), at 5 mg dose 12 kg (SD 18 
kg) and at the 1 mg dose 4 kg (SD 6 kg), while placebo group is assumed to have no increase (SD 6). This 
assumption is based on testosterone trials in older men175,195, HIV-infected men173, and in men with COPD185. A 15 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
31 
 kg increase in leg press strength is deemed clinically significant because a 10 kg increase in leg strength was 
associated with improvements in walking speed232. Under these assumptions, simulation results demonstrate that the 
planned randomization will provide >90% power to jointly detect an overall dose-response pattern and a significant 
difference between the5 mg and placebo groups. In a SARM trial48, the increase in stair climbing power in men 
receiving enobosarm averaged 15% (SD 20%). The proposed sample size provides >80% power to detect a similar 
difference between 5 mg and placebo arms. For physical function domain of MOS-SF36, the difference of interest 
between 5 mg and placebo group is 4 points (SD 7 points), which is a moderate effect.  
 
In randomized trials in older men with low testosterone, the difference in change in physical function domain score 
between testosterone and placebo groups was 4 points186. Ware et al233 have determined that a 4-point change in the 
physical function domain of the MOS SF36 score is clinically meaningful. A proposed sample size provides >80% 
power to detect this effect size between placebo and 5 mg dose group.   
 
Absent intervention, the clinical PSA recurrence rate in this group of men should be <1% over 10 years54-57, so that 
few, if any clinical recurrences, are expected in the placebo arm over the three-month trial duration. We likewise 
anticipate few if any recurrences among subjects randomized to SARM. To insure that analyses are sensitive to even 
limited evidence of safety concerns, we will conduct a one-sided comparison of the proportion of subjects 
experiencing events in each arm using a Fisher’s exact test with type-I error probability set at 0.20, as recommended 
by some FDA panels. Assuming recurrence risk on placebo is 1%, this comparison will have 85% power to detect 
an increased risk of 10% in the 15 mg group.  
 
To accommodate attrition of up to 20%, we will enroll 37:25:37:36 men (for placebo, 1 mg, 5 mg and 15 mg groups, 
respectively) for a total of 135 men. Assumption of 20% attrition rate is conservative; the attrition in our 
testosterone trial in older men was 12%174. Even in a 3-year intervention trial to determine the effects of testosterone 
on atherosclerosis, the loss-to-follow-up has been <20%. The incorporation of 6-week measurement in the mixed 
effects model and the inclusion of all 114 subjects made possible by use of multiple imputation will provide even 
higher power than that claimed here.  
 
12.6 
DATA MANAGEMENT 
 
The Data Management Center (DMC) will provide data management and statistical programming under the 
supervision of Dr. Travison. A randomization application will be available online. Upon completion of Eligibility 
Form, a subject ID will be generated, and the randomization table will be queried for study arm designation. 
Database will track subjects, provide documentation of eligibility and consent, and provide alerts to study staff 
about due dates. The database will reside on a secure, password protected server, and backed up on a nightly basis. 
The DMC will prepare standardized data collection forms to ensure that all data fields are unambiguous, items are 
easily read, response categories are in standardized units, and the instructions are clearly worded. Validation rules 
including built-in edits such as range and logic checks will be incorporated into the verification process. After forms 
have been verified, programming codes will check across-form internal inconsistencies. The statistical programmer 
will be responsible for cleaning the data, creating analytic data sets, standardized protocols for coding data, and a 
data dictionary of variables, and for writing the analysis code for all analyses. 
 
The target sample size is 114 participants study-wide.  In order to randomize 114 subjects, we estimate that we will 
need 450 subjects to enroll (sign consent).  The study intervention includes placebo and three doses of LY SARM ( 
1, 5 and 15 mg daily).  It is planned for the recruitment to be split among the Brigham and Womens Hospital 
(BWH), the University of Florida (UFL), and Johns Hopkins Medical Institutes (JHMI). Ultimately, it is planned to 
have 68 subjects randomized at BWH, 27 subjects randomized at UFL, and 40 subjects randomized at Johns 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
32 
Hopkins Medical Institute.  A target sample size of 114 participants from two trial sites will have >90% power to 
test the primary hypothesis. 
 
Randomization: After protocol amendment, last 10 subjects who meet the eligibility criteria will be randomized to 
either the placebo or 5mg SARM daily.  Due to inclusion of new treatment arm (15 mg) in the study and stopping 
enrollment into the 1 mg group, and later stopping enrollment into the 15-mg group, participants will have been 
randomized in three stages. In the first stage, then=80 subjects were randomized to one of 3 groups: placebo, 1 mg 
and 5 mg, with allocation ratio of 1:1:1; this randomization scheme was ended after the amendment was approved. 
In the second stage, (according to protocol amendment, after stopping the enrolment in 1 mg group and inclusion of 
new 15 mg LYSARM dose group) N=24 participants were randomized with allocation ratio of 1:1:3 to placebo, 5 
mg and 15 mg groups, respectively. In the third stage, after stopping the enrollment in 15-mg group, due to safety 
signal, we anticipate to randomize 10 more participants with allocation ratio 3:2 (6 in placebo and and 4 in 5-mg 
dose). At the end of the trial we expect to enroll 114 participants (80 in the first stage, 24 in the second stage and 10 
in the third stage) with group allocation of 36:28:36:14 participants, for placebo, 1 mg, 5 mg and 15 mg groups, 
respectively.. The subject assignment will be based on the randomization tables, using permuted blocks with varying 
blocks sizes. Subjects will be stratified by age (19-50 and >50) and use of phosphodiesterase 5 inhibitors (PDEIs); 
PDEIs may influence sexual function (and mood and HRQOL) independently228-231. Stratification variables will be 
included as covariates in analyses. 
 
12.7 
Sample Size, Accrual Rate and Study Duration 
 
The revised planned sample size is114.  Enrollment is targeted to be completed in 3years from start of study 
initiation.  We anticipate that enrollment will average 45 subjects per year over the three years.  If enrollment is 
slower at the start, efforts will be enhanced to meet the 3 year enrollment goal.  There is a 12-week intervention 
period after the screening and baseline measures are obtained.  Section 9 of this document contains the Schedule of 
Events. Women are not eligible for this trial as this is a study of men with prostate cancer. 
 
 
 
Accrual Targets 
Ethnic Category 
Sex/Gender 
Females 
 
Males 
 
Total 
Hispanic or Latino 
0 
+ 
17 
= 
17 
Not Hispanic or Latino 
0 
+ 
118 
= 
118 
Ethnic Category: Total of all subjects 
0 
(A1) + 
135 
(B1) = 
135 
(C1) 
Racial Category 
 
American Indian or Alaskan Native 
0 
+ 
1 
= 
1 
Asian 
0 
+ 
1 
= 
1 
Black or African American 
0 
+ 
13 
= 
13 
Native Hawaiian or other Pacific 
Islander 
0 
+ 
0 
= 
0 
White 
0 
+ 
120 
= 
120 
Racial Category: Total of all subjects 
0 
(A2) + 
135 
(B2) = 
135 
(C2) 
 
(A1 = A2) 
 
(B1 = B2) 
 
(C1 = C2) 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
33 
12.8 
Stratification Factors 
 
There is no stratification in this study design. 
 
12.9 
Interim Monitoring Plan 
 
Please refer to the Data Safety Monitoring Plan in Section 11. 
 
12.10 Analysis of Primary Endpoints 
 
Please reference the analysis section 12 of this document. 
 
12.11 Analysis of Secondary Endpoints 
 
Please reference the analysis section 12 of this document. 
 
12.12 Reporting and Exclusions 
 
12.13 Evaluation of Toxicity 
Please reference Section 5.5 of this document. 
 
12.14 Evaluation of the Primary Efficacy Endpoint 
 
Please reference Section 12 of this document. 
 
13. 
PUBLICATION PLAN 
 
 
The results will be made public within 24 months of reaching the end of the study. The end of the study is the time 
point at which the last data items are to be reported, or after the outcome data are sufficiently mature for analysis.  
 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
34 
REFERENCES 
 
1. 
Morgentaler A 2009 Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J 
Urol 181:972-979. PMID: 19150547 
2. 
Morgentaler A 2007 Testosterone replacement therapy and prostate cancer. Urol Clin North Am 34:555-563, vii. 
PMID: 17983895 
3. 
Morgentaler A 2008 Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate 
cancer. J Sex Med 5:1834-1840. PMID: 18547385 
4. 
Khera M, E.D. G, Najari B, Colen JS, Mohamed O, D.J. L, Lipshultz LI 2009 Testosterone replacement therapy 
follwing radical prostatectomy. J Sex Med 6:1165-1170. PMID: 19207277 
5. 
Khera M, Lipshultz LI 2007 The role of testosterone replacement therapy following radical prostatectomy. Urol 
Clin North Am 34:549-553, vi. PMID: 17983894 
6. 
Kaufman JM, Graydon RJ 2004 Androgen replacement after curative radical prostatectomy for prostate cancer 
in hypogonadal men. J Urol 172:920-922. PMID: 15310998 
7. 
Agarwal PK, Oefelein MG 2005 Testosterone replacement therapy after primary treatment for prostate cancer. J 
Urol 173:533-536. PMID: 15643240 
8. 
Nabulsi O, Tal R, Gotto G, Narus J, Goldenberg L, Mulhall JP 2008 Outcomes analysis of testosterone 
supplementation in hypogonadal men following radical prostatectomy. J Urol 179 (suppl):406 (abstract 1181) 
9. 
Davila HH, Arison CN, Hall MK, Salup P, Lockhart JL, Carrion RE 2008 Analysis of the PSA response after 
testosterone supplementation in patients who have previously received management for their localized prostate 
cancer, . J Urol 179 (suppl.) 428 (abstract 1247) 
10. 
Kaufman J 2006 A rational approach to androgen therapy for hypogonadal men with prostate cancer. Int J Impot 
Res 18:26-31. PMID: 16208401 
11. 
Khera M 2009 Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal 
men. J Sex Med 6 Suppl 3:234-238. PMID: 19207279 
12. 
Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA 2008 Low testosterone and risk of 
biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology 72:1240-
1245. PMID: 18692874 
13. 
Maliski SL, Kwan L, Elashoff D, Litwin MS 2008 Symptom clusters related to treatment for prostate cancer. 
Oncology nursing forum 35:786-793. PMID: 18765324 
14. 
Maliski SL, Kwan L, Orecklin JR, Saigal CS, Litwin MS 2005 Predictors of fatigue after treatment for prostate 
cancer. Urology 65:101-108. PMID: 15667873 
15. 
Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky 
AL 2000 Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the 
Prostate Cancer Outcomes Study. Jama 283:354-360. PMID: 10647798 
16. 
Helgason AR, Adolfsson J, Dickman P, Arver S, Fredrikson M, Steineck G 1997 Factors associated with waning 
sexual function among elderly men and prostate cancer patients. J Urol 158:155-159. PMID: 9186344 
17. 
Clark JA, Rieker P, Propert KJ, Talcott JA 1999 Changes in quality of life following treatment for early prostate 
cancer. Urology 53:161-168. PMID: 9886606 
18. 
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
35 
Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT 
2008 Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250-
1261. PMID: 18354103 
19. 
Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE 2007 Quality of life after surgery, 
external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 109:2239-2247. PMID: 
17455209 
20. 
Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH 1995 Quality-of-life outcomes in men 
treated for localized prostate cancer. Jama 273:129-135. PMID: 7799493 
21. 
Litwin MS, Nied RJ, Dhanani N 1998 Health-related quality of life in men with erectile dysfunction. J Gen 
Intern Med 13:159-166. PMCID: PMC1496922 
22. 
Penson DF, Latini DM, Lubeck DP, Wallace K, Henning JM, Lue T 2003 Is quality of life different for men 
with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? 
Results from the ExCEED data base. J Urol 169:1458-1461. PMID: 12629383 
23. 
Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM 1999 Sexual function and bother 
after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. 
Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 54:503-508. PMID: 10475362 
24. 
Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM 2006 
Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice 
guideline. J Clin Endocrinol Metab 91:1995-2010. PMID: 16720669 
25. 
Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld 
B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC 2008 Investigation, treatment and 
monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J 
Endocrinol 159:507-514. PMID: 18955511 
26. 
Isaacs JT 1984 Antagonistic effect of androgen on prostatic cell death. Prostate 5:545-557. PMID: 6483690   
27. 
Berry PA, Maitland NJ, Collins AT 2008 Androgen receptor signalling in prostate: effects of stromal factors on 
normal and cancer stem cells. Mol Cell Endocrinol 288:30-37. PMID: 18403105 
28. 
Ergun A, Lawrence CA, Kohanski MA, Brennan TA, Collins JJ 2007 A network biology approach to prostate 
cancer. Molecular systems biology 3:82. PMCID: PMC1828752 
29. 
Heinlein CA, Chang C 2004 Androgen receptor in prostate cancer. Endocr Rev 25:276-308. PMID: 15082523 
30. 
Wu CP, Gu FL 1991 The prostate in eunuchs. Prog Clin Biol Res 370:249-255. PMID: 1924456 
31. 
Ray G, Dhar G, Van Veldhuizen PJ, Banerjee S, Saxena NK, Sengupta K, Banerjee SK 2006 Modulation of 
cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through 
multiple signal transduction pathways. Biochemistry 45:3703-3713. PMID: 16533053 
32. 
Huggins C, Hodges CV 1941 Studies on prostate cancer. I. The effects of castration, of estrogen, and of 
androgen injection on serum phosphatases in metastatic carcinoma of the prostate. . Cancer Res 1:293 
33. 
Fowler JE, Jr., Whitmore WF, Jr. 1981 The response of metastatic adenocarcinoma of the prostate to exogenous 
testosterone. J Urol 126:372-375. PMID: 7277602 
34. 
Prout GR, Brewer WR 1967 Response of men with advanced prostatic carcinoma to exogenous administration 
of testosterone. Cancer 20:1871. PMID: 4168724 
35. 
Roddam AW, Allen NE, Appleby P, Key TJ 2008 Endogenous sex hormones and prostate cancer: a 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
36 
collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170-183. PMID: 18230794 
35. 
Shaneyfelt T, Husein R, Bubley G, Mantzoros CS 2000 Hormonal predictors of prostate cancer: a meta-analysis. 
J Clin Oncol 18:847-853. PMID: 10673527 
36. 
Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ 1996 Prospective study of sex hormone levels and 
risk of prostate cancer. J Natl Cancer Inst 88:1118-1126. PMID: 8757191 
37. 
Comstock GW, Gordon GB, Hsing AW 1993 The relationship of serum dehydroepiandrosterone and its sulfate 
to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev 2:219-221. PMID: 8318873 
38. 
Hsing AW, Comstock GW 1993 Serological precursors of cancer: serum hormones and risk of subsequent 
prostate cancer. Cancer Epidemiol Biomarkers Prev 2:27-32. PMID: 8420607 
39. 
Vatten LJ, Ursin G, Ross RK, Stanczyk FZ, Lobo RA, Harvei S, Jellum E 1997 Androgens in serum and the risk 
of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol 
Biomarkers Prev 6:967-969. PMID: 9367072 
40. 
Hoffman MA, DeWolf WC, Morgentaler A 2000 Is low serum free testosterone a marker for high grade prostate 
cancer? J Urol 163:824-827. PMID: 10687985 
41. 
Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, 
Bostwick DG, Macairan ML, Nelson PS 2006 Effect of testosterone replacement therapy on prostate tissue in 
men with late-onset hypogonadism: a randomized controlled trial. Jama 296:2351-2361. PMID: 17105798 
42. 
Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ 
2006 Persistent intraprostatic androgen concentrations after medical castration in healthy men.J Clin Endocrinol 
Metab 2006;91:3850-6. 
43. 
Sarosdy MF 2007 Testosterone replacement for hypogonadism after treatment of early prostate cancer with 
brachytherapy. Cancer 109:536-541. PMID: 17183557 
44. 
Rhoden EL, Morgentaler A 2003 Testosterone replacement therapy in hypogonadal men at high risk for prostate 
cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 170:2348. PMID: 
14634413 
45. 
Bhasin S, Calof OM, Storer TW, et al 2006 Drug insight: Testosterone and selective androgen receptor 
modulators as anabolic therapies for chronic illness and aging. Nature Clinical Practice Endocrinol Metab 2:146-
159 
46. 
Bhasin S, Jasuja R 2009 Selective androgen receptor modulators as function promoting therapies. Curr Opin 
Clin Nutr Metab Care 12(3):232-40.  
47. 
Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT 2008 Selective androgen receptor modulators in 
preclinical and clinical development. Nuclear Receptor Signaling 6:e010 
48. 
Dalton JT, Barnette KG, Bohl CE, et al 2011 The selective androgen receptor modulator GTx-024 (enobosarm) 
improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a 
double-blind, placebo-controlled phase II trial.J Cachexia Sarcopenia Muscle 2:153-161 
49. 
Miner JN, Chang W, Chapman MS, et al 2007 An orally active selective androgen receptor modulator is 
efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology 148:363-373 
50. 
Schmidt A, Kimmel DB, Bai C, et al 2010 Discovery of the selective androgen receptor modulator MK-0773 
using a rational development strategy based on differential transcriptional requirements for androgenic 
anabolism versus reproductive physiology.J Biol Chem 285:17054-64. 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
37 
51. 
Gao W, Dalton JT 2007 Expanding the therapeutic use of androgens via selective androgen receptor modulators 
(SARMs).Drug Discov Today 12(5-6):241-8. 
52. 
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ 2008 Cancer statistics, 2008. CA Cancer J Clin 
58:71-96. PMID: 18287387 
53. 
Siegel R, Ward E, Brawley O, Jemal A 2011 Cancer statistics: the impact of eliminating socioeconomic and 
racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:21236 
54. 
Hernandez DJ, Nielsen ME, Han M, Trock BJ, Partin AW, Walsh PC, Epstein JI 2008 Natural history of 
pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. 
Urology 72:172-176. PMCID: PMC2603620 
55. 
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw 
AA, Kaplan I, Beard CJ, Wein A 1998 Biochemical outcome after radical prostatectomy, external beam 
radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 280:969-974. 
PMID: 9749478 
56. 
Stokes SH 2000 Comparison of biochemical disease-free survival of patients with localized carcinoma of 
the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or 
definitive external beam irradiation. Int J Radiat Oncol Biol Phys 1;47:129-36. 
57. 
Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC 2004 Five-year 
outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl 
Cancer Inst 96:1358-1367. PMID: 15367568 
58. 
Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan 
LC 2000 Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate 
Cancer Outcomes Study. J Natl Cancer Inst 92:1582-1592. PMID: 11018094 
59. 
Dillioglugil O, Miles BJ, Scardino PT 1995 Current controversies in the management of localized prostate 
cancer. Eur Urol 28:85-101.  
60. 
Ficarra V, Novara G, Galfano A, Stringari C, Baldassarre R, Cavalleri S, Artibani W 2006 Twelve-month self-
reported quality of life after retropubic radical prostatectomy: a prospective study with Rand 36-Item Health 
Survey (Short Form-36). BJU Int 97:274-278. PMID: 16430628   
61. 
Schapira MM, Lawrence WF, Katz DA, McAuliffe TL, Nattinger AB 2001 Effect of treatment on quality of life 
among men with clinically localized prostate cancer. Medical care 39:243-253. PMID: 11242319 
62. 
Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman J, 
Goldernberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM, Thrasher JB, Thomson I 2007 
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the AUA 
Guidelines for localized prostate cancer update panel report and recommendations for a standard in reporting 
surgical outcomes  J Urol 177:540-545. PMID: 17222629 
63. 
Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, Marberger M 2001 High-grade 
prostate cancer is associated with low serum testosterone levels. Prostate 47:52-58. PMID: 11304729   
64. 
Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG 2006 Circulating 
steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15:86-91. PMID: 
16434592 
65. 
Morgentaler A, Bruning CO, 3rd, DeWolf WC 1996 Occult prostate cancer in men with low serum testosterone 
levels. Jama 276:1904-1906. PMID: 8968017 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
38 
66. 
Ahluwalia B, Jackson MA, Jones GW, Williams AO, Rao MS, Rajguru S 1981 Blood hormone profiles in 
prostate cancer patients in high-risk and low-risk populations. Cancer 48:2267-2273. PMID: 7296478.  
67. 
Chen SS, Chen KK, Lin AT, Chang YH, Wu HH, Chang LS 2002 The correlation between pretreatment serum 
hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 89:710-
713. PMID: 11966629 
68. 
Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR 2001 Longitudinal effects of aging on serum total 
and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 
86:724-731. PMID: 11158037 
69. 
Orwoll E, Lambert LC, Marshall LM, Blank J, Barrett-Connor E, Cauley J, Ensrud K, Cummings SR 2006 
Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med 166:2124-
2131. PMID: 17060543 
70. 
Gray A, Feldman HA, McKinlay JB, Longcope C 1991 Age, disease, and changing sex hormone levels in 
middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73:1016-1025. 
PMID: 1719016 
71. 
Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, Papoz L 1992 The influence of 
aging on plasma sex hormones in men: the Telecom Study. Am J Epidemiol 135:783-791. PMID: 1595678   
72. 
Baumgartner RN, Waters DL, Morley JE, Patrick P, Montoya GD, Garry PJ 1999 Age-related changes in sex 
hormones affect the sex difference in serum leptin independently of changes in body fat. Metabolism 48:378-
384. PMID: 10094117 
73. 
Morley JE, Kaiser FE, Perry HM, 3rd, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ 
1997 Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy 
older men. Metabolism 46:410-413. PMID: 9109845 
74. 
Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, 
Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D 2008 Hypothalamic-pituitary-testicular axis 
disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging 
Study. J Clin Endocrinol Metab 93:2737-2745. PMID: 18270261 
75. 
Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH 1997 Longitudinal relation between 
endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of 
former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol 146:609-617. PMID: 9345114 
76. 
Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB 2002 
Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from 
the Massachusetts male aging study. J Clin Endocrinol Metab 87:589-98. 
77. 
Ferrini RL, Barrett-Connor E 1998 Sex hormones and age: a cross-sectional study of testosterone and estradiol 
and their bioavailable fractions in community-dwelling men. Am J Epidemiol 147:750-4. 
78. 
Dai WS, Kuller LH, LaPorte RE, Gutai JP, Falvo-Gerard L, Caggiula A 1981 The epidemiology of plasma 
testosterone levels in middle-aged men. Am J Epidemiol 114:804-16. 
79. 
Liverman CT, Blazer DG 2004 Testosterone and aging: clinical research directions. Washington, DC: National 
Academies Press. 
80. 
Burnett AL 2005 Erectile dysfunction following radical prostatectomy. Jama 293:2648-2653. PMID: 15928287 
81. 
Hyun JS. Prostate cancer and sexual function.World J Mens Health 2012;30:99-107. PMID: 596596 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
39 
82. 
Basaria S 2008 Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient 
truth. J Androl 29:534-539. PMID: 18567642 
83. 
Basaria S 2009 Prostate cancer: Cardiovascular mortality and androgen deprivation. Nature reviews 6:252-253. 
PMID: 19424172 
84. 
Basaria S, Lieb J, 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS 2002 Long-term effects of 
androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 56:779-786 
85. 
Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS 2006 Hyperglycemia and insulin resistance in men with 
prostate carcinoma who receive androgen-deprivation therapy. Cancer 106:581-588. PMID: 16388523 
86. 
Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS 2007 Relation between duration of androgen deprivation 
therapy and degree of insulin resistance in men with prostate cancer. Arch Intern Med 167:612-613. PMID: 
17389294 
87. 
Smith MR, Lee H, Nathan DM 2006 Insulin sensitivity during combined androgen blockade for prostate cancer. 
J Clin Endocrinol Metab 91:1305-1308. PMID: 16434464 
88. 
Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR 2004 Osteoporosis in men with prostate carcinoma 
receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100:892-899. 
PMID: 14983482 
89. 
Pirl WF, Siegel GI, Goode MJ, Smith MR 2002 Depression in men receiving androgen deprivation therapy for 
prostate cancer: a pilot study. Psycho-oncology 11:518-523. PMID: 12476433.  
90. 
Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS 
2001 The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in 
males with prostate cancer. J Clin Endocrinol Metab 86:4261-4267. PMID: 11549659 
91. 
Smith MR 2002 Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 60:79-85; 
discussion 86. PMID: 12231056 
92. 
Smith MR 2004 Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. 
Urology 63:742-745. PMID: 15072892 
93. 
Smith MR, Fallon MA, Goode MJ 2003 Cross-sectional study of bone turnover during bicalutamide 
monotherapy for prostate cancer. Urology 61:127-131. PMID: 12559282 
94. 
Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW 2002 Changes 
in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599-
603. PMID: 11836291 
95. 
Penson DF, Litwin MS 2003 The physical burden of prostate cancer. Urol Clin North Am 30:305-313. PMID: 
12735506 
96. 
Glickman L, Godoy G, Lepor H 2009 Changes in continence and erectile function between 2 and 4 years after 
radical prostatectomy. J Urol 181:731-735. PMID: 19091349 
97. 
Masterson TA, Wedmid A, Sandhu JS, Eastham JA 2009 Outcomes after radical prostatectomy in men receiving 
previous pelvic radiation for non-prostate malignancies. BJU Int. PMID: 19239447 
98. 
Mulhall JP 2008 Penile rehabilitation following radical prostatectomy. Current opinion in urology 18:613-620. 
PMID: 18832948 
99. 
Mulhall JP 2009 Defining and reporting erectile function outcomes after radical prostatectomy: challenges and 
misconceptions. J Urol 181:462-471. PMID: 19084865 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
40 
100. 
Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, 
Potosky AL, Stanford JL 2008 5-year urinary and sexual outcomes after radical prostatectomy: results from the 
Prostate Cancer Outcomes Study. J Urol 179:S40-44. PMID: 18405749 
101. 
Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie 
JP, Kantoff PW 1998 Patient-reported symptoms after primary therapy for early prostate cancer: results of a 
prospective cohort study. J Clin Oncol 16:275-283. PMID: 9440753 
102. 
Talcott JA, Rieker P, Propert KJ, Clark JA, Wishnow KI, Loughlin KR, Richie JP, Kantoff PW 1997 Patient-
reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 89:1117-
1123. PMID: 9262249 
103. 
Fowler FJ, Jr., Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE 1993 Patient-reported complications 
and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated 
June 1993). Urology 42:622-629. PMID: 8256394 
104. 
Crawford ED, Blumenstein BA, Goodman PJ, Davis MA, Eisenberger MA, McLeod DG, Spaulding JT, Benson 
R, Dorr FA 1990 Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66:1039-1044. 
PMID: 2118417 
105. 
Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, 
Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J 
Med 321:419-424. PMID: 2503724 
106. 
Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, 
Culkin DJ, Thompson IM, Jr., Bueschen AJ, Lowe BA 1998 Bilateral orchiectomy with or without flutamide for 
metastatic prostate cancer. N Engl J Med 339:1036-1042. PMID: 9761805 
107. 
Maroni PD, Crawford ED 2008 The benefits of early androgen blockade. Best practice & research 22:317-329. 
PMID: 18471789 
108. 
Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD 2006 Neo-adjuvant and adjuvant hormone 
therapy for localised and locally advanced prostate cancer. Cochrane database of systematic reviews 
(Online):CD006019. PMID: 17054269 
109. 
Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, Stephenson RA, Hoover DR, 
Rajaram L, Mazer NA 1997 Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced 
testosterone transdermal system. Urology 49:191-196. PMID: 9037280 
110. 
Behre HM, Bohmeyer J, Nieschlag E 1994 Prostate volume in testosterone-treated and untreated hypogonadal 
men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 40:341-349. PMID: 7514512 
111. 
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, 
Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW 2001 Testosterone dose-response 
relationships in healthy young men. Am J Physiol Endocrinol Metab 281:E1172-1181. PMID: 11701431 
112. 
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, 
Dzekov J, Magliano L, Storer TW 2005 Older men are as responsive as young men to the anabolic effects of 
graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 90:678-688. PMID: 15562020. 
113. 
Wu CP, Gu FL 1987 The prostate 41-65 years post castration. An analysis of 26 eunuchs. Chin Med J (Engl) 
100:271-272 
114. 
Wu CP, Gu FL 1991 The prostate in eunuchs. Prog Clin Biol Res 370;249-255 PMID: 1924456 
115. 
Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M 2011 Testosterone therapy in men 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
41 
with untreated prostate cancer.J Urol 185:1256-60. PMID: 21334649 
116. 
Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, Ulloor J, Zhang A, Eder R, Zientek H, Gordon 
G, Kazmi S, Sheffield-Moore M, Bhasin S 2012 The Safety, Pharmacokinetics, and Effects of LGD-4033, a 
novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.J Gerontol A Biol Sci 
Med Sci 2012 Mar 28. PMID: 11549629 
117. 
Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS 2013 Effects 
of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised 
controlled phase 2 trial.Lancet Oncol 14:335-45. PMID: 23499390 
118. 
Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC 2003 Biochemical (prostate specific antigen) 
recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-
523. PMID: 12544300 
119. 
Kupelian PA, Katcher J, Levin HS, Klein EA 1997 Stage T1-2 prostate cancer: a multivariate analysis of factors 
affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 37:1043-
1052. PMID: 9169811 
120. 
Bhasin S, Enzlin P, Coviello A, Basson R 2007 Sexual dysfunction in men and women with endocrine disorders. 
Lancet 369:597-611. PMID: 17307107 
121. 
Davidson JM, Camargo CA, Smith ER 1979 Effects of androgen on sexual behavior in hypogonadal men. J Clin 
Endocrinol Metab 48:955-958. PMID: 447801 
122. 
Davidson JM, Kwan M, Greenleaf WJ 1982 Hormonal replacement and sexuality in men. Clin Endocrinol 
Metab 11:599-623. PMID: 6814798 
123. 
Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM 1983 The nature of androgen action on male sexuality: 
a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 57:557-562. PMID: 
6874890 
124. 
Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, 
Swerdloff RS 2004 Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual 
function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 
89:2085-2098. PMID: 15126525 
125. 
Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman 
N 2000 Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition 
parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 85:2839-2853. PMID: 
10946892 
126. 
Alexander GM, Sherwin BB 1991 The association between testosterone, sexual arousal, and selective attention 
for erotic stimuli in men. Horm Behav 25:367-381. PMID: 1937428 
127. 
Arver S, Dobs AS, Meikle AW, Allen RP, Sanders SW, Mazer NA 1996 Improvement of sexual function in 
testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 
155:1604-1608. PMID: 8627833 
128. 
Carani C, Bancroft J, Granata A, Del Rio G, Marrama P 1992 Testosterone and erectile function, nocturnal 
penile tumescence and rigidity, and erectile response to visual erotic stimuli in hypogonadal and eugonadal men. 
Psychoneuroendocrinology 17:647-654. PMID: 1287683 
129. 
Carani C, Granata AR, Bancroft J, Marrama P 1995 The effects of testosterone replacement on nocturnal penile 
tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
42 
Psychoneuroendocrinology 20:743-753. PMID: 8848520 
130. 
Cunningham GR, Hirshkowitz M, Korenman SG, Karacan I 1990 Testosterone replacement therapy and sleep-
related erections in hypogonadal men. J Clin Endocrinol Metab 70:792-797. PMID: 2307732 
131. 
Shabsigh R, Kaufman, J, Aurora, CO, Steidle, C, Padma-Natha, H. 2003 Testosterone repalcement therapy with 
testosterone gel 1% converts sildenafil non-responders in men with hypogonadism and erectile dysfunction who 
failed prior sidlenafil therapy. J Urol 169:247 (854A) 
132. 
Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H 2004 Randomized study of testosterone gel as adjunctive 
therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 
172:658-663. PMID: 15247755 
133. 
Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H 2008 Randomized study of testosterone gel as adjunctive 
therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 
179:S97-S102. PMID: 18405769 
134. 
Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A 2003 Androgens improve cavernous vasodilation and 
response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 58:632-638. PMID: 12699447 
135. 
Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV 2003 Oral testosterone undecanoate reverses erectile 
dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 
6:94-99. PMID: 12898793 
136. 
Trigo-Rocha F, Aronson WJ, Hohenfellner M, Ignarro LJ, Rajfer J, Lue TF 1993 Nitric oxide and cGMP: 
mediators of pelvic nerve-stimulated erection in dogs. Am J Physiol 264:H419-422. PMID: 8383456 
137. 
Reilly CM, Stopper VS, Mills TM 1997 Androgens modulate the alpha-adrenergic responsiveness of vascular 
smooth muscle in the corpus cavernosum. J Androl 18:26-31. PMID: 9089065 
138. 
Shabsigh R, Raymond JF, Olsson CA, O'Toole K, Buttyan R 1998 Androgen induction of DNA synthesis in the 
rat penis. Urology 52:723-728. PMID: 9763105 
139. 
Fournier GR, Jr., Juenemann KP, Lue TF, Tanagho EA 1987 Mechanisms of venous occlusion during canine 
penile erection: an anatomic demonstration. J Urol 137:163-167. PMID: 3795360 
140. 
Mills TM, Lewis RW 1999 The Role of Andorgens in the Erectile Response: A 1999 Perspective. Mol Urol 
3:75-86. PMID: 10851308 
141. 
Mills TM, Lewis RW, Stopper VS 1998 Androgenic maintenance of inflow and veno-occlusion during erection 
in the rat. Biol Reprod 59:1413-1418. PMID: 9828186 
142. 
Mills TM, Stopper VS, Wiedmeier VT 1994 Effects of castration and androgen replacement on the 
hemodynamics of penile erection in the rat. Biol Reprod 51:234-238. PMID: 7948478 
143. 
Reilly CM, Zamorano P, Stopper VS, Mills TM 1997 Androgenic regulation of NO availability in rat penile 
erection. J Androl 18:110-115. PMID: 9154504 
144. 
Reilly CM, Lewis RW, Stopper VS, Mills TM 1997 Androgenic maintenance of the rat erectile response via a 
non-nitric-oxide-dependent pathway. J Androl 18:588-594. PMID: 9432131 
145. 
Reilly CM, Stopper VS, Mills TM 1997 Androgens modulate the alpha-adrenergic responsiveness of vascular 
smooth muscle in the corpus cavernosum. J Androl 18:26-31. PMID: 9089065 
146. 
Lugg JA, Rajfer J, Gonzalez-Cadavid NF 1995 Dihydrotestosterone is the active androgen in the maintenance of 
nitric oxide-mediated penile erection in the rat. Endocrinology 136:1495-1501. PMID: 7534702 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
43 
147. 
Trigo-Rocha F, Aronson WJ, Hohenfellner M, Ignarro LJ, Rajfer J, Lue TF 1993 Nitric oxide and cGMP: 
mediators of pelvic nerve-stimulated erection in dogs. Am J Physiol 264:H419-422. PMID: 8383456 
148. 
Fournier GR, Jr., Juenemann KP, Lue TF, Tanagho EA 1987 Mechanisms of venous occlusion during canine 
penile erection: an anatomic demonstration. J Urol 137:163-167. PMID: 3795360 
149. 
Shabsigh R, Raymond JF, Olsson CA, O'Toole K, Buttyan R 1998 Androgen induction of DNA synthesis in the 
rat penis. Urology 52:723-728. PMID: 9763105 
150. 
Jain P, Rademaker AW, McVary KT 2000 Testosterone supplementation for erectile dysfunction: results of a 
meta-analysis. J Urol 164:371-375. PMID: 10893588 
151. 
Bolona ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, Caples SM, Erwin PJ, Montori VM 
2007 Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized 
placebo-controlled trials. Mayo Clin Proc 82:20-28. PMID: 17285782 
152. 
Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin 
A, Meuleman E, Eardley I, Dean JD, Shabsigh R 2011 Hypogonadal men nonresponders to the PDE5 inhibitor 
tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the 
treatment of erectile dysfunction (TADTEST study).J Sex Med 8:284-93 
153. 
Spitzer M, Basaraia S, Travison TG, Davda M, Mazer NA, Paley A, Mohammed N, Hanka S, Knapp P, Rosen 
R, DeRogatis L, Bhasin S 2012 The effect of testosterone on response to sildeanfil in men with erectile 
dysfunciton: a randomized controlled trial. Ann Intern Med in press 
 154. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D 1999 Bioavailable testosterone and depressed mood in 
older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 84:573-577. PMID: 10022418 
155. 
Seidman SN, Araujo AB, Roose SP, McKinlay JB 2001 Testosterone level, androgen receptor polymorphism, 
and depressive symptoms in middle-aged men. Biol Psychiatry 50:371-376. PMID: 11543741 
156. 
Seidman SN, Araujo AB, Roose SP, Devanand DP, Xie S, Cooper TB, McKinlay JB 2002 Low testosterone 
levels in elderly men with dysthymic disorder. Am J Psychiatry 159:456-459. PMID: 11870011 
157. 
Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, 
Swerdloff RS 1996 Testosterone replacement therapy improves mood in hypogonadal men--a clinical research 
center study. J Clin Endocrinol Metab 81:3578-3583. PMID: 8855804 
158. 
Pope HG, Jr., Cohane GH, Kanayama G, Siegel AJ, Hudson JI 2003 Testosterone gel supplementation for men 
with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 160:105-111. PMID: 
12505808 
159. 
Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, 
Leiblum SR, Caramelli KE, Mazer NA 2000 Transdermal testosterone treatment in women with impaired sexual 
function after oophorectomy. N Engl J Med 343:682-688. PMID: 10974131 
160. 
Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, 
Schulte HM, Allolio B 1999 Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl 
J Med 341:1013-1020. PMID: 10502590 
161. 
Wagner GJ, Rabkin JG, Rabkin R 1998 Testosterone as a treatment for fatigue in HIV+ men. Gen Hosp 
Psychiatry 20:209-13.  
162. 
Rabkin JG, Wagner GJ, Rabkin R 2000 A double-blind, placebo-controlled trial of testosterone therapy for HIV-
positive men with hypogonadal symptoms. Arch Gen Psychiatry 57:141-147; discussion 155-146. PMID: 
10665616 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
44 
163. 
Rosen RC, Araujo AB, Connor MK, Elstad EA, McGraw SA, Guay AT, Morgentaler A, Miner MM 2009 
Assessing symptoms of hypogonadism by self-administered questionnaire: qualitative findings in patients and 
controls. Aging Male 12:77-85. 
164. 
Rabkin J, Wagner G, McElhiney M, Rabkin R, Lin S 2004 Testosterone versus fluoxetine for depression and 
fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology 24:379-385.  
165. 
Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R 2000 DHEA treatment for HIV+ patients: effects on mood, 
androgenic and anabolic parameters. Psychoneuroendocrinology 25:53-68.  
166. 
Knapp PE, Storer TW, Herbst KL, Singh AB, Dzekov C, Dzekov J, LaValley M, Zhang A, Ulloor J, Bhasin S 
2008 Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and 
fatigue in men with HIV-associated weight loss. Am J Physiol Endocrinol Metab 2008;294(6):E1135-43. 
167. 
http://www.hiv.va.gov/provider/manual-primary-care/androgen-deficiency.asp. 
168. 
http://www.savvyhealth.com/disp.asp?doc_id=544. 
169. 
http://www.aidsmeds.com/articles/Fatigue_4832.shtml. 
170. 
http://www.thebody.com/Forums/AIDS/Fatigue/Q214266.html. 
 
171. 
Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, 
Casaburi R 1996 The effects of supraphysiologic doses of testosterone on muscle size and strength in normal 
men. N Engl J Med 335:1-7. PMID: 8637535 
172. 
Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R 1997 
Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 
82:407-413. PMID: 9024227 
173. 
Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, Dike M, Sinha-Hikim I, Shen R, 
Hays RD, Beall G 2000 Testosterone replacement and resistance exercise in HIV-infected men with weight loss 
and low testosterone levels. Jama 283:763-770. PMID: 10683055 
174. 
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, 
Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW 2001 Testosterone dose-response 
relationships in healthy young men. Am J Physiol Endocrinol Metab 281:E1172-1181. PMID: 11701431 
175. 
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, 
Dzekov J, Magliano L, Storer TW 2005 Older men are as responsive as young men to the anabolic effects of 
graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 90:678-688. PMID: 15562020 
176. 
Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S 2003 Testosterone 
dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific 
tension. J Clin Endocrinol Metab 88:1478-1485. PMID: 12679426 
177. 
Storer TW, Woodhouse LJ, Sattler F, Singh AB, Schroeder ET, Beck K, Padero M, Mac P, Yarasheski KE, 
Geurts P, Willemsen A, Harms MK, Bhasin S 2005 A randomized, placebo-controlled trial of nandrolone 
decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant 
human growth hormone as active reference treatment. J Clin Endocrinol Metab 90:4474-4482. PMID: 15914526 
178. 
Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R 2003 AA2500 testosterone gel normalizes 
androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol 
Metab 88:2673-2681. PMID: 12788872 
179. 
Woodhouse LJ, Reisz-Porszasz S, Javanbakht M, Storer TW, Lee M, Zerounian H, Bhasin S 2003 Development 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
45 
of models to predict anabolic response to testosterone administration in healthy young men. Am J Physiol 
Endocrinol Metab 284:E1009-1017. PMID: 12517741 
180. 
Brodsky IG, Balagopal P, Nair KS 1996 Effects of testosterone replacement on muscle mass and muscle protein 
synthesis in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab 81:3469-3475. PMID: 
8855787 
181. 
Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A 1996 Increase in bone 
density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin 
Endocrinol Metab 81:4358-4365. PMID: 8954042 
182. 
Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes 
JH, Kapoor SC, Atkinson LE, Strom BL 2000 Effects of testosterone replacement in hypogonadal men. J Clin 
Endocrinol Metab 85:2670-2677. PMID: 10946864 
183. 
Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, 
Swerdloff RS 2004 Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual 
function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 
89:2085-2098. PMID: 15126525 
184. 
Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman 
N 2000 Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition 
parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 85:2839-2853. PMID: 
10946892 
185. 
Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, Lewis MI, Fournier M, Storer TW 2004 Effects of 
testosterone and resistance training in men with chronic obstructive pulmonary disease. American journal of 
respiratory and critical care medicine 170:870-878. PMID: 15271690 
186. 
Bhasin S, Calof O, Storer TW, al. E 2006 Drug insights: anabolic applications of testosterone and selective 
androgen receptor modulators in aging and chronic illness. Nature CPEM 2:133-140. PMID: 19011296 
187. 
Blazer DG, Liverman C 2004 The Institute of Medicine Expert Panel Report on the Future of Testosterone 
Research in Older Men. The National Academies Press, Washington, DC. 
188. 
Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL 2004 Exogenous 
Testosterone (T) Alone or with Finasteride Increases Physical Performance, Grip Strength, and Lean Body Mass 
in Older Men with Low Serum T. J Clin Endocrinol Metab. PMID: 15572415 
189. 
Brill KT, Weltman AL, Gentili A, Patrie JT, Fryburg DA, Hanks JB, Urban RJ, Veldhuis JD 2002 Single and 
combined effects of growth hormone and testosterone administration on measures of body composition, physical 
performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin 
Endocrinol Metab 87:5649-5657. PMID: 15579792 
190.  
Ware JE. SF-36® Health Survey Update. Version 2.  
191. 
Watson D, Clark LA 1984 Negative affectivity: the disposition to experience aversive emotional states. 
Psychological bulletin 96:465-490. PMID: 6393179 
192. 
Watson D, Clark LA, Carey G 1988 Positive and negative affectivity and their relation to anxiety and depressive 
disorders. Journal of abnormal psychology 97:346-353. PMID: 3192830 
 193. Crawford JR, Henry JD 2004 The positive and negative affect schedule (PANAS): construct validity, 
measurement properties and normative data in a large non-clinical sample. The British journal of clinical 
psychology / the British Psychological Society 43:245-265. PMID: 15333231   


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
46 
194. 
Almagor M, Ben-Porath YS 1989 The two-factor model of self-reported mood: a cross-cultural replication. J 
Pers Assess 53:10-21. PMID: 2918447 
195. 
Basaria S, Coviello A, Travison TG, Storer TW, Farwell WR, Jette A, Eder R, Tennstedt S, Ulloor J, Zhang A, 
Choong K, Lakshman K, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp P, Brooks B, Bhasin G, Appleman E, 
Aggarwal S, Collins L, LeBrasseur N, Fiore L, Bhasin S 2010 Adverse effects associated with testosterone 
administration in older men. N Engl J Med 363:109-22. PMID 2059229 
196. 
Bhasin S, Storer TW, Berman N, Hays R, Beall G 2000 Effects of testosterone replacement and resistance 
exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283:756-762. PMID: 
1068305 
197. 
Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M, Mazer NA, Ngyuen AH, Davda MN, Jara H, 
Aakil A, Anderson S, Knapp PE, Hanka S, Mohammed N, Daou P, Miciek R, Ulloor J, Zhang A, Brooks B, 
Orwoll K, Hede-Brierley L, Eder R, Elmi A, Bhasin G, Collins L, Singh R, Basaria S 2012  Effect of 
testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in adult men with 
suppressed testosterone production: a randomized trial. JAMA 307:931-9. PMID: 22396515 
198. 
Berry D, Halpenny B, Hong F, et al 2011 The Personal Patient Profile-Prostate for Men With Newly Diagnosed 
Localized Prostate Cancer: A Multi-center Randomized Trial. Urologic Oncology; E-pub ahead of print, 7 Dec, 
2011; PMID: 22153756. 
199. 
Berry D, Blumenstein B, Halpenny B, Wolpin S, Fann  JR, Austin-Seymour M. Bush N, Karras BT, Lober WB, 
McCorkle R 2011 Enhancing Patient-Provider Communication with the Electronic Self-Report Assessment for 
Cancer (ESRA-C): A Randomized Trial. J Clin Oncol 29:1029-35. 
200. 
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram 
S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, 
Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr 2013 Intermittent versus continuous 
androgendeprivation in prostate cancer.N Engl J Med 368:1314-25. 
201. 
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG 2000 Development and validation of the expanded 
prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men 
with prostate cancer. Urology 56:899-905. PMID: 11113727 
202. 
Buena F, Swerdloff RS, Steiner BS, Lutchmansingh P, Peterson MA, Pandian MR, Galmarini M, Bhasin S 1993 
Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal 
male range. Fertil Steril 59:1118-1123. PMID: 8486184 
203. 
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, 
Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW 2001 Testosterone dose-response 
relationships in healthy young men. Am J Physiol Endocrinol Metab 281:E1172-1181. PMID: 15827094 
204. 
Fielder TJ, Peacock NR, McGivern RF, Swerdloff RS, Bhasin S 1989 Testosterone dose-dependency of sexual 
and nonsexual behaviors in the gonadotropin-releasing hormone antagonist-treated male rat. J Androl 10:167-
173. PMID: 2501257 
205. 
Bhasin S, Fielder T, Peacock N, Sod-Moriah UA, Swerdloff RS 1988 Dissociating antifertility effects of GnRH-
antagonist from its adverse effects on mating behavior in male rats. Am J Physiol 254:E84-91. PMID: 3276216 
206. 
Bhasin S, Zhang A, Coviello A, Jasuja R, Ulloor J, Singh R, Vesper H, Vasan RS 2008 The impact of assay 
quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids 
73:1311-1317  PMID: 18687348 
207. 
Vesper HW, Bhasin S, Wang C, Tai SS, Dodge LA, Singh RJ, Nelson J, Ohorodnik S, Clarke NJ, Salameh WA, 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
47 
Parker CR, Jr., Razdan R, Monsell EA, Myers GL 2009 Interlaboratory comparison study of serum total 
testoserone measurements performed by mass spectrometry methods. Steroids 74:498-503 PMID: 19428438 
208. 
Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, Wang PY, Nielson C, Wu F, Tajar A, 
Labrie F, Vesper H, Zhang A, Ulloor J, Singh R, D'Agostino R, Vasan RS 2011 Reference ranges for 
testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based 
sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically 
distinct cohorts.J Clin Endocrinol Metab 2011;96:2430-9. PMID: 21697255 
209. 
Berry DL, Moinpour CM, Pauler Ankerst D, Jiang CS, Petrylak DP, Vinson LV, Lara PN, Lanier S, Taplin ME, 
Burch PA, Hussain MHA and Crawford ED. Quality of Life and Pain in Advanced Stage Prostate Cancer: 
Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel/estramustine to 
Mitoxantrone/prednisone. J Clin Oncology 2006; 2418:2828-35. 
210. 
Berry DL, Ellis WJ, Russell KJ, Blasko JC, Bush N. Blumenstein BA, Lange PH. Factors That Predict 
Treatment Choice and Satisfaction with the Decision in Men with Localized Prostate Cancer. Clinical 
Genitourinary Cancer 2006; 5: 219-226. PMC 3189855 
211. 
Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, 
Goldenberg SL, Hernandez J, Higano CS, Kraus S, Liebert M, Moul JW, Tangen C, Thrasher JB, Thompson I; 
American Urological Association Prostate Cancer Guideline Update Panel 2007 Erectile function outcome 
reporting after clinically localized prostate cancer treatment. J Urol 178(2):597-601. 
212. 
Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, 
Oh WK, Penson DF, Kibel AS. 2013. Castration-Resistant Prostate Cancer: AUA Guideline.J Urol S0022-
5347(13)04327-9. PMID: 23665272 
213.  Nepple KG, Stephenson AJ, Kallogjeri D, Michalski J, Grubb RL 3rd, Strope SA, Haslag-Minoff J, Piccirillo JF, 
Ciezki JP, Klein EA, Reddy CA, Yu C, Kattan MW, Kibel AS 2013 Mortality After Prostate Cancer Treatment 
with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without 
Comorbidity.Eur Urol S0302-2838(13)00229-7. 
214.  Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J, Deasy JO, Michalski JM, Kallogjeri 
D, Piccirillo JF, Rabah DM, Yu C, Kattan MW, Stephenson AJ 2012 Survival among men with clinically 
localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen 
era.J Urol 187:1259-65. 
215. 
Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, Eeles R, Fernandez P, Giri VN, Gueye 
SM, Haiman CA, Henderson BE, Heyns CF, Hu JJ, Ingles SA, Isaacs W, Jalloh M, John EM, Kibel AS, Kidd 
LR, Layne P, Leach RJ, Neslund-Dudas C, Okobia MN, Ostrander EA, Park JY, Patrick AL, Phelan CM, Ragin 
C, Roberts RA, Rybicki BA, Stanford JL, Strom S, Thompson IM, Witte J, Xu J, Yeboah E, Hsing AW, Zeigler-
Johnson CM 2013 Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african 
descent.Prostate Cancer 2013:560857 
 
216. 
Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR, Choong K, Lakshman K, Mazer NA, 
Coviello AD, Knapp PE, Ulloor J, Zhang A, Brooks B, Nguyen A-H, Eder R, LeBrasseur N, Elmi A, Appleman 
E, Hede-Brierley L, Bhasin G, Bhatia A, Lazzari A, Davis S, Ni P, Collins L, Bhasin S 2011 Clinical 
meaningfulness of the changes in muscle performance and physical function associated with testosterone 
administration in older men with mobility limitation. J. Gerontol. A Biol. Sci. Med. Sci 66:1090–9.  


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
48 
217. 
Bachman E, Feng R, Travison TG, Li M, Olbina G, Ostland V, Ulloor J, Zhang A, Basaria S, Ganz T, 
Westerman M, Bhasin S 2010 Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-
induced erythrocytosis. J Clin Endocrinol Metab 95:4743–7.  
218. 
Coviello AD, Lakshman K, Mazer NA, Bhasin S 2006 Differences in the apparent metabolic clearance rate of 
testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone. J 
Clin Endocrinol Metab 91:4669-75. 
219. 
Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S 2008 Effects of graded doses of 
testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 93:914-9.  
220. 
Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov J, Dzekov C, Sinha-Hikim I, Bhasin S 
2005 Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. 
J Clin Endocrinol Metab 90:3838-46. 
221. 
Lee KK, Berman N, Alexander GM, Hull L, Swerdloff RS, Wang C 2003 A simple self-report diary for 
assessing psychosexual function in hypogonadal men.J Androl 24:688-98. 
222. 
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A 1997 The international index of erectile 
function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822-830. PMID: 
9187685 
223. 
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM 1999 Development and evaluation of an abridged, 5-
item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. 
Int J Impot Res 11:319-326. PMID: 10637462 
224. 
Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH 1999 Diagnostic evaluation of the erectile function 
domain of the International Index of Erectile Function. Urology 54:346-351. PMID: 10443736 
225. 
Rosen RC, Catania J, Pollack L, Althof S, O'Leary M, Seftel AD 2004 Male Sexual Health Questionnaire 
(MSHQ): scale development and psychometric validation. Urology 64:777-782.  
226. 
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA 1998 Oral sildenafil in the treatment 
of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338:1397-1404 PMID: 9580646.  
227. 
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA 2002 Oral sildenafil in the treatment 
of erectile dysfunction. 1998. J Urol 167:1197-1203; discussion 1204. PMID: 11905901 
228. 
Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC 2001 On-
demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 13:2-9. 
PMID: 11313831 
229. 
Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H 2004 Randomized study of testosterone gel as adjunctive 
therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 
172:658-663. PMID: 15247755 
230. 
Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H 2008 Randomized study of testosterone gel as adjunctive 
therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 
179:S97-S102. PMID: 18405769 
231. 
Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV 2003 Oral testosterone undecanoate reverses erectile 
dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 
6:94-99. PMID: 12898793 
232. 
Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ 1990 High-intensity strength training 
in nonagenarians. Effects on skeletal muscle. Jama 263:3029-3034. PMID: 2342214 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
49 
233. Ware JE.SF-36® Health Survey Update. Version 2.  
234. Travison TG, Morley JE, Araujo AB, O'Donnell AB, McKinlay JB 2006 The relationship between libido and 
testosterone levels in aging men. J Clin Endocrinol Metab 91:2509-2513. PMID: 16670164 
235. Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, Studenski S, Berkman LF, Wallace RB 
2000 Lower extremity function and subsequent disability: consistency across studies, predictive models, and value 
of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci 
55:M221-231. PMID: 10811152 
236. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB 1995 Lower-extremity function in persons over 
the age of 70 years as a predictor of subsequent disability. N Engl J Med 332:556-561. PMID: 7838189 
237. Lai JS, Crane PK, Cella D 2006 Factor analysis techniques for assessing sufficient unidimensionality of cancer 
related fatigue. Qual Life Res 15:1179-1190. PMID: 17001438 
238. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE 2002 Combining anchor and distribution-based methods to 
derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia 
and fatigue scales. Journal of pain and symptom management 24:547-561. PMID: 12551804 
239. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J 2005 Validation of the Functional Assessment 
of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. 
The Journal of rheumatology 32:811-819. PMID: 1586861 
240. Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz HJ, Nortier JW 2003 Epoetin alfa treatment results in 
clinically significant improvements in quality of life in anemic cancer patients when referenced to the general 
population. J Clin Oncol 21:366-373. PMID: 12525531 
241. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG 2000. Development and validation of the 
expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in 
men with prostate cancer. Urology 56:899-905. 
242. Szymanski KM, Wei JT, Dunn RL, Sanda MG 2010 Development and validation of an abbreviated version of the 
expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate 
cancer survivors. Urology 76(5):1245-50. 
243. Wagner G, Fugl-Meyer KS, Fugl-Meyer AR 2000 Impact of erectile dysfunction on quality of life: patient and 
partner perspectives. Int J Impot Res 12 Suppl 4:S144-146. PMID: 11035403 
244. Watson D, Clark LA, Tellegen A 1988 Development and validation of brief measures of positive and negative 
affect: the PANAS scales. Journal of personality and social psychology 54:1063-1070. PMID: 3397865 
245. Watson D, Clark LA, Carey G 1988 Positive and negative affectivity and their relation to anxiety and depressive 
disorders. Journal of abnormal psychology 97:346-353. PMID: 3192830 
246. Watson D, Clark LA 1984 Negative affectivity: the disposition to experience aversive emotional states. 
Psychological bulletin 96:465-490. PMID: 6393179 
247. Smith BW, Zautra AJ 2002 The role of personality in exposure and reactivity to interpersonal stress in relation to 
arthritis disease activity and negative affect in women. Health Psychol 21:81-88. PMID: 11846348 
248. Lord SR, Menz HB 2002 Physiologic, psychologic, and health predictors of 6-minute walk performance in older 
people. Arch Phys Med Rehabil 83:907-911. PMID: 12098148 
249. Voogt E, van der Heide A, van Leeuwen AF, Visser AP, Cleiren MP, Passchier J, van der Maas PJ 2005 Positive 
and negative affect after diagnosis of advanced cancer. Psycho-oncology 14:262-273. PMID: 15386769 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
50 
250. Koller M, Kussman J, Lorenz W, Jenkins M, Voss M, Arens E, Richter E, Rothmund M 1996 Symptom reporting 
in cancer patients: the role of negative affect and experienced social stigma. Cancer 77:983-995. PMID: 8608494 
251. LeBrasseur NK, Bhasin S, Miciek R, Storer TW 2008 Tests of muscle strength and physical function: reliability 
and discrimination of performance in younger and older men and older men with mobility limitations. J Am 
Geriatr Soc 56:2118-23. 
252. Mitchell JH, Sproule BJ, Chapman CB. The physiological meaning of the maximal oxygen intake test. J Clin 
Invest 1958;37(4):538-47. 
253. Taylor Hl, Buskirk E, Henschel A. Maximal oxygen intake as an objective measure of cardio-respiratory 
performance. J Appl Physiol 1955;8(1):73-80. 
254. Whipp BJ, Davis JA, Torres F, Wasserman K. A test to determine parameters of aerobic function during exercise. 
J Appl Physiol 1981;50(1):217-21. 
255. Vestergaard S, Nayfield SG, Patel KV, Eldadah B, Cesari M, FerrucciL,Ceresini G, Guralnik JM.  Fatigue in a 
representative population of older persons and its association with functional impairment, functional limitation, 
and disability. J Gerontol A Biol Sci Med Sci 2009;64:76-82. 
256. Wood S 2006 Generalized Additive Models: An Introduction with R. 1st ed. Chapman and Hall/CRC. 
257.  van Buuren S 2007 Multiple imputation of discrete and continuous data by fully conditional specification. 
Statistical Methods in Medical Research 16(3):219–242. 
258. White IR, Royston P, Wood AM 2011 Multiple imputation using chained equations: Issues and guidance for 
practice. Statistics in Medicine 30:377–399. 
259. Buuren S, Groothuis-Oudshoorn K 2011 MICE: multivariate imputation by chained equations in R. Journal of 
Statistical Software. 2011;45(3). Available at: http://doc.utwente.nl/78938/. Accessed September 8, 2012. 
260. Zeger SL, Liang K-Y 1986 Longitudinal Data Analysis for Discrete and Continuous Outcomes.Biometrics 
42(1):121–130. 
261. Yelland LN, Salter AB, Ryan P 2011 Performance of the modified Poisson regression approach for estimating 
relative risks from clustered prospective data. Am. J. Epidemiol 174(8):984–992. 
258. Zou G 2004 A modified poisson regression approach to prospective studies with binary data.Am. J. Epidemiol 
159:702–706. 
259. Zou GY, Donner A 2011 Extension of the modified Poisson regression model to prospective studies with 
correlated binary data. Stat Methods Med Res. 2011. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/22072596. Accessed March 1, 2012. 
260. Hall DB 2000 Zero-inflated Poisson and binomial regression with random effects: a case study. Biometrics 
56(4):1030–1039. 
261. Harada ND, Chiu V, Stewart AL 1999 Mobility-related function in older adults: assessment with a 6-minute walk 
test. Arch Phys Med Rehabil 80:837-841. PMID: 10414771 
262. Jylha M, Guralnik JM, Balfour J, Fried LP 2001 Walking difficulty, walking speed, and age as predictors of self-
rated health: the women's health and aging study. J Gerontol A Biol Sci Med Sci 56:M609-617. PMID: 11584033 
263. Melzer D, Lan TY, Guralnik JM 2003 The predictive validity for mortality of the index of mobility-related 
limitation--results from the EPESE study. Age and ageing 32:619-625. PMID: 14600003 
264. Newman AB, Simonsick EM, Naydeck BL, Boudreau RM, Kritchevsky SB, Nevitt MC, Pahor M, Satterfield S, 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
51 
Brach JS, Studenski SA, Harris TB. Association of long-distance corridor walk performance with mortality, 
cardiovascular disease, mobility limitation, and disability.JAMA. 2006 May 3;295(17):2018-26. 
265. Kennedy DM, Stratford PW, Wessel J, Gollish JD, Penney D 2005 Assessing stability and change of four 
performance measures: a longitudinal study evaluating outcome following total hip and knee arthroplasty. BMC 
musculoskeletal disorders 6:3. PMID: 15679884 
266. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH 1997 Interpreting small differences in functional status: 
the Six Minute Walk test in chronic lung disease patients. American journal of respiratory and critical care 
medicine 155:1278-1282. PMID: 9105067 
267. Perera S, Mody SH, Woodman RC, Studenski SA 2006 Meaningful change and responsiveness in common 
physical performance measures in older adults. J Am Geriatr Soc 54:743-749. PMID: 16696738 
268. Margaria R, Aghemo P, Rovelli E 1966 Measurement of muscular power (anaerobic) in man. J Appl Physiol 
21:1662-1664. PMID: 5923240 
269. Heymsfield SB, Smith R, Aulet M, Bensen B, Lichtman S, Wang J, Pierson RN, Jr. 1990 Appendicular skeletal 
muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr 52:214-218. PMID: 2375286 
270. Heymsfield SB, Wang J, Lichtman S, Kamen Y, Kehayias J, Pierson RN, Jr. 1989 Body composition in elderly 
subjects: a critical appraisal of clinical methodology. Am J Clin Nutr 50:1167-1175; discussion 1231-1165. PMID: 
2683725 
271. Kim J, Wang Z, Heymsfield SB, Baumgartner RN, Gallagher D 2002 Total-body skeletal muscle mass: estimation 
by a new dual-energy X-ray absorptiometry method. Am J Clin Nutr 76:378-383. PMID: 12145010 
272. Wang ZM, Pierson RN, Jr., Heymsfield SB 1992 The five-level model: a new approach to organizing body-
composition research. Am J Clin Nutr 56:19-28. PMID: 1609756 
273. Silva AM, Shen W, Wang Z, Aloia JF, Nelson ME, Heymsfield SB, Sardinha LB, Heshka S 2004 Three-
compartment model: critical evaluation based on neutron activation analysis. Am J Physiol Endocrinol Metab 
287:E962-969. PMID: 15186997 
274. Schoeller DA, Tylavsky FA, Baer DJ, Chumlea WC, Earthman CP, Fuerst T, Harris TB, Heymsfield SB, Horlick 
M, Lohman TG, Lukaski HC, Shepherd J, Siervogel RM, Borrud LG 2005 QDR 4500A dual-energy X-ray 
absorptiometer underestimates fat mass in comparison with criterion methods in adults. Am J Clin Nutr 81:1018-
1025. PMID: 15883424 
275. Soriano JM, Ioannidou E, Wang J, Thornton JC, Horlick MN, Gallagher D, Heymsfield SB, Pierson RN 2004 
Pencil-beam vs fan-beam dual-energy X-ray absorptiometry comparisons across four systems: body composition 
and bone mineral. J Clin Densitom 7:281-289. PMID: 15319498 
276. Cooper, CB and Storer, TW 2001  Exercise testing and Interpretation: a Practical Approach.  Cambridge, UK.  
Cambridge University Press. 
277. Buchfuhrer MJ, Hansen JE, Robinson TE, Sue DY, Wasserman K, Whipp BJ 1983 Optimizing the exercise 
protocol for cardiopulmonary assessment. J Appl Physiol 55:1558-64. PMID: 1264567 
278. Casaburi R, Storer TW, Ben-Dov I, Wasserman K 1987 Effect of endurance training on possible determinants of 
VO2 during heavy exercise. . J Appl Physiol 62:199-207. PMID: 2397864 
279. Forster HV DJ, Thomson J, Vidruk E, DoPico GA 1972 Estimation of arterial PO2, PCO2, pH, and lactate from 
arterialized venous blood. J Appl Physiol 32(1):134-7. 
280. Wasserman K, Hansen JE, Sue DY, Stringer WW, Sietzema K, Sun X-G, Whipp, BJ 2012  Principles of Exercise 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
52 
Testing and Interpretation. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2012. 
281. Pescatello LS, ed. 2012  ACSM’s Guidelines for Exercise Testing and Prescription.  9thed.  Philadelphia: Wolters 
Kluwer/Lippincott Williams & Wilkins. 
282. ATS/ACCP Statement on Cardiopulmonary Exercise Testing.  Am J Respir Crit Care Med Vol 167. pp 211–277, 
2003. 
283. Ickovics JR, Meisler AW.  Adherence in AIDS clinical trials: A framework for clinical research and clinical 
practice. J Clin Epidemiol 1997;50:385-391. PMID: 9179096 
284. Miller L, Hays RD 2000 Measures of adherence to antiretroviral drugs in clinical trials. HIV Clinical Trials 2000; 
1:36-46. PMID: 11590488 
285. Davis LL, Broome ME, Cox RP. Maximizing retention in community-based clinical trials. Journal of Nursing 
Scholarship. 2002; 34:47-53 PMID: 11901967 
286. Wilcox S, Shumaker SA, Bowen DJ, Naughton MJ, Rosal MC, Ludlam SS, Dugan E, Hunt JR, Stevens S 2001 
Promoting adherence and retention to clinical trials in special populations: A Women's Health Initiative 
Workshop. Controlled Clinical Trials 22:279-28. PMID: 11384790 
287. McDonald AM, Treweek S, Shakur H, Free C, Knight R, Speed C, Campbell MK 2011 Using a business model 
approach and marketing techniques for recruitment and retention to clinical trials.Trials. 11;12:74. PMID: 
21396088 
288. Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R, Entwistle V, Garcia J, Roberts I, 
Grant A, Grant A; STEPS group 2007 Recruitment to randomised trials: strategies for trial enrollment and 
participation study. The STEPS study.Health Technol Assess 11:iii, ix-105. PMID: 17999843 
289. Treweek S, Pitkethly M, Cook J, Kjeldstrøm M, Taskila T, Johansen M, Sullivan F, Wilson S, Jackson C, Jones 
R, Mitchell E 2010. Strategies to improve recruitment to randomised controlled trials.Cochrane Database Syst 
Rev MR000013. PMID: 23396504 
290. Reddy P, White CM, Dunn AB, Moyna NM, Thompson PD 2000 The effect of testosterone on health-related 
quality of life in elderly males - a pilot study. Journal of clinical pharmacy and therapeutics 25:421-426. PMID: 
11123495 
291. Brock G, Heiselman D, Maggi M, Kim SW, Rodríguez Vallejo JM, Behre HM, McGettigan J, Dowsett SA, Hayes 
RP, Knorr J, Ni X, Kinchen K.2015Effect of Testosterone Solution 2% on Testosterone Concentration, Sex Drive 
and Energy in Hypogonadal Men: Results of a Placebo Controlled Study. J Urol. (15)05023-5 [Epub ahead of 
print]. PMID: 26498057 
292. Hayes RP, Henne J, Kinchen KS2015Establishing the content validity of the Sexual Arousal, Interest, and Drive 
Scale and the Hypogonadism Energy Diary. International Journal of Clinical Practice.69(4):454-65. PMID: 
25382263 
293. Cohen DR, Todd S, Gregory WM, Brown JM. Adding a treatment arm to an ongoing clinical trial: a review of 
methodology and practice. Trials. 2015 Apr 22;16:179. PMID: 25897686 
 
294. Elm JJ, Palesch YY, Koch GG, Hinson V, Ravina B, Zhao W. Flexible analytical methods for adding a treatment 
arm mid-study to an ongoing clinical trial. J Biopharm Stat. 2012;22(4):758-72. PMID: 22651113 
 
 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DFCI IRB Protocol #: 15-120 
 
 
 
APPENDIX A 
 
Dana-Farber/Harvard Cancer Center 
Multi-Center Data and Safety Monitoring Plan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
54 
APPENDIX A-TABLE OF CONTENTS 
1. 
OBJECTIVES ...................................................................................................................... 5 
1.1 
Study Design ....................................................................................................................... 5 
1.2 
Primary Objectives .............................................................................................................. 5 
1.3 
Secondary Objectives .......................................................................................................... 5 
2. 
BACKGROUND ................................................................................................................. 6 
2.1 
Study Disease(s) .................................................................................................................. 6 
2.2 
IND Agent ........................................................................................................................... 6 
2.3 
Rationale ............................................................................................................................. 7 
2.4 
Correlative Studies Background .......................................................................................... 8 
3. 
PARTICIPANT SELECTION ............................................................................................ 8 
3.1 
Eligibility Criteria ............................................................................................................... 9 
3.2 
Exclusion Criteria ................................................................................................................ 9 
3.3 
Screening, Recruitment, and Enrollment .......................................................................... 10 
4. 
REGISTRATION PROCEDURES ................................................................................... 11 
4.1 
General Guidelines for DF/HCC and DF/PCC Institutions .............................................. 11 
4.2 
Registration Process for DF/HCC and DF/PCC Institutions ............................................. 11 
4.3 
General Guidelines for Other Investigative Sites .............................................................. 12 
4.4 
Registration Process for Other Investigative Sites ............................................................ 12 
5. 
TREATMENT AND/OR IMAGING PLAN .................................................................... 12 
5.1 
Criteria and Process for Unblinding .................................................................................. 12 
5.2 
Treatment Regimen ........................................................................................................... 12 
5.3 
Pre-Treatment Criteria ....................................................................................................... 14 
5.4 
Agent Administration ........................................................................................................ 14 
5.5 
General Concomitant Medication and Supportive Care Guidelines ................................. 15 
5.6 
Criteria for Taking a Participant Off Protocol Therapy .................................................... 16 
5.7 
Duration of Follow Up ...................................................................................................... 17 
5.8 
Criteria for Taking a Participant Off Study ....................................................................... 17 
5.9 
Study Stopping Rules ........................................................................................................ 18 
6. 
DOSING DELAYS/DOSE MODIFICATIONS ............................................................... 18 
7. 
ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS ............................ 18 
7.2 
Adverse Event Characteristics .......................................................................................... 19 
7.3 
Expedited Adverse Event Reporting ................................................................................. 19 
7.4 
Expedited Reporting to the Food and Drug Administration (FDA) .................................. 20 
7.5 
Expedited Reporting to Hospital Risk Management ......................................................... 20 
7.6 
Routine Adverse Event Reporting ..................................................................................... 20 
8. 
PHARMACEUTICAL INFORMATION ......................................................................... 21 
8.1 
LY SARM ......................................................................................................................... 21 
8.2 
Placebo .............................................................................................................................. 23 
9. 
STUDY CALENDAR ....................................................................................................... 24 
10. 
MEASUREMENT OF EFFECT ....................................................................................... 26 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
55 
10.1 
Primary Outcome .............................................................................................................. 26 
10.2 
Secondary outcomes .......................................................................................................... 26 
11. 
DATA REPORTING / REGULATORY REQUIREMENTS ........................................... 27 
11.1 
Data Reporting .................................................................................................................. 27 
11.2 
Data Safety Monitoring ..................................................................................................... 28 
11.6 
Multicenter Guidelines ...................................................................................................... 28 
11.7 
Collaborative Agreements Language ................................................................................ 28 
12. 
STATISTICAL CONSIDERATIONS .............................................................................. 28 
12.7 
Sample Size, Accrual Rate and Study Duration ................................................................ 32 
12.8 
Stratification Factors ......................................................................................................... 33 
12.9 
Interim Monitoring Plan .................................................................................................... 33 
12.10 Analysis of Primary Endpoints ......................................................................................... 33 
12.11 Analysis of Secondary Endpoints ..................................................................................... 33 
12.12 Reporting and Exclusions .................................................................................................. 33 
13. 
PUBLICATION PLAN ..................................................................................................... 33 
REFERENCES .............................................................................................................................. 34 
284. 
Miller L, Hays RD 2000 Measures of adherence to antiretroviral drugs in clinical trials. HIV Clinical 
Trials 2000; 1:36-46. PMID: 11590488 ............................................................................ 52 
285. 
Davis LL, Broome ME, Cox RP. Maximizing retention in community-based clinical trials. Journal of 
Nursing Scholarship. 2002; 34:47-53 PMID: 11901967 ................................................... 52 
APPENDIX A................................................................................................................................ 53 
1. 
INTRODUCTION ............................................................................................................. 57 
1.1 
Purpose .............................................................................................................................. 57 
1.2 
Multi-Center Data and Safety Monitoring Plan Definitions ............................................. 57 
2. 
GENERAL ROLES AND RESPONSIBILITIES ............................................................. 57 
2.1 
DF/HCC Sponsor .............................................................................................................. 57 
2.2 
Coordinating Center .......................................................................................................... 58 
2.3 
Participating Institution ..................................................................................................... 58 
3. 
DF/HCC REQUIREMENTS FOR MULTI-CENTER PROTOCOLS ............................. 59 
3.1 
Protocol Distribution ......................................................................................................... 59 
3.2 
Protocol Revisions and Closures ....................................................................................... 59 
3.3 
Informed Consent Requirements ....................................................................................... 59 
3.4 
IRB Documentation........................................................................................................... 60 
3.5 
IRB Re-Approval .............................................................................................................. 60 
3.6 
Participant Confidentiality and Authorization Statement.................................................. 60 
3.7 
DF/HCC Multi-Center Protocol Registration Policy ........................................................ 60 
3.8 
DF/HCC Protocol Case Number ....................................................................................... 61 
3.9 
Safety Assessments and Toxicity Monitoring ................................................................... 62 
3.10 
Data Management ............................................................................................................. 63 
4. 
REQUISITIONING INVESTIGATIONAL DRUG ......................................................... 63 
5. 
MONITORING: QUALITY CONTROL .......................................................................... 63 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
56 
5.1 
Ongoing Monitoring of Protocol Compliance ................................................................... 63 
5.2 
Monitoring Reports ........................................................................................................... 63 
5.3 
Accrual Monitoring ........................................................................................................... 64 
6. 
AUDITING: QUALITY ASSURANCE ........................................................................... 64 
6.1 
Audit Plan: NCI Sponsored Trials .................................................................................... 64 
6.3 
Audit Notification ............................................................................................................. 64 
6.4 
Audit Reports .................................................................................................................... 64 
6.5 
Participating Institution Performance ................................................................................ 64 
7. 
ThisquestionnaireisdesignedtomeasureQualityofLifeissuesinpatientswithProstatecancer. 
Tohelpusgetthemostaccuratemeasurement,itisimportantthatyouanswerallquestionshonestlyandcomple
tely. .................................................................................................................................... 80 
8. 
Today'sDate(pleaseenterdatewhensurveycompleted):MonthDayYear ............................... 80 
1. 
duringthelast4 weeks? ........................................................................ 82 
 
 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
57 
1. INTRODUCTION 
 
1.1 
Purpose 
 
To establish standards that will ensure that a Dana-Farber/Harvard Cancer Center Multi-Center protocol will 
comply with Federal Regulations, Health Insurance Portability and Accountability Act (HIPAA) requirements and 
applicable DF/HCC Standard Operating Procedures.         
 
1.2 
Multi-Center Data and Safety Monitoring Plan Definitions 
 
DF/HCC Multi-Center Protocol:  A research protocol in which one or more outside institutions are collaborating 
with Dana-Farber/Harvard Cancer Center where a DF/HCC investigator is the sponsor. DF/HCC includes Dana-
Farber/Partners Cancer Care (DF/PCC) Network Clinical Trial Affiliates.  
 
Lead Institution:  Brigham and Women’s Hospital (BWH))  
 
DF/HCC Sponsor:  Shalender Bhasin, MD 
 
Participating Institutions:  Johns Hopkins Medical Institute and the University of Florida 
 
Supporting Referral Site to BWH:  Beth Israel Deaconess Medical Center 
 
Coordinating Center: Brigham and Women’s Hospital 
 
DF/HCC Office of Data Quality: ODQ 
 
2. GENERAL ROLES AND RESPONSIBILITIES 
 
2.1 
DF/HCC Sponsor 
 
The DF/HCC Sponsor, Shalender Bhasin, MD accepts responsibility for all aspects of conducting a DF/HCC Multi-
Center protocol which includes but is not limited to:  
• Oversee the coordination, development, submission, and approval of the protocol as well as subsequent 
amendments.  
• Ensure that the investigators, study team members, and Participating Institutions are qualified and 
appropriately resourced to conduct the protocol.   
• Include the Multi-Center Data and Safety Monitoring Plan as an appendix to the protocol. 
• Ensure all Participating Institutions are using the correct version of the protocol. 
• Ensure that each participating investigator and study team member receives adequate protocol training 
and/or a Site Initiation Visit prior to enrolling participants and throughout trial’s conduct as needed. 
• Ensure the protocol will be provided to each participating site in a language understandable to all applicable 
site personnel when English is not the primary language.  
• Monitor progress and overall conduct of the study at all Participating Institutions.  
• Ensure all DFCI Institutional Review Board (IRB), DF/HCC, NINR, and FDA reporting requirements are 
met.  
• Review data and maintain timely submission of data for study analysis.  
• Act as the single liaison with FDA (investigator-held IND trials) 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
58 
• Ensure compliance with all requirements as set forth in the Code of Federal Regulations, applicable 
DF/HCC requirements, HIPAA requirements, and the approved protocol. 
• Commit to the provision that the protocol will not be rewritten or modified by anyone other than the 
DF/HCC Sponsor. 
• Identify and qualify Participating Institutions and obtain accrual commitments prior to extending the 
protocol to that site. 
• Monitor accrual and address Participating Institutions that are not meeting their accrual requirements.  
 
2.2 
Coordinating Center 
 
The general responsibilities of the Coordinating Center may include but are not limited to: 
• Assist in protocol development.  
• Maintain FDA correspondence. 
• Review registration materials for eligibility and register participants from Participating Institutions with 
DF/HCCODQ. 
• Distribute protocol and informed consent document updates to Participating Institutions as needed. 
• Oversee the data collection process from Participating Institutions. 
• Maintain documentation of Serious Adverse Event (SAE) reports and deviations/violation submitted by 
Participating Institutions and provide to the DF/HCC Sponsor for timely review.   
• Distribute serious adverse events reported to the DF/HCC Sponsor that fall under the DFCI IRB Adverse 
Event Reporting Policy to all Participating Institutions. 
• Provide Participating Institutions with information regarding DF/HCC requirements that they will be 
expected to comply with. 
 
• Carry out plan to monitor Participating Institutions either by on-site or remote monitoring.  
Conduct regular communications with all Participating Institutions (conference calls, emails, etc) with 
relevant documentation maintained.  
 
2.3 
Participating Institution 
 
The Johns Hopkins Medical Institute and the University of Florida are expected to comply with all applicable 
federal regulations and DF/HCC requirements, the protocol and HIPAA requirements.  
 
The general responsibilities of the Participating Institution include but are not limited to: 
• Document the delegation of research specific activities to study personnel. 
• Commit to the accrual of participants to the protocol. 
• Submit protocol and/or amendments to their local IRB. 
• Maintain regulatory files as per sponsor requirements. 
• Provide the Coordinating Center with regulatory documents or source documents as requested. 
• Participate in protocol training prior to enrolling participants and throughout the trial as required (i.e. 
teleconferences). 
• Update Coordinating Center with research staff changes on a timely basis. 
• Register participants through the Coordinating Center prior to beginning research related activities.  
• Submit Serious Adverse Event (SAE) reports to local IRB per local requirements and to the Coordinating 
Center, in accordance with DF/HCC requirements.  
• Submit protocol deviations and violations to local IRB per local requirements and to the DF/HCC Sponsor 
in accordance with DF/HCC requirements. 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
59 
• Order, store and dispense investigational agents and/or other protocol mandated drugs per federal guidelines 
and protocol requirements. 
• Have office space, office equipment, and internet access that meet HIPAA standards. 
• Participate in any quality assurance activities and meet with monitors or auditors at the conclusion of a visit 
to review findings. 
• Promptly provide follow-up and/or corrective action plans for any monitoring queries or audit findings. 
 
3. DF/HCC REQUIREMENTS FOR MULTI-CENTER PROTOCOLS 
 
 
3.1 
Protocol Distribution 
 
The Coordinating Center will distribute the final DFCI IRB approved protocol and any subsequent amended 
protocols to all Participating Institutions.    
 
3.2 
Protocol Revisions and Closures 
 
The Participating Institutions will receive notification of protocol revisions and closures from the Coordinating 
Center.  It is the individual Participating Institution’s responsibility to notify its IRB of these revisions. 
 
• Non life-threatening revisions: Participating Institutions will receive written notification of protocol 
revisions regarding non life-threatening events from the Coordinating Center. Non-life-threatening protocol 
revisions must be IRB approved and implemented within 90 days from receipt of the notification. 
 
• Revisions for life-threatening causes: Participating Institutions will receive immediate notification from 
the Coordinating Center concerning protocol revisions required to protect lives with follow-up by fax, mail, 
e-mail, etc.  Life-threatening protocol revisions will be implemented immediately followed by IRB request 
for approval. 
 
• Protocol closures and temporary holds: Participating Institutions will receive notification of protocol 
closures and temporary holds from the Coordinating Center. Closures and holds will be effective 
immediately.  In addition, the Coordinating Center, will update the Participating Institutions on an ongoing 
basis about protocol accrual data so that they will be aware of imminent protocol closures. 
 
3.3 
Informed Consent Requirements 
 
 
Participating Institutions will send their version of the informed consent document and HIPAA authorization, if a 
separate document, to the Coordinating Center for review and approval prior to submission to their local IRB. The 
approved consent form must also be submitted to the Coordinating Center after approval by the local IRB for all 
consent versions. 
 
The Principal Investigator (PI) at each Participating Institution will identify the physician members or responsible 
study members of the study team who will be obtaining consent and signing the consent form for therapeutic 
protocols.  Participating institutions must follow the DF/HCC requirement that only attending physicians obtain 
informed consent and re-consent to interventional trials (i.e. drug and/or device trials).   
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
60 
 
3.4 
IRB Documentation 
 
The following must be on file with the Coordinating Center: 
• Initial approval letter of the Participating Institution's IRB.  
• Copy of the Informed Consent Form(s) approved by the Participating Institution’s IRB.  
• Participating Institution’s IRB approval for all amendments. 
• Annual approval letters by the Participating Institution's IRB. 
 
 
3.5 
IRB Re-Approval 
 
Verification of IRB re-approval from the Participating Institutions is required in order to continue research 
activities.  There is no grace period for continuing approvals. 
 
The Coordinating Center will not register participants if a re-approval letter is not receive from the Participating 
Institution on or before the anniversary of the previous approval date.   
 
 
3.6 
Participant Confidentiality and Authorization Statement 
 
The Coordinating Center, with the approval from the DFCI IRB, will provide a consent template, with 
information regarding authorization for the disclosure of protected health information. Subject confidentiality will 
be maintained except as may be required by law. All identifying information will be kept in a secure area at all 
times. Consent form(s) will be maintained in a separate folder from original Case Report Forms at the conclusion 
of the study. Only de-identified data will be used for analyses. 
The DF/HCC Sponsor will use all efforts to limit its use of protected health information in its trials. However, 
because of the nature of these trials, certain protected health information must be collected. DF/HCC has chosen to 
use authorizations, signed by the participant in the trial, rather than limited data sets with data use agreements. 
 
3.6.1 
 DF/HCC Multi-Center Protocol Confidentiality 
 
All documents, investigative reports, or information relating to the participant are strictly confidential. Whenever 
reasonably feasible, any participant specific reports submitted to the Coordinating Center should be de-identified. 
It is recommended that the assigned DF/HCC ODQ case number be used for all participant specific documents. 
Participant initials may be included or retained for cross verification of identification.  
 
3.7 
DF/HCC Multi-Center Protocol Registration Policy 
 
3.7.1 
 Participant Registration and Randomization  
The following documents will be completed by the Participating Institution and e-mailed to the Coordinating 
Center, Maricelle Ramirez (mramirez5@partners.org) 
• Copy of required laboratory tests including: CBC, PSA, chemistry panel, TSH, total and free 
testosterone 
• Copy of the signed informed consent document (original to remain on site) 
• HIPAA authorization form (if separate from the informed consent document) 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
61 
• Other appropriate forms: Eligibility Screening Worksheet, Registration form 
 
The Coordinating Center will review the submitted documents in order to verify eligibility and consent. To 
complete the registration process, the Coordinating Center will: 
• Register the participant on the study with the DF/HCC ODQ 
• Upon receiving confirmation of registration by the ODQ, the Coordinating Center will inform the 
Participating Institution and provide the study specific participant case number. The QACT will 
communicate the treatment assignment directly to the site’s research pharmacy.  
 
Treatment may not begin without confirmation from the Coordinating Center that the participant has been 
registered.  
 
• It should be noted that subjects referred through BIDMC to BWH will be registered via the BWH 
registration procedures. 
 
 
3.7.2 
 Initiation of Therapy 
 
Participants must be registered with the DF/HCC ODQ before receiving treatment.  Treatment may not be initiated 
until the Participating Institution receives confirmation of the participant’s registration from the Coordinating 
Center. The DF/HCC Sponsor and DFCI IRB must be notified of any violations to this policy. 
 
3.7.3 
 Eligibility Exceptions 
 
The DF/HCC ODQ will make no exceptions to the eligibility requirements for randomized trials.  
 
3.8 
DF/HCC Protocol Case Number 
 
At the time of registration, ODQ requires the following identifiers for all subjects: initials, date of birth, gender, 
race and ethnicity. Once eligibility has been established and the participant successfully registered, the participant 
is assigned a unique protocol case number.  Participating Institutions should submit all de-identified subsequent 
communication and documents to the Coordinating Center, using this case number to identify the subject.   
 
3.8.1 
Protocol Deviations, Exceptions and Violations 
 
The site investigators are not allowed to initiate changes in approved research without IRB review and approval, 
except when necessary to eliminate apparent immediate hazards to the participant. Any departure from the defined 
procedures set forth in the IRB approved protocol must be reported to the DF/HCC Sponsor, who in turn is 
responsible for reporting to the DFCI IRB. 
 
 
3.8.2 
 Definitions 
 
Protocol Deviation: Any departure from the defined procedures set forth in the IRB-approved protocol which is 
prospectively approved prior to its implementation. 
 
Protocol Exception:  Any protocol deviation that relates to the eligibility criteria, e.g. 
enrollment of a participant who does not meet all inclusion/exclusion criteria. 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
62 
 
 
 
Protocol Violation: Any protocol deviation that was not prospectively approved by the IRB prior to its initiation or 
implementation.  
 
 
3.8.3 
 Reporting Procedures 
 
DF/HCC Sponsor, Shalender Bhasin, MD, is responsible for ensuring that clear documentation is available in the 
medical record and/or regulatory documents to describe all protocol exceptions, deviations and violations. The 
DF/HCC Sponsor will also be responsible for ensuring that all protocol violations/deviations are promptly reported 
per DFCI IRB guidelines.  
 
Participating Institutions: Protocol deviations require prospective approval from the DFCI IRB. The Participating 
Institution must submit the deviation request to the Coordinating Center who will then submit the deviation request 
to the DFCI IRB. Upon DFCI IRB approval the deviation is submitted to the Participating Institution IRB, per 
institutional policy. A copy of the Participating Institution’s IRB report and determination will be forwarded to the 
Coordinating Center within 10 business days after the original submission.  
 
All protocol violations must be sent to the Coordinating Center in a timely manner.  
 
Coordinating Center:  Upon receipt of the violation/deviation report from the Participating Institution, the 
Coordinating Center will submit the report to the DF/HCC Sponsor for review. Subsequently, the Participating 
Institution’s IRB violation/deviation report will be submitted to the DFCI IRB for review per DFCI IRB reporting 
guidelines. DF/HCC will forward all violation reports to CTEP via an internal DF/HCC process, as applicable. 
 
3.9 
Safety Assessments and Toxicity Monitoring 
 
The study teams at all participating institutions are responsible for protecting the safety, rights and well-being of 
study participants. Recording and reporting of adverse events that occur during the course of a study help ensure 
the continuing safety of study participants.  
 
All participants receiving investigational agents and/or other protocol mandated treatment will be evaluated for 
safety. The safety parameters include complete blood counts, blood chemistries, PSA, periodic physical 
examination findings, and spontaneous reports of adverse events reported by participants.  All toxicities 
encountered during the study will be evaluated according to the criteria specified in the protocol. Life-threatening 
toxicities must be reported immediately to the DF/HCC Sponsor via the Coordinating Center.  
 
3.9.1 
Guidelines for Reporting Serious Adverse Events  
 
Guidelines for reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) are detailed in the Data and 
Safety Monitoring Plan (appended to this document). 
 
 
 
 
Participating Institutions must report the SAEs to the DF/HCC Sponsor and the Coordinating Center following the 
DFCI IRB Adverse Event Reporting Policy.  
 
The Coordinating Center will maintain documentation of all Participating Institution Adverse Event reports and be 
responsible for communicating to all participating investigators, any observations reportable under the DFCI IRB 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
63 
Reporting Requirements.  Participating Institutions will review and submit to their IRB according to their 
institutional policies and procedures 
 
3.9.2 
Guidelines for Processing IND Safety Reports  
 
The DF/HCC Sponsor will review all IND Safety Reports and ensure that all IND Safety Reports are distributed 
to the Participating Institutions. Participating Institutions will review and submit to their IRB according to their 
institutional policies and procedures. 
 
 
3.10 
Data Management 
 
The trial’s Data Coordinating Center in collaboration with the study team will develop case report forms (CRF), 
for use with the protocol.  These forms are designed to collect data for each study. Each institution is responsible 
for its own data quality and review. 
 
Data is required to be entered within 14 days of data collection. 
 
 
4. REQUISITIONING INVESTIGATIONAL DRUG 
 
The ordering of investigational agent is specified in the protocol section 8.0. 
 
5. MONITORING: QUALITY CONTROL 
 
The Coordinating Center, with the aid of the ODQ provides quality control oversight for the protocol. 
 
5.1 
Ongoing Monitoring of Protocol Compliance 
 
The Coordinating Center will implement ongoing monitoring activities to ensure that Participating Institutions are 
complying with regulatory and protocol requirements, data quality, and participant safety. Monitoring will occur 
during protocol performance and through study completion. Additional monitoring practices may include but are 
not limited to; source verification, review and analysis of the following: eligibility requirements of all participants, 
informed consent procedures, adverse events and all associated documentation, study drug administration/treatment, 
regulatory files, protocol departures, pharmacy records, response assessments, and data management.  
Monitoring will occur every 6 months during the first year and then annually.  Additional monitoring may occur at 
the discretion of the DF/HCC Sponsor if incidences of non-compliance are discovered. 
Participating institutions will be required to participate in monthly Coordinating Center initiated teleconferences.  
Source documentation verification (SDV) will be conducted by having access to participants’ complete study 
records and source documents. 
 
5.2 
Monitoring Reports 
 
The DF/HCC Sponsor, Shalender Bhasin, MD, will review all monitoring reports for on-site and remote monitoring 
of Participating Institutions to ensure protocol compliance. Participating Institutions may also be subject to an audit 
as determined by the DF/HCC Sponsor. 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
64 
 
5.3 
Accrual Monitoring 
 
Prior to extending a protocol to an external site, the DF/HCC Sponsor will establish accrual requirements for each 
participating institution. Each site will accrue at least 3  subjects per year. Accrual will be monitored for each 
participating institution by the DF/HCC Sponsor or designee. Sites that are not meeting their accrual expectations 
may be subject to termination.  
 
6. AUDITING: QUALITY ASSURANCE 
 
6.1 
Audit Plan: NCI Sponsored Trials 
 
Not applicable 
 
6.2 Audit Plan: DF/HCC Sponsored Trials 
 
One on-site audit will be scheduled by the ODQ, assuming at least three participants have been treated on protocol 
at the site. Approximately 3-4 participants would be audited at the site over a 2 day period.  If violations which 
impact participant safety or the integrity of the study are found, more participant records may be audited.  
 
6.3 
Audit Notification 
 
It is the Participating Institution’s responsibility to notify the Coordinating Center of all scheduled audit dates 
(internal or NCI) and re-audit dates (if applicable), which involve this protocol. All institutions will forward a copy 
of final audit and/or re-audit reports and corrective action plans (if applicable) to the Coordinating Center, within 
12 weeks after the audit date.  
 
6.4 
Audit Reports 
 
The DF/HCC Sponsor, Shalender Bhasin, MD, will review all final audit reports and corrective action plans if 
applicable. The Coordinating Center, will forward these reports to the DF/HCC ODQ per DF/HCC policy for 
review by the DF/HCC Audit Committee. Based upon the audit assessments the DF/HCC Audit Committee could 
accept or conditionally accept the audit rating and final report. Conditional approval could require the DF/HCC 
Sponsor to implement recommendations or require further follow-up.  For unacceptable audits, the DF/HCC Audit 
Committee would forward the final audit report and corrective action plan to the DFCI IRB as applicable. 
 
6.5 
Participating Institution Performance 
 
The DF/HCC Sponsor is charged with considering the totality of an institution’s performance in considering 
institutional participation in the protocol. 
6.5.1 
Corrective Actions 
 
Participating Institutions that fail to meet the performance goals of accrual, submission of timely and accurate data, 
adherence to protocol requirements, and compliance with state and federal regulations, may be recommended for a six-
month probation period. Such institutions must respond with a corrective action plan and must demonstrate during the 
probation period that deficiencies have been corrected, as evidenced by the improved performance measures. Participating 
Institutions that fail to demonstrate significant improvement will be considered by the DF/HCC Sponsor for revocation 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
65 
of participation. A DF/HCC Sponsor may terminate a site’s participation if it is determined that a site is not fulfilling its 
responsibilities as described above. 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
66 
DFCI IRB Protocol #: 15-120 
 
 
 
 
 
APPENDIX B- NINR Data and Safety Monitoring Plan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
67 
 
DATA AND SAFETY MONITORING PLAN 
1RO1NR014502-01A1, PI: Bhasin, Shalender 
 
The Data and Safety Monitoring Plan (DSMP) for this trial, described below, will be reviewed and approved by 
the NINR staff prior to the commencement of any human subjects activities in this trial. The DSMP approved by 
the NINR staff will then be submitted to the local IRB for its review and approval. It is understood that the IRB 
approval of the NINR-approved DSMP is required before human subjects activities can take place within the trial, 
and that the awardee institution is responsible for approving the DSMB. 
The responsibility for compliance with the DSMP rests with the PI. The oversight of the monitoring activity 
described in the DSMP is the responsibility of the NINR staff. NINR will be notified within 7 days if the human 
subjects research or DSMP is changed prior to or during the implementation of the clinical trial. The NINR 
program staff must approve the changes prior to implementation.   
 
The essential components of the DSM Plan are the following: 
a. A Data and Safety Monitoring Board (DSMB), an independent committee charged with reviewing safety 
and trial progress and providing advice with respect to study continuation, modification, and termination, 
will assume oversight of the study, in accordance with NINR policy, once the study is underway. The 
procedures that will be used for data and safety monitoring are outlined below. 
b. The DSMB will include five individuals, including a chair and a separate executive secretary. All five 
members will be voting members. The DSMB members will have expertise in prostate cancer, androgen 
biology, biostatistical analysis of clinical trials data, and the conduct and oversight of clinical trials in 
prostate cancer patients.  These individuals will be approved by the institutional review board for human 
subjects research (IRB) after review of their expertise and potential conflicts of interest. The composition 
of the DSMB will consist of the following:  
• Two nationally or internationally recognized experts in prostate cancer and clinical trials of men with prostate 
cancer  
• An expert with nursing background and experience in symptom management including fatigue and other 
outcomes being assessed in this trial 
• An endocrinologist with expertise in clinical trials of androgens in men 
• A biostatistician with expertise in the design and analysis of clinical trials 
 
Safety Review Procedures: 
1.) 
The DSMB will meet to review the safety data every 6 months.   This review will take place by 
teleconference.  A majority must be present at the DSMB meeting to have a quorum.  
2.) 
Generation of safety reports. The Study’s PI, with the assistance of the Data Management Center 
(DMC) will prepare and submit the safety reports for DSMB review, This will be done in a blinded 
fashion, while protecting the confidentiality of participant data.  The reports will be given to an 
independent third party who will add a code (A, B, or C) to the data for each treatment group.  The 
third party will place the finished report into an envelope, seal the envelope and sign across the seal.  


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
68 
He/she will place this envelope containing the coded safety report into Fed Ex envelopes, pre-
prepared by the research coordinators, and seal those.  The reports will be sent, by Fed Ex, to the 
various DSMB members.  This will allow the DSMB to review the safety data by individual treatment 
groups.  The third party will store, in a locked cabinet, the code for the trial.  In the event that the 
DSMB requests unblinding of the study, the code will be sent from the third party directly to the 
DSMB. Thus, the DSMB members can have access to the categorized data, while the investigating 
team remains blinded.  
3.) 
Review of all adverse events will be performed by treatment group (coded A, B, or C). 
4.) 
Each safety report will include the enrollment status, including the number of subjects recruited, 
screened, and randomized.  In addition, it will incorporate the number of dropouts and the reason for 
the dropouts.  The investigating team will comply with NIH, FDA, and institutional policies on 
reporting adverse events.  The report will list all adverse events since the previous reporting period.  
In addition, a cumulative list of all adverse events will also be provided to the DSMB members. The 
summary of all adverse events will allow for a comprehensive overview or analysis of the events 
rates.  All AE’s will be evaluated for severity and attribution.  In order to protect participant 
confidentiality, the data provided to the DSMB will be coded so that individual patients cannot be 
identified. 
5.) 
Each DSMB meeting will be comprised of 2 portions.  Research personnel will arrange and be 
present for the “open discussions” at the start of the DSMB meetings.  The initial “open” portion of 
the meeting will have study personnel available to give a brief update on the status of the trial and to 
respond to any questions that the DSMB may have.  The second portion of the meetings will be 
“closed” to study personnel so that DSMB members may have independent deliberations.  Provisions 
will be made for study personnel to be available to the DSMB committee during these deliberations, 
should their input be required. 
6.) 
In addition to these review procedures the DSMB will receive copies of all serious adverse events, 
with study group assignment (A or B), as they occur. 
Transmission of DSMB Recommendations and Summary Reports of Adverse Events to IRBs  
A summary of the DSMB review and recommendations without treatment assignment information will be sent to 
the Principal Investigator after each DSMB meeting.  The PI will then forward the DSMB report, including the 
DSMB’s assessment of adverse events within the trial, to the IRBs of the participating institutions. 
Transmission of Summary of Closed Deliberations to the NINR Staff 
The NINR Program Officer will receive a copy of the “closed” deliberations. This information will be kept in a secure 
file, accessible only to the NINR Program Staff. 
Procedures for monitoring study safety: 
1. Monitoring schedule 
a. Adverse events are solicited and recorded by study staff at each study visit. 
b. PSA is measured at screening and weeks 2, 4, 6, and 12. 
c. Other safety labs – complete blood counts and chemistries – are measured at screening, baseline and 
during weeks 6 and 12. 
2. Auditing of selected cases for compliance with IRB requirements, conformance with informed consent 
requirements, verification of source documents, and investigator compliance will be performed by Brigham 
and Women’s Hospital’s institutional compliance officer annually. 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
69 
3. Procedures for minimizing research-associated risk.  
All subjects will be monitored by frequent physical examinations, blood counts, chemistries and PSA levels. We 
will follow hematocrit, plasma lipids, blood chemistries, PSA and record all adverse events reported by the subjects 
every 4-weeks.  
The risks of blood drawing will be minimized by having only experienced practitioners perform phlebotomy.  
 
The risk of injury from participating in exercise testing will be minimized by several safety measures.  The 
subjects will be instructed in proper technique and the risks minimized by careful supervision.  Patients will be screened 
with cardiopulmonary exercise testing with continuous monitoring of the ECG to rule out cardiac ischemia and serious 
arrhythmias.  This test will be administered and supervised according to current American Heart Association 
guidelines1.  The likelihood of musculoskeletal injury from exercise testing will be minimized by providing a warm-up 
period preceding each exercise session including low speed treadmill walking and stretching exercises.  Further, a 
certified exercise physiologist will oversee all exercise testing sessions. 
 
The risks of SARM therapy will be minimized by close monitoring with serial physical examinations, 
hematocrit, and PSA levels. We have incorporated all the procedures recommended by the Expert Panel of the 
Endocrine Society on Androgen Deficiency Syndromes, ISSAM, and the American College of Physicians/American 
Society of Internal Medicine Disease Management Module for Male Hypogonadism for monitoring of men receiving an 
androgen. Although these guidelines were developed for testosterone therapy, they are appropriate for following men 
receiving any type of androgen therapy. We have incorporated in this trial several additional measures to minimize risk: 
a. The selection of LY SARM, which not only spares the prostate but has been shown in preclinical models to act 
as an androgen antagonist on the prostate, induce prostate atrophy in a canine model, inhibit the growth of 
prostate cancer explants in mice, and lower PSA in men.  
b. The inclusion and exclusion criteria will assure selection of subjects at very low risk of disease recurrence. 
c. We have established rigorously defined criteria for biochemical recurrence and for progression from stage 1. 
d. We have established a priori stopping rules based on PSA change. 
e. We will perform frequent PSA measurements to ensure early detection of biochemical recurrence. 
f. We will designate study clinicians to monitor PSA and other laboratory tests at each site. 
g. An independent DSMB will oversee the study after its initiation   
Protecting the confidentiality of participant data 
Subject confidentiality will be maintained except as may be required by law. All identifying information will be 
kept in a secure area at all times. Consent form(s) will be maintained in a separate folder from original Case Report 
Forms at the conclusion of the study. Only de-identified data will be used for analyses. 
Procedures for identifying, reviewing, and reporting of adverse events and unanticipated problems to the IRB, 
NINR, and FDA 
The adverse events will be identified by the study staff and reviewed by a study physician on an ongoing basis. Serious 
adverse events will be reported by the study PI to the DSMB Chair, FDA and NINR staff. Unanticipated problems will 
be reported to the DSMB, IRB, FDA, and NINR staff by the study’s PI. 
Termination Criteria 
The following Termination Criteria will be used: 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
70 
• 
An increase in PSA to 0.2 ng/mL or higher, if confirmed by a repeated test, will result in treatment 
discontinuation and referral to a urologist. 
• 
Any evidence of disease recurrence will lead to immediate treatment discontinuation.  
• 
An increase in hematocrit above 54%, if confirmed by a repeated test, would warrant discontinuation of treatment. 
• 
Transaminase elevation above 3 times the upper limit of normal, if confirmed by a repeated test, would warrant 
discontinuation of treatment. 
• 
Myocardial infarction or stroke   
We recognize that other unexpected adverse events can occur. Therefore, we have instituted a comprehensive plan for 
early detection of adverse events; the Data Safety Monitoring Board will be empowered to discontinue treatment in one 
or more subjects, or halt the study, should the occurrence of adverse events so warrant. 
Procedures ensuring compliance with the monitoring plan and reporting requirements across sites 
As this is a three-site study, a study monitor will visit each of the three sites to monitor compliance with the study 
protocol, monitoring plan, and reporting requirements. These visits will take place every 6 months in the first year and 
then annually. 
 
An assessment of external factors or relevant information that may have an impact on safety of the participants 
or on the ethics of the study.  
The study team will provide this assessment to the DSMB (6-monthly) and IRB (annual) reports.  
 
Interim or Futility Analysis 
There are no plans for an interim or futility analysis. 
 
Additional Components of the DSM Plan 
The PI will provide reporting to the NINR staff of the following. All personal identifiers will be removed from any 
documents sent to NINR staff. 
1. Unanticipated problems or unexpected serious adverse events that may be related to the study protocol 
2. IRB-approved revisions to the study protocol that indicate a change in risks to the participants 
3. A summary of recommendations made by the DSMB and if applicable, an action plan for response 
4. Notice of any actions taken by the IRB or regulatory bodies regarding the research and any responses to those 
actions 
 
REFERENCES 
 
Myers J, Forman DE, Balady GJ, Franklin BA, Nelson-Worel J, Martin BJ, Herbert WG, Guazzi M, Arena R 2014, 
Sept 16. Supervision of exercise testing by nonphysicians: a scientific statement from the American Heart Association. 
American Heart Association Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention of the Council on 
Clinical Cardiology, Council on Lifestyle and Cardiometabolic Health, Council on Epidemiology and Prevention, and 
Council on Cardiovascular and Stroke Nursing. 130 (12): 1014-1027. PMID: 25223774 
 
 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DFCI IRB Protocol #: 15-120 
 
APPENDIX C- Study Questionnaires 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
72 
FACIT Fatigue Questionnaire 
 
Below is a list of statements that other people with your illness have said are important. Please circle or mark 
one number per line to indicate your response as it applies to the past 7 days. 
 
 
 
 
Not 
at all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
 
HI7 
I feel fatigued
 ..........................................................................................  
0 
1 
2 
3 
4 
HI12 
I feel weak all over
 ..........................................................................................  
0 
1 
2 
3 
4 
An1 
I feel listless (“washed out”)
 ..........................................................................................  
0 
1 
2 
3 
4 
An2 
I feel tired
 ..........................................................................................  
0 
1 
2 
3 
4 
An3 
I have trouble starting things because I am tired
 ..........................................................................................  
0 
1 
2 
3 
4 
An4 
I have trouble finishing things because I am tired
 ..........................................................................................  
0 
1 
2 
3 
4 
An5 
I have energy
 ..........................................................................................  
0 
1 
2 
3 
4 
An7 
I am able to do my usual activities
 ..........................................................................................  
0 
1 
2 
3 
4 
An8 
I need to sleep during the day
 ..........................................................................................  
0 
1 
2 
3 
4 
An12 
I am too tired to eat
 ..........................................................................................  
0 
1 
2 
3 
4 
An14 
I need help doing my usual activities
 ..........................................................................................  
0 
1 
2 
3 
4 
An15 
I am frustrated by being too tired to do the things I want 
to do
 ..........................................................................................  
 
0 
 
1 
 
2 
 
3 
 
4 
An16 
I have to limit my social activity because I am tired
 ..........................................................................................  
0 
1 
2 
3 
4 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
73 
 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
74 
IIEF Questionnaire 
 
INSTRUCTIONS: These questions ask about your sex life over the past 4 weeks. Please answer the following 
questions as honestly and clearly as possible. In answering these questions, the following definitions apply: 
 
Sexual activity includes intercourse, caressing, foreplay, masturbation, or any other types of sex 
Sexual intercourse is defined as penetration of the partner (you entered your partner) 
Sexual stimulation includes situations like foreplay with a partner, looking at erotic pictures, etc. 
Ejaculate the ejection of semen from the penis (or the feeling of this) 
 
Circle ONLY one answer (number) per question. 
Q1) Over the past 4 weeks, how often were you able to get an erection during sexual activity? 
 
0 = No sexual activity 
 
1 = Almost never / never 
 
2 = A few times (much less than half the time) 
 
3 = Sometimes (about half the time) 
 
4 = Most times (much more than half the time) 
 
5 = Almost always / always 
 
Q2)  Over the past 4 weeks, when you had erections with sexual stimulation, how often were your        erections hard 
enough for penetration? 
 
0 = No sexual activity 
 
1 = Almost never / never 
 
2 = A few times (much less than half the time) 
 
3 = Sometimes (about half the time) 
 
4 = Most times (much more than half the time) 
 
5 = Almost always / always 
 
Q3)  Over the past 4 weeks, when you attempted sexual intercourse, how often were you able to penetrate (enter) your 
partner? 
 
0 = Did not attempt intercourse 
 
1 = Almost never / never 
 
2 = A few times (much less than half the time) 
 
3 = Sometimes (about half the time) 
 
4 = Most times (much more than half the time) 
 
5 = Almost always / always 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
75 
Q4)  Over the past 4 weeks, during sexual intercourse, how often were you able to maintain your erection after you had 
penetrated (entered) your partner?. 
 
0 = Did not attempt intercourse 
 
1 = Almost never / never 
 
2 = A few times (much less than half the time) 
 
3 = Sometimes (about half the time) 
 
4 = Most times (much more than half the time) 
 
5 = Almost always / always 
 
Q5)  Over the past 4 weeks, during sexual intercourse, how difficult was it to maintain your erection to completion of 
intercourse? 
 
0 = Did not attempt intercourse 
 
1 = Extremely difficult 
 
2 = Very difficult 
 
3 = Difficult 
 
4 = Slightly difficult 
 
5 = Not difficult 
Q6)  Over the past 4 weeks, how many times have you attempted sexual intercourse? 
 
0 = No attempts 
 
1 = One to two attempts 
 
2 = Three to four attempts 
 
3 = Five to six attempts 
 
4 = Seven to ten attempts 
 
5 = Eleven+ attempts 
 
Q7)  Over the past 4 weeks, when you attempted sexual intercourse, how often was it satisfactory for you? 
 
0 = Did not attempt intercourse 
 
1 = Almost never / never 
 
2 = A few times (much less than half the time) 
 
3 = Sometimes (about half the time) 
 
4 = Most times (much more than half the time) 
 
5 = Almost always / always 
 
Q8)  Over the past 4 weeks, when you attempted sexual intercourse, how much have you enjoyed sexual intercourse? 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
76 
 
0 = No intercourse 
 
1 = No enjoyment 
 
2 = Not very enjoyable 
 
3 = Fairly enjoyable 
 
4 = Highly enjoyable 
 
5 = Very highly enjoyable 
 
Q9)  Over the past four weeks, when you had sexual stimulation or intercourse, how often did you ejaculate? 
 
0 = No sexual stimulation / intercourse 
 
1 = Almost never / never 
 
2 = A few times (much less than half the time) 
 
3 = Sometimes (about half the time) 
 
4 = Most times (much more than half the time) 
 
5 = Almost always / always 
 
Q10)   Over the past 4 weeks, when you had sexual stimulation or intercourse, how often did you have the feeling of 
orgasm or climax? 
 
0 = No sexual stimulation / intercourse 
 
1 = Almost never / never 
 
2 = A few times (much less than half the time) 
 
3 = Sometimes (about half the time) 
 
4 = Most times (much more than half the time) 
 
5 = Almost always / always 
 
Q11)  Over the past 4 weeks, how often have you felt sexual desire? 
 
1 = Almost never / never 
 
2 = A few times (much less than half the time) 
 
3 = Sometimes (about half the time) 
 
4 = Most times (much more than half the time) 
 
5 = Almost always / always 
 
 
Q12)  Over the past 4 weeks, how would you rate your level of sexual desire? 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
77 
 
1 = Very low / not at all 
 
2 = Low 
 
3 = Moderate 
 
4 = High 
 
5 = Very high 
 
Q13)  Over the past 4 weeks, how satisfied have you been with your overall sex life? 
 
1 = Very dissatisfied 
 
2 = Moderately dissatisfied 
 
3 = About equally satisfied and dissatisfied 
 
4 = Moderately satisfied 
 
5 = Very satisfied 
 
Q14)   Over the past 4 weeks, how satisfied have you been with your sexual relationship with your partner? 
 
1 = Very dissatisfied 
 
2 = Moderately dissatisfied 
 
3 = About equally satisfied and dissatisfied 
 
4 = Moderately satisfied 
 
5 = Very satisfied 
 
Q15)   Over the last 4 weeks, how would you rate your confidence that you could get and keep an erection? 
 
1 = Very low 
 
2 = Low 
 
3 = Moderate 
 
4 = High 
 
5 = Very high 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
78 
IPSS - International Prostate Symptom Score 
 
Put an X in the box (beside the number) that most closely corresponds to your response for each question.  
 
1.) Incomplete emptying: Over the past month, how often have you had a sensation of not emptying your 
bladder completely after you finished urinating?  
Not at all 
Less than 1 
time in 5 
Less than half 
the time 
About half the 
time 
More than half 
the time 
Almost always 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
2.) Frequency: Over the past month, how often have you had to urinate again less than 2 hours after you 
finished urinating? 
Not at all 
Less than 1 
time in 5 
Less than half 
the time 
About half the 
time 
More than half 
the time 
Almost always 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
3.) Intermittency: Over the last month, how often have you found that you stopped and started again several 
times when you urinated? 
Not at all 
Less than 1 
time in 5 
Less than half 
the time 
About half the 
time 
More than half 
the time 
Almost always 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
4.) Urgency: Over the last month, how difficult have you found it to postpone urination? 
Not at all 
Less than 1 
time in 5 
Less than half 
the time 
About half the 
time 
More than half 
the time 
Almost always 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
5.) Weak-stream: Over the past month, how often have you had a weak urinary stream? 
Not at all 
Less than 1 
time in 5 
Less than half 
the time 
About half the 
time 
More than half 
the time 
Almost always 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
6.) Straining: Over the past month, how often have you had to push or strain to begin urination? 
Not at all 
Less than 1 
time in 5 
Less than half 
the time 
About half the 
time 
More than half 
the time 
Almost always 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
7.) Nocturia: Over the past month, how many times did you typically get up to urinate from the time you went 
to bed until the time you got up in the morning? 
1 time 
2 times 
3 times 
4 times 
5 times 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
Subject initials and Date: _______________ 
8.) Quality of life due to urinary symptoms 
Delighted 
Pleased 
Mostly 
satisfied 
Mixed – 
about equally 
satisfied and 
dissatisfied 
Mostly 
dissatisfied 
Unhappy 
Terrible 
If you were to spend the rest of your life with your urinary 
condition the way it is now, how would you feel about that? 
0 
1 
2 
3 
4 
5 
6 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
79 
 
FOR STUDY STAFF ONLY 
Total Score___________________  
Note: Only score questions 1-7 
 
1-7 mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic. 
 
 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
80 
 
 
 
This questionnaire is designed to measure Quality of Life issues in patients with Prostate 
cancer.  To help us get the most accurate measurement, it is important that you answer all 
questions honestly and completely. 
 
Remember, as with all medical records, information contained within this survey will remain 
strictly confidential. 
 
 
 
 
 
 
 
 
Today's Date (please enter date when survey completed):  Month 
Day 
Year  
 
 
 
Study ID:    
 
 
 
 
 
EPIC 
 
The Expanded Prostate Cancer Index Composite 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
81 
Page  2 
Do Not Mark in This Space 
 
 
 
 
 
 
1. Over the past 4 weeks, how often have you leaked urine? 
More than once a day ...................... 1 
About once a day ............................. 2 
More than once a week.................... 3 
(Circle one number) 
23/ 
About once a week........................... 4 
Rarely or never.................................. 5 
2. Over the past 4 weeks, how often have you urinated blood?  
More than once a day ...................... 1 
About once a day ............................. 2 
More than once a week.................... 3 
(Circle one number) 
24/ 
About once a week .......................... 4 
Rarely or never ................................. 5 
3. 
Over the past 4 weeks, how often have you had pain or burning with urination?  
More than once a day ...................... 1 
About once a day ............................. 2 
More than once a week.................... 3 
(Circle one number) 
25/ 
About once a week .......................... 4 
Rarely or never ................................. 5 
4. 
Which of the following best describes your urinary control during the last 4 weeks?  
No urinary control whatsoever  ......... 1 
Frequent dribbling..............................2 
(Circle one number) 
26/ 
Occasional dribbling ......................... 3 
Total control ..................................... 4 
 
 
URINARY FUNCTION 
This section is about your urinary habits. Please consider ONLY THE LAST 4 WEEKS. 


NCI Protocol #:Not Applicable 
DF/HCC Protocol #:15-120 
Protocol Version Date: 09/12/2018 
 
82 
EPIC 2.2002 
Copyright 2002. The University of Michigan. All rights reserved.
Page  3 
Do Not Mark in This Space 
 
5. How many pads or adult diapers per day did you usually use to control leakage 
1. during the last 4 weeks? 
 
None ......................................................................... 
0 
1 pad per day..........................................................… 
1 
2 pads per day............................................................ 
2 
(Circle one number) 
3 or more pads per day............................................... 
3 
27/ 
 
 
6. How big a problem, if any, has each of the following been for you during the last 4 weeks? 
(Circle one number on each line) 
 
 
No 
Problem 
Very Small 
Problem 
Small 
Problem 
Moderate 
Problem 
Big Problem 
 
a. Dripping or leaking urine …...... 
0 
1 
2 
3 
4 
28/ 
b. Pain or burning on urination..... 
0 
1 
2 
3 
4 
29/ 
c. Bleeding with urination............. 
0 
1 
2 
3 
4 
30/ 
d. Weak urine stream or incomplete 
emptying……….. 
0 
1 
2 
3 
4 
31/ 
e. Waking up to urinate………….. 
0 
1 
2 
3 
4 
32/ 
f. Need to urinate frequently during 
the day ………………………….. 
0 
1 
2 
3 
4 
33/ 
 
 
 
7. Overall, how big a problem has your urinary function been for you during the last 4 weeks? 
No problem ...................................... .1 
Very small problem .......................... .2 
Small problem..................................... 3 
(Circle one number) 
34/ 
Moderate problem. .......................... .4 
Big problem ..................................... .5 
 
 
 
 
 
 
 
 
 
 
EPIC 2.2002 
                                                                        Copyright 2002. The University of Michigan. All rights reserved. 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
 
83 
 
Page  4 
 
 
 
 
 
 
 
                 Do Not Mark in This Space 
 
 
 
 
 
8. How often have you had rectal urgency (felt like I had to pass stool, but did not) during 
the last 4 weeks? 
More than once a day ................................. 1 
About once a day ....................................... 2 
More than once a week................................ 3 (Circle one number) 
42/ 
About once a week ..................................... 4 
Rarely or never ............................................. 5 
9. How often have you had uncontrolled leakage of stool or feces? 
More than once a day ................................. 1 
About once a day ....................................... 2 
More than once a week................................ 3 (Circle one number) 
43/ 
About once a week ..................................... 4 
Rarely or never ............................................. 5 
10. How often have you had stools (bowel movements) that were loose or liquid 
(no form, watery, mushy) during the last 4 weeks? 
Never...................................................... 1 
Rarely ..................................................... 2 
About half the time................................... 3 (Circle one number) 
44/ 
Usually ..................................................... 4 
Always ..................................................... 5 
11. How often have you had bloody stools during the last 4 weeks? 
Never. .............................................. 1 
Rarely ............................................... 2 
About half the time............................. 3 (Circle one number) 
45/ 
Usually ............................................... 4 
Always ............................................... 5 
 
BOWEL HABITS 
The next section is about your bowel habits and abdominal 
pain. Please consider ONLY THE LAST 4 WEEKS. 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
 
84 
EPIC 2.2002 
                                                                        Copyright 2002. The University of Michigan. All rights reserved.
Page  5 
 
 
 
 
 
 
 
      Do Not Mark in This Space 
12. How often have your bowel movements been painful during the last 4 weeks? 
Never. .............................................. 1 
Rarely ............................................... 2 
About half the time............................ 3 (Circle one number) 
46/ 
Usually ............................................... 4 
Always ............................................... 5 
13. How many bowel movements have you had on a typical day during the last 4 weeks? 
Two or less. ...................................... 1 
Three to four.......................................2 
(Circle one number) 
47/ 
Five or more ..................................... 3 
14. How often have you had crampy pain in your abdomen, pelvis or rectum during the last 4 weeks? 
More than once a day ....................... 1 
About once a day ............................. 2 
More than once a week..................... 3 
(Circle one number) 
48/ 
About once a week ........................... 4 
Rarely or never .................................. 5 
15. How big a problem, if any, has each of the following been for you? (Circle one number on each line) 
 
a. Urgency to have 
No 
Problem 
Very Small 
Problem 
Small 
Problem 
Moderate 
Problem 
Big 
Problem 
a bowel movement  .................. 
0 
1 
2 
3 
4 
49/ 
b. Increased frequency of 
bowel movements..................... 
0 
1 
2 
3 
4 
50/ 
c. Watery bowel movements......... 
0 
1 
2 
3 
4 
51/ 
d. Losing control of your stools...... 
0 
1 
2 
3 
4 
52/ 
e. Bloody stools ............................ 
0 
1 
2 
3 
4 
53/ 
f. Abdominal/ Pelvic/Rectal pain... 
0 
1 
2 
3 
4 
54/ 
 
 
 
 
EPIC 2.2002 
                                                                        Copyright 2002. The University of Michigan. All rights reserved


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
 
85 
Page  6 
 
 
 
 
 
 
 
      Do Not Mark in This Space 
 
16. Overall, how big a problem have your bowel habits been for you during the last 4 weeks? 
No problem ...................................... 1 
Very small problem .......................... 2 
Small problem.................................... 3 
(Circle one number) 
55/ 
Moderate problem. .......................... 4 
Big problem ..................................... 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EPIC 2.2002 
                                                                        Copyright 2002. The University of Michigan. All rights reserved


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
 
86 
Page  7 
 
 
 
 
 
 
 
      Do Not Mark in This Space 
 
17. How would you rate each of the following during the last 4 weeks? (Circle one number on each line) 
 
Very 
Poor to 
None 
Poor Fair 
Good Very 
Good 
 
a. Your level of sexual desire?....................................... 
1 
2 
3 
4 
5 
56/ 
b. Your ability to have an erection?................................ 
1 
2 
3 
4 
5 
57/ 
c. Your ability to reach orgasm (climax)?....................... 
1 
2 
3 
4 
5 
58/ 
 
18. How would you describe the usual QUALITY of your erections during the last 4 weeks? 
 
None at all......................................................................................... 
1 
Not firm enough for any sexual activity.............................................. 
2 
Firm enough for masturbation and foreplay only............................... 
3 
(Circle one number) 
59/ 
Firm enough for intercourse.............................................................. 
4 
 
19. How would you describe the FREQUENCY of your erections during the last 4 weeks? 
 
I NEVER had an erection when I wanted one................................... 
1 
I had an erection LESS THAN HALF the time I wanted one............. 
2 
I had an erection ABOUT HALF the time I wanted one .................... 3 
(Circle one number) 
60/ 
I had an erection MORE THAN HALF the time I wanted one............ 4 
I had an erection WHENEVER I wanted one..................................... 5 
 
20. How often have you awakened in the morning or night with an erection during the last 4 weeks? 
 
Never …................................................................ 1 
Less than once a week.......................................... 2 
About once a week................................................ 
3 
(Circle one number) 
61/ 
Several times a week.......................…................. 
4 
Daily………………….........................…................. 
5 
 
 
EPIC 2.2002 
                                                                        Copyright 2002. The University of Michigan. All rights reserved
SEXUAL FUNCTION 
The next section is about your current sexual function and sexual satisfaction. Many of 
the questions are very personal, but they will help us understand the important issues 
that you face every day.  Remember, THIS SURVEY INFORMATION IS COMPLETELY 
CONFIDENTIAL. Please answer honestly about THE LAST 4 WEEKS ONLY. 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
 
87 
Page  8 
 
 
 
 
 
 
 
      Do Not Mark in This Space 
21. During the last 4 weeks, how often did you have any sexual activity? 
Not at all ..................................................................1 
 
 
 
 
 
 
22. During the last 4 weeks, how often did you have sexual intercourse? 
Not at all ..................................................................1 
 
 
 
 
 
 
 
23. Overall, how would you rate your ability to function sexually during the last 4 weeks? 
 
Very poor.............................................................. 
1 
Poor...................................................................... 
2 
Fair....................................................................... 
3 
(Circle one number) 
64/ 
Good.................................................................... 
4 
Very good............................................................. 
5 
24. How big a problem during the last 4 weeks, if any, has each of the following been for you? 
(Circle one number on each line) 
 
 
 
 
 
 
 
25. Overall, how big a problem has your sexual function or lack of sexual function been for you during 
the last 4 weeks? 
 
No problem........................................................... 
1 
Very small problem............................................... 2 
Small problem....................................................... 
3 
(Circle one number) 
68/ 
Moderate problem................................................ 
4 
Big problem.......................................................... 
5 
 
EPIC 2.2002 
   Copyright 2002. The University of Michigan. All rights reserved
Less than once a week.......................................... 2 
About once a week................................................ 
3 
(Circle one number) 
62/ 
Several times a week.......................…................. 
4 
Daily………………….........................…................. 
5 
Less than once a week.......................................... 2 
About once a week................................................ 
3 
(Circle one number) 
63/ 
Several times a week.......................…................. 
4 
Daily………………….........................…................. 
5 
No 
Very Small 
Small 
Moderate 
Big 
Problem Problem 
Problem 
Problem 
Problem 
a. Your level of sexual desire........ 
0 
1 
2 
3 
4 
65/ 
b. Your ability to have an erection. 
0 
1 
2 
3 
4 
66/ 
c. Your ability to reach an orgasm. 
0 
1 
2 
3 
4 
67/ 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
88 
Page  9 
 
 
 
 
 
 
 
   Do Not Mark in This Space 
 
 
 
 
 
26. Over the last 4 weeks, how often have you experienced hot flashes?  
More than once a day ....................... 1 
About once a day ............................. 2 
More than once a week....................   3 
(Circle one number) 
69/ 
About once a week ........................... 4 
Rarely or never .................................. 5 
27. How often have you had breast tenderness during the last 4 weeks?  
More than once a day ....................... 1 
About once a day ............................. 2 
More than once a week....................   3 
(Circle one number) 
70/ 
About once a week ........................... 4 
Rarely or never .................................. 5 
28. During the last 4 weeks, how often have you felt depressed?  
More than once a day ....................... 1 
About once a day ............................. 2 
More than once a week....................   3 
(Circle one number) 
71/ 
About once a week ........................... 4 
Rarely or never .................................. 5 
29. During the last 4 weeks, how often have you felt a lack of energy?  
More than once a day ....................... 1 
About once a day ............................. 2 
More than once a week....................  3 
(Circle one number) 
72/ 
About once a week ........................... 4 
Rarely or never .................................. 5 
 
 
 
EPIC 2.2002 
                           Copyright 2002. The University of Michigan. All rights reserved 
 
HORMONAL FUNCTION 
The next section is about your hormonal function.  Please consider ONLY THE LAST 4 WEEKS. 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
89 
 
Page  9 
 
 
 
 
 
 
 
Do Not Mark in This Space 
 
30. How much change in your weight have you experienced during the last 4 weeks, if any?  
Gained 10 pounds or more…………..1 
Gained less than 10 pounds …..…….2 
No change in weight………. …..……. 3 
(Circle one number) 
73/  
Lost less than 10 pounds …..…….….4 
Lost 10 pounds or more…….…..……5 
 
 
31. How big a problem during the last 4 weeks, if any, has each of the following been for you? 
(Circle one number on each line) 
 
 
No 
Problem 
Very Small 
Problem 
Small 
Problem 
Moderate 
Problem 
Big 
Problem 
a. 
Hot flashes………...................... 
0 
1 
2 
3 
4 
74/ 
b. 
Breast tenderness/enlargement.. 
0 
1 
2 
3 
4 
75/ 
c. 
Loss of Body Hair...…................. 
0 
1 
2 
3 
4 
76/ 
d. 
Feeling depressed..…................. 
0 
1 
2 
3 
4 
77/ 
e. 
Lack of energy........…................. 
0 
1 
2 
3 
4 
78/ 
f. 
Change in body weight 
0 
1 
2 
3 
4 
79/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EPIC 2.2002 
 
 
 
Copyright 2002. The University of Michigan. All rights reserved 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
90 
Page  10 
 
 
 
 
 
 
 
Do Not Mark in This Space 
 
 
 
32. Overall, how satisfied are you with the treatment you received for your prostate cancer? 
Extremely dissatisfied ................................................ 1 
Dissatisfied................................................................ 2 
Uncertain....................................................................  3 
(Circle one number) 
80/ 
Satisfied .................................................................... 4 
Extremely satisfied .................................................... 5 
 
 
 
 
 
 
 
 
 
 
THANK YOU VERY MUCH!! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EPIC 2.2002 
 
 
 
 
Copyright 2002. The University of Michigan. All rights reserved 
 
 
Overall Satisfaction 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
91 
Men’s Sexual Health Questionnaire (MSHQ) 
 
INTRODUCTION: These next questions ask about your urge or desire to have sex with your MAIN PARTNER. 
Some people refer to this as “feeling horny”. In answering these questions, we only want to know about the sexual urges 
you have felt toward your MAIN PARTNER, and not whether you actually had sex. Some of these questions might be 
difficult to answer, but we would appreciate you being as honest as possible. Remember, all of your answers are 
confidential.  
 
 
Do you have a “MAIN PARTNER”? __ Yes __ No 
IF YOU DO NOT HAVE A MAIN PARTNER, PLEASE ANSWER ALL QUESTIONS WITHOUT THE 
REFERENCE TO “MAIN PARTNER” UNLESS OTHERWISE DIRECTED. 
 
1. In the last month, how often have you felt an urge or desire to have sex with your MAIN PARTNER? 
 
Would you say (Check only one): 
__ All of the time 
__ Most of the time 
__ About half of the time 
__ Less than half of the time 
__ None of the time 
 
 
2. In the last month, how would you rate your urge or desire to have sex with your MAIN PARTNER? 
 
(Check only one) 
__ Very high 
__ High 
__ Moderate 
__ Low 
__ Very low or none at all 
 
 
3. In the last month, have you been bothered by your level of sexual desire?  
 
Have you been… (Check only one): 
__ Not at all bothered 
__ A little bit bothered 
__ Moderately bothered 
__ Very bothered 
__ Extremely bothered 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
92 
4. Compared to ONE month ago, has your urge or desire for sex with your MAIN PARTNER increased or decreased?  
 
Has it… (Check only one): 
__ Increased a lot 
__ Increased moderately 
__ Neither increased nor decreased 
__ Decreased moderately 
__ Decreased a lot 
 
INTRODUCTION: The next set of questions asks about the sexual activity you have had in the last month. In 
answering these questions, we want to know about all of the sexual activity you have had with your MAIN PARTNER, 
with other partners, or masturbating. By sexual activity, we mean any type of sex you may have had, including 
intercourse, oral sex, or any other sexual activities that could lead to ejaculation or cumming. 
 
5. In the last month, how often have you had sexual activity, including masturbating, intercourse, oral sex, or any 
other type of sex?  
 
(Check only one): 
__ 0 times per month 
__ 1-3 times per month 
__ 4-6 times per month 
__ More than 6 times per month 
__ Daily or almost daily 
 
If your answer is “0” for item 5, please answer the following questions: 
 
A. When was the last time you had sex? (Check only one) 
__1-3 months ago 
__ 4-6 months ago 
__ 7-12 months ago 
__ More than 1 year to 2 years ago 
__ More than 2 years ago 
 
B. What are the reasons you have not had sex? 
- I could not have sex because I could not get an erection: __ Yes __ No 
- I could not have sex because I could not ejaculate or “cum”: __ Yes __ No 
- I had no partner: __ Yes __ No 
 
Other (specify): __________________________________________________ 
 
 
 
 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
93 
6. Compared to ONE month ago, has the number of times you have had sexual activity increased or decreased?  
 
Would you say it has… (Check only one): 
__ Increased a lot 
__ Increased moderately 
__ Neither increased nor decreased 
__ Decreased moderately 
__ Decreased a lot 
 
7.  In the last month, have you been bothered by these changes in the number of times you have had sexual activity?  
 
Have you been… (Check only one): 
__ Not at all bothered 
__ A little bit bothered 
__ Moderately bothered 
__ Very bothered 
__ Extremely bothered 
 
INTRODUCTION: These next questions deal with various aspects of your ability to have sex. In answering these 
questions, we want to know about all of the sexual activity you have had with your MAIN PARTNER, with other 
partners, or masturbating. By sexual activity, we mean any type of sex you may have had, including intercourse, oral 
sex, or any other sexual activities that could lead to ejaculation or cumming. Some of these questions might be difficult 
to answer. We hope that you can answer as many of them as possible, and be as honest as possible when answering 
them. Please remember that all of your answers are confidential. First, we would like to ask you a few questions about 
your erections, which some people refer to as “hard-ons”.  
 
 
In the last month have you taken Viagra or any similar drugs for problems with your erection?    __  Yes   __ No 
 
 
 
8.  In the last month, without using drugs like Viagra, how often have you been able to get an erection when you 
wanted to?  
 
Would you say… (Check only one): 
__ All of the time 
__ Most of the time 
__ About half of the time 
__ Less than half of the time 
__ None of the time 
__ Used Viagra or similar drug with every sexual encounter 
 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
94 
9.  In the last month, if you were able to get an erection without using drugs like Viagra, how often were you able to 
stay hard as long as you wanted to?  
 
Would you say… (Check only one): 
__ All of the time 
__ Most of the time 
__ About half of the time 
__ Less than half of the time 
__ None of the time 
__ Used Viagra or similar drug with every sexual encounter 
 
 
10. In the last month, if you were able to get an erection, without using drugs like Viagra, how would you rate the 
hardness of your erection?  
 
Would you say they were… (Check only one): 
__ Completely hard 
__ Almost completely hard 
__ Mostly hard, but can be slightly bent 
__ A little hard, but bends easily 
__ Not at all hard 
__ Used Viagra or similar drug with every sexual encounter 
 
 
 
11. In the last month, if you have had difficulty getting hard or staying hard without using drugs like Viagra, have 
you been bothered by this problem?…  
 
(Check only one): 
__ Not at all bothered/Did not have a problem with erection 
__ A little bit bothered 
__ Moderately bothered 
__ Very bothered 
__ Extremely bothered 
 
 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
95 
INTRODUCTION: The next section deals with male ejaculation and the pleasure you have with ejaculation. 
Ejaculation or cumming is the release of semen or cum during sexual climax. In answering these questions, we want to 
know about all of your ejaculations when having sexual activity. These could include ejaculations you have had with 
your MAIN PARTNER, as well as with other partners, or ejaculations you could have had when masturbating. 
 
12.  In the last month, how often have you been able to ejaculate or cum when having sexual activity? 
 
(Check only one) 
__ All of the time 
__ Most of the time 
__ About half of the time 
__ Less than half of the time 
__ None of the time/Could not ejaculate 
 
 
13.  In the last month, when having sexual activity, how often have you felt like you were ejaculating or cumming but 
no fluid came out?  
 
Would you say… (Check only one) 
__ All of the time 
__ Most of the time 
__ About half of the time 
__ Less than half of the time 
__ None of the time 
__ Could not ejaculate 
 
 
14.  In the last month, when having sexual activity, how often did you feel that you took too long to ejaculate or cum?  
 
Would you say… (Check only one) 
__ All of the time 
__ Most of the time 
__ About half of the time 
__ Less than half of the time 
__ None of the time 
__ Could not ejaculate 
 
 
15. In the last month, when having sexual activity, how often did you feel that you ejaculated or came faster than you 
would have wanted to?  
 
(Check only one) 
__ All of the time 
__ Most of the time 
__ About half of the time 
__ Less than half of the time 
__ None of the time 
__ Could not ejaculate 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
96 
16.  Compared to ONE month ago, would you say the amount of time it takes from when you first start ejaculating or 
cumming to when you have stopped ejaculating or cumming has...  
 
(Check only one) 
__ Increased a lot 
__ Increased moderately 
__ Neither increased nor decreased 
__ Decreased moderately 
__ Decreased a lot 
__ Could not ejaculate 
 
 
17.  Some men have a medical condition called retrograde ejaculation. Men with this condition say it feels like their 
ejaculation goes backwards into their bladder rather than out through their penis. In the last month, when having 
sexual activity, how often did you feel that your ejaculation or cum was going backwards?  
 
Would you say… (Check only one) 
__ All of the time 
__ Most of the time 
__ About half of the time 
__ Less than half of the time 
__ None of the time 
__ Could not ejaculate 
 
 
18.    In the last month, how would you rate the strength or force of your ejaculation? Would you say it is…  
 
(Check only one) 
__ As strong as it always was 
__ A little less strong than it used to be 
__ Somewhat less strong than it used to be 
__ Much less strong than it used to be 
__ Very much less strong than it used to be 
__ Could not ejaculate 
 
 
19.  In the last month, how would you rate the amount or volume of semen or fluid when you ejaculate? 
 
Would you say it is… (Check only one) 
__ As much as it always was 
__ A little less than it used to be 
__ Somewhat less than it used to be 
__ Much less than it used to be 
__ Very much less than it used to be 
__ Could not ejaculate 
 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
97 
20.  Compared to ONE month ago, would you say the physical pleasure you feel when you ejaculate or cum has…  
 
(Check only one) 
__ Increased a lot 
__ Increased moderately 
__ Neither increased nor decreased 
__ Decreased moderately 
__ Decreased a lot 
__ Could not ejaculate 
 
 
21. In the last month, when having sexual activity, how much physical pleasure did you have when you were 
ejaculating or cumming?  
 
Would you say… (Check only one) 
__ A great deal 
__ A moderate amount 
__ A slight amount 
__ Very little 
__ None 
__ Could not ejaculate 
 
 
22.   In the last month, when having sexual activity, how pleasurable has the feeling of ejaculating or cumming been?  
 
Would you say… (Check only one) 
__ Very pleasurable 
__ Somewhat pleasurable 
__ Neither pleasurable nor unpleasurable 
__ Somewhat unpleasurable 
__ Very unpleasurable 
__ Could not ejaculate 
 
 
23.  Do you think that the amount of physical pleasure you have when you ejaculate or cum is dependent on the 
amount or volume of your ejaculation?  
 
Would you say it is… (Check only one) 
__ Very dependent 
__ Dependent 
__ Somewhat dependent 
__ Not very dependent 
__ Not at all dependent 
__ Could not ejaculate 
 
 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
98 
24.  Do you think the amount of physical pleasure you have when you ejaculate or cum is dependent on the strength or 
force of your ejaculation?  
 
Would you say it is… (Check only one) 
__ Very dependent 
__ Dependent 
__ Somewhat dependent 
__ Not very dependent 
__ Not at all dependent 
__ Could not ejaculate 
 
 
25.  In the last month, have you experienced any physical pain or discomfort when you ejaculated or came?  
 
Would you say you have… (Check only one) 
__ No pain at all 
__ Slight amount of pain or discomfort 
__ Moderate amount of pain or discomfort 
__ Strong amount of pain or discomfort 
__ Extreme amount of pain or discomfort 
__ Could not ejaculate 
 
 
26.  In the last month, if you have had any ejaculation difficulties or have been unable to ejaculate or cum, have you 
been bothered by this?  
 
Would you say… (Check only one) 
__ Not at all bothered/ Did not have a problem with ejaculation 
__ A little bit bothered 
__ Moderately bothered 
__ Very bothered 
__ Extremely bothered 
 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
99 
These next few questions ask about your relationship with your MAIN PARTNER over the last month. Some of these 
questions are about your sexual relationship only, while others are about your general relationship, and not just your 
sexual relationship. SKIP NEXT SIX QUESTIONS IF NO MAIN PARTNER  
 
27.  Generally, how satisfied are you with the overall sexual relationship you have with your MAIN PARTNER? 
 
Would you say you are… (Check only one) 
__ Extremely Satisfied 
__ Moderately Satisfied 
__ Neither Satisfied nor Unsatisfied 
__ Moderately Unsatisfied 
__ Extremely Unsatisfied 
 
 
28.  Generally, how satisfied are you with the quality of the sex life you have with your MAIN PARTNER? 
 
Would you say you are… (Check only one) 
__ Extremely Satisfied 
__ Moderately Satisfied 
__ Neither Satisfied nor Unsatisfied 
__ Moderately Unsatisfied 
__ Extremely Unsatisfied 
 
 
29.  Generally, how satisfied are you with the number of times you and your MAIN PARTNER have sex? 
 
Would you say you are… (Check only one) 
__ Extremely Satisfied 
__ Moderately Satisfied 
__ Neither Satisfied nor Unsatisfied 
__ Moderately Unsatisfied 
__ Extremely Unsatisfied 
 
 
30.  Generally, how satisfied are you with the way you and your MAIN PARTNER show affection during sex? 
 
Would you say you are… (Check only one) 
__ Extremely Satisfied 
__ Moderately Satisfied 
__ Neither Satisfied nor Unsatisfied 
__ Moderately Unsatisfied 
__ Extremely Unsatisfied 
 
 
 
 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
100 
31.  Generally, how satisfied are you with the way you and your MAIN PARTNER communicate about sex? 
 
Would you say you are… (Check only one) 
__ Extremely Satisfied 
__ Moderately Satisfied 
__ Neither Satisfied nor Unsatisfied 
__ Moderately Unsatisfied 
__ Extremely Unsatisfied 
 
 
32.  Generally, not counting your sexual relationship, how satisfied are you with all other aspects of the relationship 
you have with your MAIN PARTNER?  
 
Would you say you are… (Check only one): 
__ Extremely Satisfied 
__ Moderately Satisfied 
__ Neither Satisfied nor Unsatisfied 
__ Moderately Unsatisfied 
__ Extremely Unsatisfied 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
101 
Harbor-UCLA 7-day Sexual Function Questionnaire  
 
Psychosexual Daily Questionnaire 
 
 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
102 
PANAS 
 
This scale consists of a number of words that describe different feelings and emotions. Read each item and then circle the appropriate answer 
next to that word. Indicate to what extent you have felt this way during the past week.  
Use the following scale to record your answers. 
(1) = Very slightly or not 
at all 
(2) = A little 
(3) = Moderately 
(4) = Quite a bit 
(5) = Extremely 
 
 
Very 
slightly or 
not at all 
A little 
Moderately 
Quite a bit 
Extremely 
1. 
Interested 
1 
2 
3 
4 
5 
2. 
Distressed 
1 
2 
3 
4 
5 
3. 
Excited 
1 
2 
3 
4 
5 
4. 
Upset 
1 
2 
3 
4 
5 
5. 
Strong 
1 
2 
3 
4 
5 
6. 
Guilty 
1 
2 
3 
4 
5 
7. 
Scared 
1 
2 
3 
4 
5 
8. 
Hostile 
1 
2 
3 
4 
5 
9. 
Enthusiastic 
1 
2 
3 
4 
5 
10. Proud 
1 
2 
3 
4 
5 
11. Irritable 
1 
2 
3 
4 
5 
12. Alert 
1 
2 
3 
4 
5 
13. Ashamed 
1 
2 
3 
4 
5 
14. Inspired 
1 
2 
3 
4 
5 
15. Nervous 
1 
2 
3 
4 
5 
16. Determined 
1 
2 
3 
4 
5 
17. Attentive 
1 
2 
3 
4 
5 
18. Jittery 
1 
2 
3 
4 
5 
19. Active 
1 
2 
3 
4 
5 
20. Afraid 
1 
2 
3 
4 
5 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
103 
Your Health and Well-Being SF-36 
 
For each of the following questions, please select the appropriate response. 
 
1. 
In general, would you say your health is: 
1Excellent 
2Very Good 
3Good 
4Fair 
5Poor 
 
2. 
Compared to one year ago, how would you rate your health in general now? 
1Much better now than one year ago 
2Somewhat better now than one year ago 
3About the same as one year ago 
4Somewhat worse now than one year ago 
5Much worse now that one year ago 
 
3. 
The following questions are about activities you might do during a typical day. Does your health now limit you in 
these activities? If so, how much? 
 
Yes, limited 
a lot 
Yes, limited 
a little 
No, not 
limited at all 
a. Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sports 
1 
2 
3 
b. Moderate activities, such as moving a table, pushing a vacuum 
cleaner, bowling, or playing golf 
1 
2 
3 
c. Lifting or carrying groceries 
1 
2 
3 
d. Climbing several flights of stairs 
1 
2 
3 
e. Climbing one flight of stairs 
1 
2 
3 
f. Bending, kneeling, or stopping 
1 
2 
3 
g. Walking more than a mile 
1 
2 
3 
h. Walking several hundred yards 
1 
2 
3 
i. Walking one hundred yards 
1 
2 
3 
j. Bathing or dressing yourself 
1 
2 
3 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
104 
 
4. 
During the past 4 weeks, how much of the time have you had any of the following problems with your work or other regular 
daily activities as a result of your physical health? 
 
 
5
 
During the past 4 weeks, how much of the time have you had any of the following problems with your work or other regular 
daily activities as a result of any emotional problems ( such as feeling depressed or anxious).? 
 
 
6. 
During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal social 
activities with family friends, neighbors, or groups? 
 
1 Not at all 
2 Slightly 
3 Moderately 
4 Quite a Bit 
5 Extremely 
 
7. 
How much bodily pain have you had during the past 4 weeks? 
 
1 None 
2 Very Mild 3 Mild 
4 Moderate 5 Severe 
6 Very Severe 
 
8. 
During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and 
housework)? 
1 None 
2 A little bit 
3 Moderately 
4 Quite a Bit 
5 Extremely 
 
 
 
 
All of the 
time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
a. Cut down on the amount of time you spent on 
work or other activities 
1 
2 
3 
4 
5 
b. Accomplished less than you would like 
1 
2 
3 
4 
5 
c. Were limited in the kind of work or other 
activities
1 
2 
3 
4 
5 
d. Had difficulty performing the work or other 
activities (for example, it took extra effort) 
1 
2 
3 
4 
5 
All of the 
time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
a. Cut down on the amount of time you spent on 
work or other activities 
1 
2 
3 
4 
5 
b. Accomplished less than you would like 
1 
2 
3 
4 
5 
c. Did work or other activities less carefully than 
usual 
1 
2 
3 
4 
5 
 
 
 
 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
105 
 
9. 
These questions are about how you feel and how things have been with you during the past 4 weeks. For each question, please 
give the one answer that comes close to the way you have been feeling 
 
 
 
 
 
 
 
 
 
How much of the time during the past 4 weeks…. 
All of the 
time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
a. Did you feel full of life? 
1 
2 
3 
4 
5 
b. Have you been very nervous? 
1 
2 
3 
4 
5 
c. Have you felt so down in the dumps that nothing 
could cheer you up? 
1 
2 
3 
4 
5 
d. Have you felt calm and peaceful? 
1 
2 
3 
4 
5 
e. Did you have a lot of energy? 
1 
2 
3 
4 
5 
f. Have you felt downhearted and depressed? 
1 
2 
3 
4 
5 
g. Did you feel worn out?  
1 
2 
3 
4 
5 
h. Have you been happy? 
1 
2 
3 
4 
5 
i. Did you feel tired? 
1 
2 
3 
4 
5 
10. During the past 4 weeks, how much of the time has 
your physical health or emotional problems 
interfered with your social activities (like visiting 
friends, relatives, etc.) 
1 
2 
3 
4 
5 
11. How TRUE or FALSE is each of the 
following statements for you? 
Definitely 
True 
Mostly 
True 
Don’t 
Know 
Mostly 
False 
Definitely 
False 
a. I seem to get sick a little easier than 
other people 
1 
2 
3 
4 
5 
b. I am healthy as anybody I know 
1 
2 
3 
4 
5 
c. I expect my health to get worse 
1 
2 
3 
4 
5 
d. My health is excellent 
1 
2 
3 
4 
5 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
106 
DISF-SR II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEROGATIS INTERVIEW FOR SEXUAL 
 FUNCTION II 
(Male Version) 
 
 
 
 
 
 
 
 
 
 
COPYRIGHT  2002, 2005 by LEONARD R. DEROGATIS 
 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
107 
DISF-SR II (M) 
 
NAME:   
 
 
DATE: 
 
      LOCATION  
                 
 
AGE:  
      
EDUCATION: 
 
MAR. STAT: 
ID NO.  
 
 
 
INSTRUCTIONS 
Below are listed a brief set of questions that ask about your sexual thoughts and activities. The questions 
are divided into five sections that ask about different aspects of your sexual experiences. 
Some questions request that you answer in terms of “how often” you engage in certain sexual activities. 
Other questions ask you to report “how intense” some of your sexual experiences are. A third type of question 
inquires about how much you “enjoyed” or were “satisfied” by different aspects of your sexual activities and 
relationship. 
 
For each Section, there are one or more scale definition boxes located alongside the questions. Indicators at 
the tops of the boxes tell you which questions the particular scale definition should be used with. 
 
The inventory is quite brief, so please take your time in answering all the questions. Please circle the scale 
number for each question that best describes your personal experience. If you have any questions, please ask 
the person who gave you the inventory for help or clarification. 
 
 
 
SECTION I – SEXUAL DESIRE 
 
During the last 30 days, or since the last time you completed this inventory, 
 
1.1 
How often did you have thoughts or fantasies 
about sexual, romantic, or erotic situations? 
Questions 1.1 – 1.4 0
 
1 
2 
3 
4 
5 
6 
7 
 
1.2 
How often did you feel sexual desire? 0
 
1 
2 
3 
4 
5 
6 
7 
 
1.3 
How often did you want to be involved in sexual activities? 0
 
1 
2 
3 
4 
5 
6 
7 
 
1.4 
With the partner of your choice, how often did you want to 
have sexual intercourse? 0
 
1 
2 
3 
4 
5 
6 
7 
1.5 
Usually, how strong was your sexual desire? 
 0  
1 
2 
3 
4 
5 
=  Sum of 1.1 thru 1 
 
7= 2 or more times a day 
6= once a day 
5= 4 to 6 times a week 
4= 2 or 3 times a week 
3= once a week 
2= once or twice a month 1= 
less than once a month 0= 
5= intense 
4= very strong 
3= strong 
2= moderate 
1= mild 
0= absent  
Question 1.5 
 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
108 
=0 
SECTION  II – SEXUAL AROUSAL 
During the past 30 days, or since the last time you filled out this inventory, 
 
2.1 
How often did you feel sexually aroused , that is have 
Questions 2.1 – 2.4 
a satisfactory erection with or without your partner? 
0 
1 
2 
3 
4 
5 
6 
7 
 
2.2 
How often did you have a full erection upon awakening In the morning? 
0 
1 
2 
3 
4 
5 
6 
7 
 
2.3 
How often did you have an erection that enabled you to penetrate your 
partner during intercourse? 
0 
1 
2 
3 
4 
5 
6 
7 
 
2.4 
How often were you able to maintain a good erection to your 
satisfaction throughout sexual intercourse? 
0 
1 
2 
3 
4 
5 
6 
7 
Question 2.5 
 
2.5 
Please rate your ability your ability to get and maintain an 
erection during this period? 
0 
1 
2 
3 
4 
5 
 
 
= Sum of 2.1 to 2.5 
 
 
SECTION  III – SEXUAL ACTIVITY 
 
During the last 30 days, or since the last time you filled out this inventory, 
 
3.1 
How often have you engaged in kissing, petting or sexual 
touching with your partner? 
0 
1 
2 
3 
4 
5 
6 
7 
Questions 3.1-3.5 
 
3.2 
How often have you engaged in masturbation? 
0 
1 
2 
3 
4 
5 
6 
7 
 
3.3 
How often have you initiated sexual experiences with your 
partner? 
0 
1 
2 
3 
4 
5 
6 
7 
 
3.4 
How often have you had sexual intercourse that led to orgasm for 
you or your partner? 
0 
1 
2 
3 
4 
5 
6 
7 
 
3.5 
How often have you engaged in other sexual activities that led 
to orgasm for you or your 
partner? 
= Sum 
0 
1 
2 
3 
4 
5 
6 
7 
3.1-3.5 
7= 2 or more times a day 
6= once a day 
5= 4 to 6 times a week 
4= 2 or 3 times a week 
3= once a week 
2= once or twice a month 1= 
less than once a month 0= 
N t t ll
5= excellent 
4= good 
3= fair 
2= weak 
1= very poor  
0=absent 
7= 2 or more times a day 
6= once a day 
5= 4 to 6 times a week 
4= 2 or 3 times a week 
3= once a week 
2= once or twice a month 1= 
less than once a month 0= 
 
COPYRIGHT 2002 by Leonard R. Derogatis, Ph.D. 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
109 
SECTION  IV – ORGASM 
 
During the last 30 days, or since the last time you filled out this inventory, 
(NOTE: If you did not experience an orgasm during this period circle “0” for these items) 
 
4.1 
How easy was it for you to have an orgasm? 
 
0 
1 
2 
3 
4 
Questions 
4.1, 4.2, 4.3 
4.2 
Typically, how intense were your orgasms? 
 0 
1 
2 
3 
4 
4.3 
How good was the control or timing of your orgasms? 
 0 
1 
2 
3 
4 
4.4 
How often did you experience an orgasm? 
Questions 4.4 and 4.5 
0 
1 
2 
3 
4 
5 
6 
7 
 
4.5 
How often did you experience a sense of relaxation and feeling 
good after orgasm? 
0 
1 
2 
3 
4 
5 
6 
7 
 
 
= Sum of 4.1 to 4.5 
 
SECTION V – SEXUAL SATISFACTION 
 
During the past 30 days, or since the last time you filled out this form, 
5.1 
How satisfied have you been with your sexual relationship with your partner? 
0 
1 
2 
3 
4 
5 
 
5.2 
How satisfied have you been with the emotional Intimacy and closeness you 
have shared with your partner? 
0 
1 
2 
3 
4 
5 
 
5.3 
How satisfied have you been with how often you have had sex? 
0 
1 
2 
3 
4 
5 
 
5.4 
How satisfied have you been with the variety of your sexual experiences? 
0 
1 
2 
3 
4 
5 
 
5.5 
How satisfied have you been with the sexual Sum of enjoyment you have 
experienced with your partner? 
0 
1 
2 
3 
4 
5 
 
 
4= extremely (easy, intense, good)  
3= very 
(easy, intense, good) 
2= moderately (easy, intense, good) 
1= minimally (easy, intense, good) 0= 
not at all     (easy, intense, good) 
7= 2 or more times a day 
6= once a day 
5= 4 to 6 times a week 
4= 2 to 3 times a week 
3= once a week 
2= once or twice a month 1= 
less than once a month 0= 
not at all 
5= highly satisfied 
4= satisfied 
3= somewhat satisfied 
2= somewhat dissatisfied 
1= dissatisfied 
0= highly dissatisfied 
Questions 5.1– 5.5 
= Sum of 
5.1– 5.5 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
110 
SEXUAL ACTIVITY, INTEREST, AND DESIRE SCALE 
 
The following questions ask about your interest in sexual activities and your sexual desire during the past 7 days. 
The first set of questions are about THINKING about sex, the second set of questions are about BEING SEXUALLY 
AROUSED, and the third set of questions are about SEXUAL ACTIVITY. Please answer the following questions by 
checking the box under the phrase that best describes your answer. In answering these questions, the following 
definition applies: 
Sexual activity includes intercourse, oral sex, caressing, foreplay, and masturbation. 
 
1. Thinking About Sex (But Not Engaging in Sexual Activity) 
During the past 7 days to what 
extent: 
Not at all 
A little bit 
Somewhat Quite a bit 
A great 
deal 
1a …did you THINK about sexual 
activity? 
□ 
□ 
□ 
□ 
□ 
1b …did you FANTASIZE about 
sexual activity? 
□ 
□ 
□ 
□ 
□ 
 
2. Becoming PHYSICALLY Sexually Aroused (But Not Engaging in Sexual Activity)  
During the past 7 days: 
None of 
the time 
Once or 
twice 
A few 
times 
Several 
times 
Many 
times 
2a …when seeing a sexually 
attractive person or seeing 
something sexual (for example a 
picture or a movie), how often did 
you PHYSICALLY FEEL a sense of 
sexual arousal, or a PHYSICAL 
stirring or tingling of arousal? 
□ 
□ 
□ 
□ 
□ 
 
During the past 7 days: 
0 days or 
nights 
1‐2 days or 
nights 
3‐4 days or 
nights 
5‐6 days of 
nights 
7 days 
or 
2b ...how often did you wake up 
from sleeping with an erection 
(either in the morning or in the 
middle of the night) 
□ 
□ 
□ 
□ 
□ 
 
Copyright (C) 2011 Eli Lilly and Company. All rights reserved. Confidential 2/8/11 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
111 
3. Engaging in Sexual Activity. 
During the past 7 days: 
0 times 
1‐2 times 
3‐4 times 
5‐6 times 
7 or more 
times 
3a …how many times did you 
masturbate? 
□ 
□ 
□ 
□ 
□ 
3b …how many times did you have 
some type of sexual activity with 
another person? 
□ 
□ 
□ 
□ 
□ 
 
 
For the next two questions, please circle the number that corresponds with the way that you felt during the past 
7 days. 
 
1. In general, thinking of everything you’ve thought, said, and done how would you rate your level of interest 
in sex during the last 7 days? 
 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
No 
interest 
at all 
 
 
 
 
 
 
 
 
 
Extremely 
high 
interest 
 
 
2. How would you rate your level of sexual desire during the last 7 days? 
 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
No desire 
at all 
 
 
 
 
 
 
 
 
 
Extremely 
high desire 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright (C) 2011 Eli Lilly and Company. All rights reserved. Confidential 2/8/11 


NCI Protocol #: Not Applicable 
DF/HCC Protocol #: 15-120 
Protocol Version Date: 09/12/2018 
112 
HYPOGONADISM ENERGY DIARY 
 
For the next 4 questions, thinking about how you feel now, please circle the number under the phrase that 
best describes how much you feel each word or phrase. 
 
1. Right now, how energetic do you feel? 
 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
No 
energy 
at all 
 
 
 
 
 
 
 
 
 
Full of 
energy 
 
 
 
2. Right now, how tired or exhausted do you feel? 
 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Extremely 
Not at all 
tired 
tired 
(Totally 
exhausted) 
 
 
 
3. Right now, how lethargic or sluggish do you feel? 
 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Extremely 
Not at all 
lethargic/ 
lethargic/ 
sluggish 
sluggish 
 
 
 
4. Right now, how focused (able to concentrate) do you feel? 
 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Not at all 
Extremely 
focused 
focused/ 
 
able to 
 
concentrate 
 
 
Copyright (C) 2011 Eli Lilly and Company. All rights reserved. Confidential 2/8/11